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Age-related macular degeneration (AMD) is the leading cause of blindness in
developed countries in individuals over the age of 65. High intake of the dietary carotenoids
lutein (L) and zeaxanthin (Z) is believed to reduce the risk of AMD. This study investigated
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cases. Supplementation with a 1:1 dose of L and Z increased plasma concentrations of these
carotenoids after 6 months, but baseline and month 12 levels in plasma and ocular tissues
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not cause ocular or kidney toxicity.
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INTRODUCTION
Age-Related Macular Degeneration (AMD) is the most common cause of blindness
and visual impairment in Americans age 60 or older [National Eye Institute (NEI), 2004].
NEI and the Eye Disease Prevalence Research Group estimate that 1.8 million Americans
currently suffer from AMD-related vision loss and that number will rise to a projected 2.9
million by the year 2020. The exact etiology of AMD is currently unknown.
AMD is characterized by the degeneration of the retina and the retinal pigment
epithelium (RPE) in the macular region that causes progressive vision loss. The macular
region is characterized as the small depression in the center of the retinal surface called the
fovea, and the presence of yellow pigments that accumulate there. This area is extremely
rich in cone photoreceptors that are responsible for enabling maximal visual acuity.
It was not until the publication of a case-controlled epidemiological study by Seddon
et al. in 1994 that increased attention was drawn to AMD. This study revealed that high
consumption of fruits and vegetables, specifically those rich in two dietary carotenoids,
lutein and zeaxanthin, reduced the risk of AMD (Seddon et al., 1994). High consumption
was defined as approximately 6 mg/day of combined dietary lutein and zeaxanthin, and this
level of intake was correlated with a 43% lower risk for AMD. Additionally, this status was
most readily achieved in subjects who frequently consumed dark green leafy vegetables such
as spinach or collard greens. Unfortunately, studies conducted nearly a decade later have
revealed that awareness among the general population is low in comparison to other eye
diseases (e.g., glaucoma, cataracts) and chronic diseases (e.g., coronary heart disease, high
blood pressure) (Rosenthal et al., 2003; Prahlad, 2002). 
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In 1984, Snodderly et al. first described the localization and distribution of the
yellow macular pigment within the Henle fiber layer of the fovea (Snodderly et al. 1984a &
1984b). Shortly thereafter, lutein and zeaxanthin, two dietary xanthophylls, were recognized
as the chemical compounds that comprise the macular pigment (Bone et al., 1985;
Handelman et al., 1988). Xanthophylls refer to the class of oxygenated carotenoids found
mostly in green plants. It has since been determined that the macula consists of 3 major
carotenoids (Bone et al., 1993; Khachik et al., 2002). The third major pigment present was
identified as (3R,3’S, meso)-zeaxanthin (referred to hereafter as meso-zeaxanthin). meso-
Zeaxanthin is a stereoisomer of zeaxanthin that is of non-dietary origin (Bone et al., 1993;
Khachik et al., 2002). These colored carotenoids in the macular region give the fovea its
characteristic yellow color (hence the name macula lutea). In addition to lutein, zeaxanthin,
and meso-zeaxanthin, a wide range of carotenoids have also been identified in human retinal
pigment epithelium (RPE/choroid), ciliary body, iris, lens, and in the uveal tract and other
tissues of the human eye (Khachik et al., 1997a; Bernstein et al., 2001; Khachik et al., 2002).
Unless otherwise specified in this proposal, lutein and zeaxanthin refer to dietary
(3R,3’R,6’R)-lutein and (3R,3’R)-zeaxanthin, respectively.
Lutein and zeaxanthin have been quantified in a wide range of fruits and vegetables
(Humphries et al., 2003; USDA, 2004). Humphries et al. have shown that the best dietary
sources of lutein and zeaxanthin are green leafy vegetables, yellow-orange fruits and
vegetables, and to a lesser extent, foods containing egg yolk such as wheat and pasta
products. It was observed that green vegetables tend to have higher ratios of lutein to
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zeaxanthin, while the yellow-orange fruits and vegetables tends to have a lower lutein to
zeaxanthin ratio (Humphries et al., 2003).
Prior to 1992, many studies routinely analyzed carotenoids in human blood and the
HPLC techniques employed allowed for the separation and identification of only about seven
18carotenoids. In 1992, Khachik et al. used a combination of C  reversed-phase and silica-
based nitrile-bonded high performance liquid chromatography (HPLC) columns to
effectively separate, identify, and quantify 25 carotenoids and 9 metabolites, and thus
provided a detailed method for analysis of human plasma (Khachik et al., 1992a & 1992b).
Later, the same researchers identified these carotenoids and their metabolites in human
breast milk (Khachik et al., 1997b). The carotenoid metabolites identified in human serum
and breast milk were not of dietary origin. In 1997, Khachik et al. reported that among 25
dietary carotenoids and 9 metabolites routinely found in human serum, lutein, zeaxanthin,
and their metabolites were also present in human and monkey retinas (Khachik et al. 1997a).
An extension of this work identified the complete spectrum of carotenoids in other ocular
tissues of the human eye (RPE/choroid, ciliary body, iris, lens) (Bernstein et al., 2001).
While lutein, zeaxanthin, and their metabolites were the major carotenoids found in human
ocular tissues, lycopene and a wide range of other dietary carotenoids were detected in high
concentrations in ciliary body and RPE/choroid.
Schalch reviewed a number of publications from the early 1990s and concluded that
the cumulative data from various observational studies provided circumstantial evidence for
the protective role of lutein and zeaxanthin in the retina against AMD (Schalch, 1992).
Thereafter, Snodderly suggested potential mechanisms for the protective role of these
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carotenoids in the human ocular tissues (Snodderly, 1995). These investigators suggested
that lutein and zeaxanthin play a protective role in the macula in the prevention of AMD by
absorbing short-wavelength visible light and thus preventing photochemical damage to cones
and photoreceptors (Schalch, 1992; Snodderly et al., 1984a & 1984b).
Epidemiological and observational studies have revealed that low macular pigment
optical density (MPOD) is associated with an increased risk of AMD (EDCCS, 1993; Beatty,
2001). MPOD refers to the concentration of carotenoids found in the macular region of the
retina.
Since the early 1990s a main area of focus has been oxidative damage to
photoreceptors that results from exposure to blue light. Two mechanisms have been
proposed for the protective role of lutein and zeaxanthin; these are: (1) acting as optical
filters by absorbing damaging short wavelength (blue) light; and (2) the antioxidant function
by which these carotenoids quench oxygen free radicals and singlet oxygen that result from
the simultaneous presence of light and oxygen in the macula (Kirschfield, 1982; Handelman,
1988; Snodderly, 1995; Landrum et al., 1997a; Beatty, 1999; Schalch, 1999).
In 1997, for the first time, Khachik et al. provided preliminary evidence for the
photo-protective role of lutein and zeaxanthin in the retina by an antioxidant mechanism of
action (Khachik et al., 1997a). This was accomplished by isolation, identification, and
structural elucidation of lutein, zeaxanthin, and their oxidation products in the retinas of 11
human donor eyes and that of one monkey. While lutein, zeaxanthin, and a direct oxidation
product of lutein were found to be the major carotenoids in the macula, 11 minor
carotenoids were also identified. Based on these findings, Khachik et al. postulated a series
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of oxidation-reduction reactions by which dietary lutein and zeaxanthin can be converted to
their oxidation products in order to protect the macula against bright light and prevent AMD
(Khachik et al., 1997a). As mentioned earlier, these investigators identified the metabolites
of lutein and zeaxanthin in all ocular tissues of the human eye in their subsequent follow-up
studies (Bernstein et al., 2001; Khachik et al., 2002). The proposed metabolic pathways of
lutein and zeaxanthin in the human ocular tissues will be discussed later in this thesis. The
epidemiological and supplementation studies presented are also described in detail later in
this thesis.
The age-related eye disease study (AREDS) was one of the first large-scale human
supplementation studies that investigated the protective role of carotenoids against AMD.
This multi-center clinical intervention trial that began in 1992 and involved 3,640 subjects
investigated the effects of supplementation with various combinations of antioxidant
vitamins (including b-carotene) and zinc on the development and progression of cataracts
and AMD (AREDS, 2000). Lutein and zeaxanthin, however, were not commercially
available at the outset of planning this study and were therefore not included in the
supplements. The results of this study showed a 25% decrease in the risk of AMD with the
daily supplementation of 500 mg vitamin C, 400 IU vitamin E, 15 mg b-carotene, and 80 mg
zinc (NEI, 2004).
The first human supplementation with lutein was conducted by Khachik et al. in
which three healthy Caucasian males (non-smokers) between the ages of 42–59 were given
oral supplements containing 10 mg/day of lutein dispersed in olive oil for 18 days (Khachik
et al., 1995). Plasma carotenoid profiles of the subjects were monitored by HPLC at specific
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intervals. The blood levels of lutein in all 3 subjects increased by 4- to 5-fold after one week
of supplementation. In one subject lutein blood level increased from about 16 :g/dL (0.28
X 10  mol/L) to about 64 :g/dL (1.12 X 10  mol/L) resulting in the maximum absorption-6 -6
of this compound after one week of supplementation. The levels of the lutein oxidation
products (metabolites) during this study increased significantly, confirming that the in vivo
oxidation of lutein is indeed one of the key reactions in the metabolism of this carotenoid
in humans. No apparent toxicity or side effects as a result of lutein ingestion was observed
in the subjects.
In a similarly designed study by Khachik et al., one subject ingested 20 mg/day of
lutein dispersed in olive oil for 21 days and the plasma carotenoid profile of the subject was
monitored at various intervals up to 40 days (Khachik et al., 1997c). The blood levels of
lutein increased by 9-fold from 0.21 :mol/L to 1.89 :mol/L within 3 weeks of treatment. At
the end of the supplementation period, the levels of the lutein oxidative metabolites
increased by 2- to 3-fold. A complete eye examination conducted after 21 days of
supplementation revealed no unusual accumulation of lutein in the retina or ocular toxicity
in the subject of the study.
The first supplementation study with zeaxanthin was also conducted by Khachik et
al. in which 3 subjects ingested oral supplements containing 10 mg/day of zeaxanthin in
olive oil for 3 weeks and the carotenoid plasma levels of the subjects were monitored at
various intervals (Khachik et al., 1995). The blood levels of zeaxanthin in all three subjects
increased by 4-fold after one week of supplementation. In addition, the plasma
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concentrations of the oxidation products of lutein and zeaxanthin (metabolites) increased
significantly.
In 1997, Landrum et al. conducted a study involving 2 subjects that were
supplemented with lutein esters equivalent to 30 mg of free lutein per day for 140 days
(Landrum et al., 1997b). In this study, serum lutein levels of the subjects increased by 10-
fold within 20 days and plateaued at 1761 nmol/L and remained at this level for the duration
of the study. After 40 days, these researchers observed an increase in MPOD at an average
rate of 1.13±0.12 milliabsorbance units/day.
A recent double-blind randomized clinical trial investigated the dose response of
elderly subjects with and without AMD to lutein at 3 supplemental doses (Moura et al.,
2004). Forty-five subjects aged 60 years or older were divided into 3 groups: (1) no diagnosis
of AMD, (2) middle stage of AMD, or (3) end stage of AMD, and were randomly assigned
to receive one of three oral doses of lutein containing 5% zeaxanthin for 6 months. Serum
lutein levels of all subjects increased, and subjects on doses of 2.5, 5, 10 mg/day of lutein
reached a serum plateau of 450, 490, and 810 nmol/L, respectively. This study revealed that
serum concentration of lutein was dose dependent and that the presence or absence of AMD
did not interfere with serum levels of lutein (Moura et al., 2004).
The Veterans LAST Study was a double-masked, placebo-controlled, randomized
trial of lutein and antioxidant supplementation that involved 90 subjects with atrophic AMD
and a mean age of about 75 (Richer et al., 2004). The purpose of this study was to
investigate the effect of lutein alone and lutein in combination with other carotenoids,
antioxidants, vitamins, and minerals on MPOD and central vision outcome measures in
atrophic AMD. Richer et al. showed that daily supplementation of human subjects with
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lutein alone or in combination with other antioxidant vitamins for one year effectively
increased MPOD and improved glare recovery, near visual acuity and significantly improved
most measures of quality of vision.
Although lutein and zeaxanthin have been commercially available and widely used
in the United States as a nutritional supplement for nearly a decade, the safety and efficacy
of these carotenoids had not yet been established. Meanwhile, because of the implication of
lutein and zeaxanthin in the prevention and treatment of AMD and other ocular diseases,
multi-center clinical trials with these carotenoids are in the planning stage by the NEI. Prior
to the study discussed in this thesis, metabolic and toxicity studies with lutein and
zeaxanthin had not been explored. The study outlined in this thesis was undertaken to
investigate the safety and efficacy of chronic supplementation with high doses of lutein or
zeaxanthin. Additionally, supplementation with a 1:1 combination of lutein and zeaxanthin
had not been conducted so this study also sought to examine the efficacy of such a dose as
well as possible interaction between these carotenoids. Female rhesus macaques (Macaca
mulatta) were selected as an appropriate animal model due to the invasive nature of the
proposed studies and possible toxicity associated with the administration of lutein and
zeaxanthin at pharmaceutical doses. As described earlier, the distribution of lutein,
zeaxanthin, and their metabolites in the ocular tissues of primates has been shown to be
similar to that of humans which make this animal a suitable model for metabolic and
toxicity studies. Justification for the selection of the animal model will be described later
in the thesis.
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LITERATURE REVIEW 
 
Distribution of Carotenoids in the Macular Pigment 
 In 1945, George Wald first identified the yellow pigment in the human macula as 
a carotenoid member of the xanthophyll family (Wald, 1945). Xanthophylls include 
oxygenated carotenoids that are derived from green plants (e.g., lutein). Since then, the 
relationship between dietary xanthophylls and the optical density of the yellow macular 
pigment was established in a study in which primates were fed a xanthophyll-deficient 
diet (Malinow et al., 1980). In this study, animals that were fed a xanthophyll-deficient 
diet showed a reduction in the optical density of yellow macular pigment and more 
frequently developed drusen- like bodies. Drusen, which are extracellular deposits that 
accumulate between the retinal pigment epithelium (RPE) and Bruch’s membrane, have 
been cited as possible precursors of AMD. Bruch’s membrane, together with the RPE 
serves as the blood-retinal barrier and both are therefore critical in maintaining the 
integrity of the retina (Mares-Perlman & Klein, 1999). The decrease in macular pigment 
optical density observed by Malinow et al. was related to the absence of the major 
xanthophyll component of greens, the carotenoid lutein. In 1985, the macular pigments 
were first identified by Bone et al. as lutein [(3R,3'R,6'R)-βe-carotene-3,3'-diol] and 
zeaxanthin [(3R,3'R)-β ,β-carotene-3,3'-diol] by HPLC analysis of retinal extracts (Bone 
et al., 1985). In 1988, these pigments were detected not only in the human macula, but 
throughout the entire retina (Handleman et al., 1988). 
 In 1993, the complete identification and stereochemistry of the human macular 
pigment was accomplished and the composition was shown to consist of: lutein 
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[(3R,3'R,6'R)-βe-carotene-3,3'-diol)], zeaxanthin [(3R,3'R)-β ,β-cartotene-3,3'-diol)], and 
(3R,3’S, meso)-zeaxanthin [(3R,3'S)-β ,β-carotene-3,3'-diol] (Bone et al., 1993). The 
structures of these carotenoids are shown in Figure 1. Unless specified in this thesis, 
lutein, zeaxanthin, and meso-zeaxanthin refer to dietary lutein [(3R,3’R,6’R)-β ,ε-
carotene-3,3’-diol), dietary zeaxanthin [3R,3’R)-β ,β-carotene-3,3’-diol)], and (3R,3’S, 
meso)-zeaxanthin [(3R,3'S)-β ,β-carotene-3,3'-diol]. 
Bone et al. also found that the ratio of lutein to zeaxanthin in donor retinas varied 
from the center of the macula outward. In the periphery of the retina (8.7–12.2 mm), the 
lutein to zeaxanthin ratio was found to be 2:1, and in the central region (0–.25 mm), the 
ratio was 1:2.4 with zeaxanthin predominating (Bone et al., 1988 & 1992). Additionally, 
the overall retinal carotenoid content was shown by these investigators to decrease 
considerably with increased eccentricity from the fovea. Further evidence to support the 
distribution of these carotenoids in the macula came from a study of postmortem human 
eyes (van Kuijk et al., 1997). In this study, lutein was found to be the predominant 
carotenoid associated with the rod photoreceptors, which are primarily located in the 
periphery of the retina. 
In human serum, the ratio of lutein to zeaxanthin is considerably higher than in 
the retina, perhaps because of the comparable abundance of dietary lutein in most diets. A 
compelling finding was that approximately half of the zeaxanthin in the macula was 
dietary (3R,3'R)-zeaxanthin, and the remainder was meso-zeaxanthin, which is not of 
dietary origin (Bone et al., 1993; Khachik et al., 2002). meso-Zeaxanthin was found to 
account for less than 1% of the total zeaxanthin found in human blood. More recently, in 
a study of the in vivo transformations of dietary lutein and zeaxanthin, there was no 
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detectable concentration of meso-zeaxanthin found in the human plasma or liver tissues 
(Khachik et al., 2002). Unfortunately, there was no dietary history or plasma carotenoid 
profile available for the subject whose liver was analyzed, but high levels of dietary 
lutein and zeaxanthin were detected in this liver sample. The highest concentrations of 
meso-zeaxanthin relative to dietary zeaxanthin were found in the macula and 
RPE/choroid in the ocular tissues that were analyzed. This finding confirmed the in vivo 
conversion of dietary lutein to meso-zeaxanthin in the human ocular tissues as described 
by Khachik et al. in an earlier publication (Khachik et al., 1997a). 
 
 
Figure 1. Chemical structures of lutein, zeaxanthin, and their metabolites. 
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Dietary Sources of Lutein and Zeaxanthin 
 Lutein and zeaxanthin are found in a variety of foods commonly consumed in 
Western diets. The best sources of lutein and zeaxanthin are green leafy vegetables, 
yellow-orange fruits and vegetables, and to a lesser extent, wheat and pasta products; the 
best sources of β-carotene and lycopene are carrots and tomatoes, respectively (Mangels 
et al., 1993). In 2003, a study was published that, for the first time quantified 
(3R,3'R,6'R)- lutein, (3R,3'R)-zeaxanthin, and their (E/Z)-geometrical isomers in a variety 
of fruits, vegetables, wheat, and pasta products (Humphries et al., 2003). Prior to this, 
most data that quantified lutein and zeaxanthin in foods were presented as the combined 
concentration of these carotenoids plus their geometrical isomers due to the difficulties 
associated with separation of these carotenoids by high performance liquid 
chromatography (HPLC). An extensive listing of the commonly consumed foods in the 
United States and their combined lutein and zeaxanthin content is available at 
<http://www.nal.usda.gov/fnic/foodcomp/Data/SR17/wtrank/sr17w338.pdf> (USDA, 
2004). 
The 2003 study by Humphries et al. revealed nearly identical qualitative HPLC 
profiles among green leafy vegetables (with the exception of romaine lettuce), and among 
these, the highest concentration of lutein and zeaxanthin was found in kale, parsley, 
spinach, and collards. 
Additionally, in all of the green fruits and vegetables analyzed, the ratio of lutein 
to zeaxanthin varied from 12 to 63 (Humphries et al., 2003). Romaine lettuce was the 
exception due to the presence of significant quantities of the rare dihydroxycarotenoid 
lactucaxanthin. Other sources of lutein and zeaxanthin include green beans, lima beans, 
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broccoli, lettuce, and peas. Yellow-orange fruits and vegetables including butternut 
squash, corn, oranges, and nectarines were identified as good sources of zeaxanthin. This 
study found that the ratio of lutein to zeaxanthin was close to one  in these foods; this is 
with the exception of corn and nectarines which contained higher concentrations of 
zeaxanthin than lutein. Of the wheat and pasta products analyzed, the levels of lutein and 
zeaxanthin were lower than that of the yellow-orange and green fruits and vegetables. 
The presence of these carotenoids in wheat and pasta products was attributed to the 
presence of egg yolk, which contains moderate levels of dietary lutein and zeaxanthin. 
This study enabled the identification of good sources of lutein and zeaxanthin. 
Epidemiological studies have shown that a decreased risk of neovascular AMD is 
associated with high plasma concentrations of carotenoids (lutein, zeaxanthin, β-carotene, 
α-carotene, β-cryptoxanthin, α-cryptoxanthin, and lycopene) (EDCCS, 1992; Gale et al., 
2003). While serum carotenoid levels increase quickly with supplementation (Khachik et 
al., 1995; Landrum et al., 1997a), it has been shown that the increase in MPOD as a result 
of supplementation or dietary intake of these carotenoids is a much slower process 
(Landrum et al., 1997b; Toyoda et al., 2002). Although the exact mechanism for uptake 
of dietary lutein and zeaxanthin into the macula has not yet been elucidated, retinal 
tubulin, a carotenoid binding protein has been suggested as a mediator for uptake of these 
carotenoids in the fovea (Bernstein et al., 1997). More recently, a pi isoform of glutathione s-
transferase (GSTP1) has been identified as a xanthophyll-binding protein in the human 
macula that displays a strong affinity for dietary zeaxanthin and meso-zeaxanthin and, and to 
a lesser extent, lutein (Prakash et al., 2004). 
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Proposed Metabolic Pathways of Lutein and Zeaxanthin in Humans  
 It has been hypothesized that lutein and zeaxanthin in the human macula provide 
protection against AMD by two mechanisms. First, lutein and zeaxanthin absorb short-
wavelength blue light between 400–475 nm, which peaks at 440 nm, and has the most 
damaging effects on the retina. The main absorption maxima of lutein and zeaxanthin in 
organic solvents are 448 nm and 454 nm, respectively (Britton, 1995). It has been 
suggested that lutein and zeaxanthin in the macula act as optical filters by absorbing 
damaging blue light, and as a consequence, reduce and/or prevent the amount of light-
induced oxidative damage. Secondly, carotenoids are potent antioxidants and can quench 
reactive oxygen species in the macula and thereby prevent damage to the cones and 
photoreceptors (Schalch et al., 1999; Beatty et al., 1999; Liebler et al., 1997). The retina 
is highly susceptible to oxidative damage due to the high rate of metabolic activity and 
the simultaneous presence of high levels of oxygen and light. 
 The initial hypothesis of this protective effect was based on the previously 
observed concentrations of lutein and zeaxanthin in the macula, epidemiological data, 
and animal studies (EDCCS, 1992; EDCCS, 1993; Seddon et al., 1994; Malinow et al., 
1980; Kirschfeld, 1982; Krinsky, 1989; Snodderly, 1995). A cumulative body of data was 
reviewed in 1992 by Schalch, who concluded that the presence of lutein and zeaxanthin 
in human and monkey retinas does indeed serve a specific purpose (Schalch, 1992). It 
was noted that of the 10 dietary carotenoids found in human blood, lutein and zeaxanthin 
are present in the macula due to their excellent ability to quench oxygen free radicals and 
singlet oxygen, both of which are generated in this region due to the concurrent presence 
of light and oxygen (Schalch, 1999). Additionally, Landrum et al. provided evidence for 
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the possible role of these carotenoids by showing the loss of these macular pigments 
throughout the macula in AMD donor eyes in comparison with control eyes (Landrum et 
al., 1997). It is now believed that the presence of these carotenoids in the macula may 
retard some of the destructive processes that occur in the retina and RPE that may lead to 
AMD. For a complete review of the evidence supporting the protective role of lutein and 
zeaxanthin against AMD see the publications of by Snodderly, 1995; Schalch et al., 1999; 
and Landrum & Bone, 2001. 
 The discovery of the metabolites and several oxidation products of lutein and 
zeaxanthin that are not of dietary origin in the human retina led to a postulated metabolic 
transformation by which dietary lutein and zeaxanthin in the retina may be converted to 
their metabolites (Khachik et al., 1995; Bernstein et al., 2001; Khachik et al., 2002). The 
presence of the oxidation products of lutein and zeaxanthin in the human retina provided 
preliminary evidence for the protective role of these carotenoids as antioxidants (Khachik 
et al., 1995; Khachik et al., 1997a; Landrum & Bone, 2001). According to the metabolic 
transformations proposed by Khachik et al., (3'R,3'S, meso)-zeaxanthin, (3R,3'R,6'R)-
lutein, and (3R,3'R)-zeaxanthin may be interconverted by a series of oxidation-reduction 
and double-bond isomerization reactions as shown in Figure 2. The 3 types of reactions 
that may take place are: 1) the oxidation of the allylic hydroxyl group of the ,-end group 
of lutein to give an α,β-unsaturated ketocarotenoid (e.g., 3’-oxolutein), 2) the reduction 
of the resulting ketocarotenoid via epimerization at C-3' to form 3’-epilutein, and 3) 
stereospecific double bond isomerization of the β-end group of dietary zeaxanthin to 
form 3’-epilutein, and by a similar mechanism, the conversion of dietary lutein to 
(3R,3’R, meso)-zeaxanthin. The carotenoids shown in Figure 2 have all been detected in 
 16 
human plasma and/or ocular tissues (Khachik et al., 1992a; Khachik et al., 1992b; 
Khachik et al., 1997a; Khachik et al., 1997c; Khachik et al., 1998; Bernstein et al., 2001). 
While the sources of 3’-oxolutein and 3’-epilutein in the retina may be due to the 
presence of these carotenoids in circulating blood, this is an unlikely scenario for meso-
zeaxanthin. This is because it has now been established that meso-zeaxanthin is absent in 
human plasma and liver but present in nearly all of the ocular tissues (Khachik et al., 
2002). 
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Figure 2. Proposed metabolic pathways of dietary lutein and zeaxanthin in humans. 
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Epidemiological Studies and Risk Factors Associated with AMD 
 Epidemiological studies have provided insight into the occurrence of the 2 forms 
of AMD: wet and dry AMD. AMD is defined as the late stage of age-related maculopathy 
(ARM), and exists as geographic atrophy (the end stage of dry AMD), and choroidal 
neovascularization (wet AMD). ARM is most common in persons older than 50 years of 
age, and the presence of soft drusen (≥63 µm), choroidal hyperpigmentation associated 
with drusen, and depigmentation of the RPE are the characteristic symptoms. The 
extracellular deposits know as drusen accumulate between the RPE and Bruch’s 
membrane and vary in size and morphology (Mares-Perlman & Klein, 1999). It was 
recently shown that photoreceptors of both the macular and extramacular region 
overlying drusen deposits exhibit both structural and molecular abnormalities (Johnson et 
al., 2003). 
 
 
 
Figure 3. Anatomy of retina and posterior eye. Source: < http://www.hopkinsmedicine.org >. 
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 Prevalence studies of AMD have been conducted mainly in industrialized 
countries. Three large population-based epidemiological studies have provided estimates 
for the prevalence of geographic atrophy and neovascular AMD. They are: the Beaver 
Dam Study in Wisconsin (Klein et al, 1992); the Rotterdam Study in The Netherlands 
(Vingerling et al., 1995); and the Blue Mountains Eye Study in Australia (Mitchell et al., 
1995). The data from these studies revealed the following figures for the prevalence of 
geographic atrophy: 0.44% (the Beaver Dam Study), 0.66% (the Rotterdam Study), and 
0.45% (the Blue Mountains Eye Study). Meanwhile, the same studies reported that the 
prevalence of neovascular AMD was: 0.88%, 0.72%, and 1.20%, respectively.  
AMD is a multifactorial disorder. While the etiology of AMD is unknown, it has 
been linked to the combination of numerous risk factors. One of the major risk factors for 
AMD is age. The Framingham Eye Study showed that 28% of individuals between the 
ages of 75 and 85 had AMD compared to 22% of individuals between the ages of 52 and  
74 (Kahn et al., 1977). Additionally, the Beaver Dam Eye Study, which investigated the 
10-year incidence of ARM showed a significant increase in the incidence of this disease 
with age. This study revealed a 19.5% increase of retinal pigment abnormality in subjects 
aged 75 or older at baseline from the outset of the study to its conclusion compared with 
a 0.8% increase in individuals aged 43 to 54 at baseline (Klein et al., 2002). 
Family history has also been shown to be an important risk factor associated with 
late AMD and early ARM (Smith et al., 1998). Several studies with twins  proposed 
genetic influence as an AMD risk factor, although the relative importance of genetic 
versus environmental factors was not defined (Meyers & Zachary, 1988; Klein et al., 
1994). In a study that compared monozygotic twins to dizygotic twins in order to exclude 
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the influence of shared family environment, results showed 45% heritability at the early 
stage of ARM (Hammond et al., 2002). 
More recently, variants of several genes have been identified as possible risk 
factors for AMD. A single-nucleotide polymorphism (SNP) in the complement factor H 
(CFH/HF1) gene has been associated with an increased risk of AMD (Klein et al., 2005; 
Hageman et al., 2005).  CFH plays a critical regulatory role in the complement system of 
innate immunity which protects against infection and attacks diseased cells. It has been 
hypothesized that inappropriate complement activation which causes an abnormal 
inflammatory response may result in AMD by way of tissue damage and cell death. The 
haplotype N1 within the CFH gene increases the risk for AMD significantly. In a whole-
genome case-control association study that used a subset of participants from the Age-
Related Eye Disease Study (AREDS) (96 case and 50 control subjects), being 
heterozygous for this haplotype increased the risk for AMD by a factor of 4.6 and being 
homozygous for this haplotype increased the risk for AMD by a factor of 7.4 (Klein et al, 
2005). 
In a study of 2 independent cohorts comprised of 900 AMD cases and 400 
matched controls that analyzed genetic variations in HF1, multiple HF1 variants were 
associated with elevated or reduced risk of AMD (Hageman et al., 2005). Strong 
associations with AMD were found among 3 SNPs for this gene ; the strongest was the 
A473A variant in exon 10 (rs2274700) (odds ratio = 3.42, 95% CI). Additionally, 2 
common protective haplotypes were identified in 34% of controls and 18% of cases.  
Results suggest that the HF1 protein associated with the at-risk HF1 haplotype(s) may 
attenuate complement inhibitory function leading to excessive amounts of membrane 
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attack complex and consequent tissue damage. This evidence supports the hypothesis that 
a specific and common haplotype of HF1, a complement regulator, predisposes 
individuals to AMD (Hageman et al., 2005; Klein et al, 2005). 
Also implicated as a risk factor for AMD are variants of the  ABCA4 gene.  In a 
study that screened over 1,000 unrelated AMD patients, the 2 most frequent AMD-
associated variants in ABCR were investigated (Allikmets et al., 2000). The risk of AMD 
was 3-fold higher for the variant D2177N and 5-fold higher for the variant G1961E. 
The ApoE gene has also been implicated as a risk factor for AMD (Schmidt et al., 
2000; Malek et al., 2005). In a recent experimental study, a new animal model that was 
developed, the apoE TR mouse, manifests a comprehensive range of human AMD-like 
pathologies (Malek et al., 2005). The homozygous ApoE4 genotype when combined with 
advanced age and high fat cholesterol-rich diets produced neovascularization (NV) 
associated with advanced AMD among approximately 18% of the animals in this group 
and was not observed in the age and diet matched group that expressed the other two 
apoE alleles. Additionally, the proteins detected in the NV lesions of these mice were 
consistent with those seen in human NV. 
Being Caucasian appears to increase the risk of AMD. The white population has 
been shown to have a higher prevalence of ARM (5.6%) when compared to that of the 
black population (3.7%)  (Klein et al.,1999). The Baltimore Eye Survey which involved a 
total of 5,431 participants found that the prevalence of AMD among whites over 70 years 
of age was 2.1%, while there were no cases of AMD detected among the 243 black 
participants in this age group (Friedman et al., 1999). 
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 Gender has also been shown to be a risk factor for AMD. The Beaver Dam Eye 
Study found that the prevalence of exudative AMD was 6.7% for women and 2.6% for 
men among the Caucasian population in the study (Klein et al., 1992). The gender 
difference was also apparent among the African American population as women were 
twice as likely to have AMD as men (Pieramici et al., 1994). An interesting point to note 
is that MPOD has been shown to be lower in women; men were shown to have an 
average of 38% or higher MPOD than women (Hammond et al., 1996). Low MPOD 
causes increased exposure to damaging blue light which may explain the higher 
prevalence of AMD seen in women.  
Cigarette smoking is an important modifiable risk factor for AMD. Smoking has 
been associated to a greater extent with neovascular AMD rather than with geographic 
atrophy (Hyman et al., 1992). The Eye-Disease Case Control Study Group also found a 
strong association between risk of neovascular AMD and current smokers (EDCCS, 
1992). Additonally, the Blue Mountains Eye Study assessed the relationship between 
baseline smoking and the 5-year incidence of late and early ARM in 3,654 subjects aged 
49 years or older (Blue Mountains Eye Study, 2002). This study found that current 
smokers had an increased risk in pigment abnormalities and of developed late ARM at a 
significantly earlier age than former smokers and those who had never been smokers. 
Additionally, the POLA Study found former smokers to remain at increased risk for 
AMD (Delcourt et al., 1998). 
While epidemiological studies have investigated the association between AMD 
and cardiovascular disease and related risk factors such as high blood pressure and high 
serum cholesterol, the relationship is still unclear. The Eye Case Control Study Group 
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(EDCCS, 1992), did not find a significant association between hypertension and 
neovascular AMD, but did find a significant trend with higher systolic blood pressure. 
Conversely, the AMD Risk Factors Study Group found a positive association between 
neovascular AMD and diastolic blood pressure greater than 95 mm Hg (odds ratio [OR] = 
4.4) (Hyman et al., 2000). Additionally, a direct association between elevated HDL 
cholesterol levels and the incidence of AMD has been suggested but the reason is not 
known (Hyman et al., 2000; Klein et al., 2003a). Several epidemiological studies did not 
find any association between AMD and hypertension, stroke, angina, and acute 
myocardial infarction (Smith et al., 1998; Klein et al., 2003b). Examined cumulatively, 
the results of studies investigating these associations are inconclusive. 
Chronic or abnormal inflammatory responses have emerged as possible indicators 
of AMD risk. It has been noted that cardiovascular disease and AMD share common 
antecedents and biomarkers of systemic inflammation such as elevated C-Reactive Protein 
(CRP) levels (Snow et al., 1999). In a study of over 250 subjects with a mean age of 72 
years, analysis of biomarkers of inflammation showed: 1) physical activity was inversely 
related to CRP, interleukin-6 (IL-6), and tumor necrosis factor-a-R2 (TNF-a-R2); 2) 
smoking was associated with all biomarkers but vascular cell adhesion molecule-1 
(VCAM-1); and CVD; 3) systolic blood pressure were positively related to most markers; 
and 4) body mass was positively associated with CRP, TNF-a-R2, and VCAM-1. 
Statistical analysis from this study showed a 2-fold greater risk of progression of AMD 
among the highest quartile of CRP, and odds ratio of 1.81 for the highest quartile of IL-6; 
and both smoking and BMI were positively related high levels of CRP and IL-6 and to 
AMD. The identification of the factor H gene (HF1) as an AMD risk gene provides 
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support for the role of inflammation in AMD (Bok et al., 2005; Klein et al., 2005). HF1 
codes for a protein involved in the innate system, the body’s first line of defense against 
infection. A broader haplotype of the regulator of complement activation (RCA) gene 
located nearby on the same chromosome was recently found to be present in nearly half 
of those with AMD compared to approximately 29 % of controls (Hageman et al., 2005). 
It has been hypothesized that dysfunction of the complement system which leads to 
chronic inflammation could contribute to chronic diseases and, in the case of AMD, 
disruption of Bruch’s membrane and subsequent lesion formation (Hageman et al., 2005). 
Prolonged inflammatory response, a condition seen in obesity and in other chronic 
diseases, may provide a link between the aforementioned diseases and increased AMD 
risk. 
Obesity, high BMI, and waist-to-hip ratio have been cited as risk factors for AMD 
(AREDS 2000). In a study of 680 men and women from two sites in the United States, 
there was an inverse relationship between MPOD and BMI (p <0.0008) and MPOD and 
body fat percentage (p < 0.01) (B.R. Hammond et al., 2002). These relationships were 
observed only in the group of subjects with a BMI above 29 and fat percentage above 
27%. However, dietary intake of lutein and zeaxanthin was also lower in these groups. In 
the 5-year follow-up of the Beaver Dam Eye Study (n=3722), researchers found a 
significant association between age-related maculopathy and both BMI and waist-to-hip 
ratio among women, but found that waist-to-hip ratio was more strongly associated with 
nearly every outcome (Klein et al., 2001). These researchers found little difference 
between BMI and waist-to-hip ratio as indicators of age-related eye disease among men 
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(Klein et al., 2001). While there is a greater range of waist-to-hip ratios in women than 
men, these results suggest the distribution of adiposity might be related to AMD risk.   
 There is some evidence to suggest that light iris color (i.e., blue, green irises) is 
associated with increased risk of AMD, but this is controversial. Analysis of the cross-
sectional data from the Blue Mountain Study revealed a significant association between 
blue iris color and an increased risk of early ARM (odds ratio=1.45) and late ARM (odds 
ratio=1.69) (Mitchell et al., 1998). However, the Beaver Dam Eye Study showed that 
individuals with brown eyes were more likely to develop soft indistinct drusen than those 
with blue irises (Tomany et al., 2003). Additionally, the Eye Disease Case Control Study 
group found no significant association between iris color and AMD (EDCCS, 1992). 
 Dietary factors have been cited as possible factors in the development of AMD. 
Dietary fat is one potential risk factor for AMD, however results from studies have been 
inconsistent. The Beaver Dam Eye Study reported that subjects in the highest quintile of 
saturated fatty acid intake were at a significantly higher risk for early AMD than those in 
the lowest quintile. (Mares-Perlman et al.,1995a). Alternatively, The Blue Mountains 
Study did not find a significant association between AMD and saturated fat, but instead 
found a relationship between intake of monounsaturated fat and a significant borderline 
increase in the risk of early AMD (Smith et al., 2000). In yet another study, 
polyunsaturated fat, such as linoleic acid, was associated with risk of AMD (Seddon et 
al., 2001). 
 Antioxidants, alternatively, may prevent the progression of AMD. Carotenoids 
have been cited as being among the most effective and abundant dietary antioxidants that 
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prevent oxidative damage by quenching singlet oxygen and other reactive oxygen species 
in liposomes, lipoproteins, membranes, and cells (Krinsky, 1989). 
 Evidence for the protective role of carotenoids against AMD was collected in a 
study conducted by the Eye Disease Case-Control Study Group, specifically for the 
beneficial role of carotenoids in the prevention of neovascular (wet) AMD (EDCCS, 
1993). The study subjects included 421 patients with neovascular AMD and 615 controls, 
and the goal was to evaluate antioxidant status (including vitamins C and E, carotenoids, 
and selenium) and the risk factors for wet AMD. The results of this study showed that the 
subjects with medium and high serum carotenoid levels as compared to those with low 
serum carotenoid concentrations were at significantly reduced risk of neovascular AMD. 
However, a nested case-control study (Beaver Dam Eye Study), examined subjects with 
retinal pigment abnormalities with the presence of drusen (n = 127), late AMD/geographic  
atrophy (n = 9), or exudative AMD (n = 31), and an equal number of controls (n = 167), 
and found no correlation between serum lutein and zeaxanthin concentrations and risk of 
AMD. This study revealed that the subjects with serum lycopene levels in the lowest 
quintile were twice as likely to develop AMD (Mares-Perlman et al., 1995b).  
Another study, published in 1994 reported that diets high in fruits and vegetables, 
specifically those rich in lutein and zeaxanthin, were correlated with a reduced risk of 
AMD (Seddon et al., 1994). Seddon et al. examined 356 case subjects with advanced 
stage of AMD and 520 control subjects who were within the same age range and from the 
same geographic region, but had ocular diseases other than AMD. This study showed that 
the subjects in the highest quintile of carotenoid intake had a 43% lower risk for AMD 
compared with those in the lowest quintile. More specifically, frequent consumption of 
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spinach or collard greens, which contain high concentrations of lutein and zeaxanthin, 
was associated with a substantially lower risk for AMD. 
 The epidemiological and observational studies that provided such promising 
results in the early 1990s were the impetus for the large-scale clinical intervention trial 
with β-carotene known as the Age-Related Eye Disease Study (AREDS, 2000; Sackett & 
Schenning, 2002). AREDS began in 1992 and was concluded in 2001, and involved over 
4,600 subjects at 11 eye disease centers across the United States. The intent of this study 
was to examine whether long-term supplementation of patients at various stages of AMD 
or cataract with β-carotene, vitamins C and E, and zinc, alone or in combination, could 
prevent or slow the progression of these eye diseases.  An important point to note is that 
at the outset of planning AREDS, lutein and zeaxanthin were not yet commercially 
available, but β-carotene was both commercially available and accepted as a safe dietary 
supplement. Although β-carotene does not accumulate in the retina, it was selected for 
this study based on its role in the human visual cycle as a precursor of retinol (vitamin 
A). The subjects of this study were categorized into one of 4 groups: 1) no diagnosis of 
AMD, 2) early stage of AMD, 3) intermediate AMD, and 4) advanced stage of AMD. 
Nutritional supplements given to members of each group were randomized. Results of 
this study showed that a daily dose of 500 mg vitamin C, 400 I.U. vitamin E, 15 mg β-
carotene, and 80 mg zinc oxide with 2 mg cupric oxide reduced the risk of developing 
advanced AMD by about 25% in individuals at high risk for developing advanced AMD 
(i.e., those with intermediate AMD or advanced AMD in one eye) (AREDS, 2000; Sacket 
& Schenning, 2002). 
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  Because lutein and zeaxanthin are concentrated in the human retina and it has 
been suggested that they have possible protective roles against disease, blood levels of 
these carotenoids were examined in 7059 participants of the Third National Health and 
Nutrition Examination Survey aged 40 and over (Gruber et al., 2004). It was shown that 
lower serum lutein and zeaxanthin were significantly associated with smoking, heavy 
drinking, higher fat- free mass, being white, female, or not being physically active, having 
lower dietary cholesterol, and the presence of inflammatory markers such as higher white 
blood cell count, and high levels of C-reactive protein (p < 0.05). This study, in finding 
associations between low serum concentrations of lutein and zeaxanthin and previously 
identified risk factors for AMD further demonstrates the multi- factorial nature of this 
disease. Unfortunately, the results provide no information about the relative contribution 
of the individual risk factors to AMD risk. 
 
Supplementation Studies with Lutein and Zeaxanthin 
 There have been few studies involving human supplementation of lutein and/or 
zeaxanthin; these studies provide a foundation for current research. Results of the first 
human studies of supplementation with lutein and zeaxanthin were published in 1995 
(Khachik et al., 1995). In these studies, Khachik and 2 colleagues were the subjects of a 
lutein supplementation study. All 3 subjects were healthy nonsmoking Caucasian males 
between the ages of 42 and 59. Subjects were placed on a restricted diet that excluded 
green and yellow-orange fruits and vegetables containing lutein, and they were 
supplemented daily with 10 mg oral doses of lutein that were dispersed in olive oil. 
Otherwise, subjects were on self-selecting diets and kept dietary records throughout the 
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study. Baseline levels of plasma carotenoids were determined 25 and 11 days prior to the 
supplementation period (3 data points: days -25, -11, and baseline). Plasma carotenoid 
profiles were monitored at baseline and on days 2, 4, 7, 18, 26, 33, 40, and 57, and 
analyzed by HPLC. Lutein serum levels in all 3 subjects increased by 4- to 5-fold after 
one week of supplementation and peaked in one subject after one week of supplementation. 
Additionally, the levels of lutein oxidation products during this study increased 
significantly, providing preliminary evidence for the in vivo oxidation of lutein as a result 
of the metabolism of this carotenoid (Khachik et al., 1995). 
 A similar study was conducted by the same researchers in order to investigate the 
effects of short-term zeaxanthin supplementation on serum carotenoid levels (Khachik et 
al., 1995). The 3 subjects ingested 10 mg/day of zeaxanthin orally for 3 weeks. After one 
week of supplementation, the plasma zeaxanthin concentrations increased by 4-fold in all 
subjects, and plasma concentrations of lutein, 3'-epilutein, and the oxidation products 
(ketocarotenoids) of these carotenoids increased significantly. 
 Another study conducted by the same researchers sought to examine the short-
term effects of a higher daily dose of lutein. In this study, one subject ingested a daily 
dose of 20 mg of lutein for a period of 21 days (Khachik et al., 1997c). The supplements 
were prepared in the same manner as previously described. Serum analysis was 
performed at baseline and on days 2, 4, 7, 9, 11, 15, 18, 18, 21, 25, 31, and 39 that 
measured the levels of 22 carotenoids, vitamin A, and vitamin E (α- and ?-tocopherol). 
There was a 9-fold increase in lutein serum levels of subjects from 12 µg/dL at baseline 
to 108 µg/dL after 3 weeks of supplementation. At the end of the supplementation period, 
the levels of lutein oxidation products were shown to increase by 2- to 3-fold. Because of 
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the known accumulation of lutein in the retinas, a complete eye examination of the 
subject was performed after 21 days of supplementation at the National Eye Institute. No 
unusual accumulation of lutein in the retina or ocular toxicity was observed. 
 The Veterans Lutein Antioxidant Supplementation Trail (LAST) investigated the 
effects of long-term lutein supplementation in patients with atrophic AMD (Richer et al., 
2004). This double-masked, placebo-controlled, randomized trial of lutein and 
antioxidant supplementation involved 90 subjects with a mean age of about 75. Subjects 
were randomly assigned to one of the following 3 treatments for 12 months: 1) 
supplementation with 10 mg/day of lutein, 2) supplementation with 10 mg/day of lutein 
plus a wide range of antioxidants, vitamins, and minerals including zinc (L/A), and 3) 
administration of a placebo. Lutein in the supplements was in its non-esterified form to 
approximate food-equivalent lutein intake from spinach. The results of this study 
demonstrated that long-term supplementation (12 months) of lutein alone or in 
combination with additional carotenoids, antioxidants, vitamins, and minerals 
significantly improved MPOD, glare recovery, near visual acuity, and most measures of 
quality of vision.  Additionally, in the patients receiving L/A supplementation, there was 
no observed progression of AMD retinopathy. However, while it was shown that 
improved visual function resulted from lutein supplementation, the researchers of this 
study identified the preliminary nature of the results due to limitations such as the small 
number of subjects and the population studied, as well as a lack of statistical significance 
among the 3 groups.  
Another recent human supplementation study involving 45 subjects aged 60 or 
older investigated the association of 3 daily doses of orally ingested lutein supplements 
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with the serum levels of this carotenoid among 3 groups: 1) those without AMD, 2) those 
with middle stage AMD, and 3) those with end stage AMD (Moura et al., 2004; Chew et 
al., 2003). The supplemental doses of lutein, which contained 5% zeaxanthin, were 2.5, 5, 
and 10 mg/day. The data from this study showed a direct correlation between serum 
lutein concentrations and the 3 dose levels for all subjects, revealing that serum lutein 
concentration is dose-dependent. Serum concentrations of lutein increased in all subjects, 
and after 3 weeks of supplementation all groups reached a plateau. Subjects on doses of 
2.5, 5, and 10 mg/day of lutein reached a serum plateau of 450, 490, and 810 nmol/L, 
respectively. Subjects given a dose of 10 mg/day showed a 3- to 4-fold increase in serum 
lutein levels after 3 weeks, while the subjects receiving 2.5 and 5 mg/day lutein doses 
showed almost a 2-fold increase. There was no significant difference between these 2 
treatment groups (2.5 and 5 mg/day) until after week 25 of supplementation when 
subjects receiving 2.5 mg/day of lutein showed a decrease in serum plasma levels. It was 
shown that the presence or absence of AMD did not interfere with serum levels of lutein. 
Additionally, all subjects showed an increase in serum levels of 3’-oxolutein and 3’-
epilutein (lutein and zeaxanthin metabolites), which supports the metabolic pathways 
previously discussed in this proposal (see Figure 2) (Khachik et al., 1995; Khachik et al., 
1998; Khachik et al., 2002). Overall, the results from this study suggested that 
supplementation with a dose of at least 5 mg/day of lutein would provide the serum lutein 
level needed to lower the risk of AMD (Moura et al., 2004). This correlates with the 
plasma lutein level reported by the Eye Disease Case-Control Study to be associated with 
the lowest risk of AMD (670 nm/L) (EDCCS, 1993). 
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A series of recently published papers presented the results of a long-term study 
involving 18 Rhesus monkeys that were raised from birth until 7–16 years of age on a 
semipurified xanthophyll- free diet. Six of these primates were then fed pure lutein 
supplements (L-treated) and 6 with fed pure zeaxanthin supplements (Z-treated) at a daily 
dose of 2.2 mg/kg (3.9 µmol/kg) for 24–56 weeks; 6 were maintained on the xanthophyll-
free diet until death (Neuringer et al., 2004; Leung et al., 2004; Johnson et al., 2005; 
Leung et al., 2005).  These 3 groups were subdivided and assigned to diets containing 
either low or adequate n-3 fatty acids to see whether n-3 fatty acid status affects uptake of 
lutein or zeaxanthin into blood or tissues. Serum carotenoid levels and MPOD, which 
were measured at baseline and various intervals, were compared to control monkeys fed a 
stock diet (n=15) that provided a daily dose of ~150 µg (0.26 µmol)/kg of lutein and 
~135 µg (0.26 µmol)/kg of zeaxanthin. Reversed-phase HPLC was used for qualitative 
and quantitative analysis of serum, and two-wavelength monochromatic fundus 
reflectometry and monochromatic fundus photographs were used to determine MPOD. 
After primate sacrifice the central retinas were serially sectioned and the number of RPE 
cells were counted and compared to the data from 15 animals fed the stock diet described 
(Leung et al., 2004). 
Results showed that prior to supplementation, primates on the semipurified diet 
had no measurable serum lutein or zeaxanthin, while the stock diet- fed primates had a 
mean concentration of 0.074 ± 0.009 µmol/L of lutein (trans form only) and 0.081 ± 
0.007 µmol/L of combined cis and trans zeaxanthin (Neuringer et al., 2004). After 2 
weeks of supplementation the L-treated and Z-treated animals’ serum xanthophylls levels 
exceeded those of the stock diet- fed animals and reached levels approximately 10-fold for 
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lutein and 10- to 20-fold for zeaxanthin compared to those of the control group. The 
researchers noted high inter- individual variability as the reason for the serum level 
differences between the L-treated and Z-treated primates not reaching statistical 
significance  (p = 0.12) using repeated measures ANOVA. MPOD measured within the 
central 1mm of the retina of the xanthophyll- free primates were zero or very low. In the 
L-treated and Z-treated primates, MPODs increased during the first 24 to 32 weeks, but 
showed no consistent increases thereafter. No significant differences were observed 
between the L- and Z-treated animals. Both serum and ocular tissue data showed no 
effect of n-3 fatty acid status. It was also found that MPOD was not significantly related 
to total serum xanthophylls concentrations. While MPOD of the primates raised on a 
xanthophylls-free diet increased significantly, levels were only about  half that of the 
primates fed stock diets. 
Retina analysis revealed that foveal and parafoveal RPE cell densities increased 
with age and that the xanthophyll- free monkeys had a dip in the cell density profile of the 
RPE, unlike the control monkeys (Leung et al., 2004). After supplementation, n-3 fatty 
acid status seemed to interact with the supplemental lutein or zeaxanthin causing 
asymmetries in the RPE profile leading the researchers to conclude that adequate 
xanthophylls and n-3 fatty acids are essential for developing and maintaining normal 
distribution and/or maintenance of such a distribution. 
A third paper published about this group of xanthophyll- free primates examined 
the effects of the aforementioned lutein or zeaxanthin supplementation on serum, adipose 
tissue, and retina  concentrations of these carotenoids in the primates (Johnson et al., 
2005). Results showed that adipose tissue, as well as the serum and retinas of the 
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xanthophyll- free primates had no lutein or zeaxanthin, but that concentrations increased 
significantly in both the L-treated and Z-treated groups after supplementation. Further, 
lutein and non-dietary meso-zeaxanthin were detected in the retina of the L-treated 
animals, but only all-trans zeaxanthin and no t meso-zeaxanthin was detected in the Z-
treated animals. The researchers concluded that lutein is a precursor of meso-zeaxanthin. 
Another study of the xanthophyll- free primates examined the density of S-cone 
and rod cells in the foveal region (Leung et al., 2005). Serial sections 2 µm thick from the 
region containing the foveal depression were cut and outer segments of S-cones and 
nuclei of rods were counted. Results showed no consistent effect of n-3 fatty acid status 
or xanthophyll supplementation on the density profiles. There was, however, high inter-
individual variability. Data suggested that some of the animals were resistant to the  
imposed nutritional manipulations while others may have been affected. 
The study presented in this thesis followed a logical progression to the recent 
supplementation studies discussed in this review by investigating chronic high-dose 
supplementation with lutein or zeaxanthin in primates. While supplemental lutein at 
doses as high as 10 mg/day resulted in no interaction with other carotenoids, retinol, and 
α- and γ-tocopherols, and no adverse side effects, there were no data available for the 
effects of long-term supplementation with pharmaceutical doses of this carotenoid. 
Therefore, a study to begin investigating the effect of long-term supplementation with 
pharmaceutical doses of lutein was needed. Pharmaceutical doses refer to doses 
significantly higher than the average dietary intake levels. Also, there had been no studies 
to investigate the effects of long-term supplementation with pharmaceutical doses of 
zeaxanthin. This study also sought to investigate the effects of supplementation with a 1:1 
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combination of lutein and zeaxanthin on the plasma and tissue deposition of these 
carotenoids and their metabolites, which had not previously been investigated. Prior to 
the studies described in this thesis, the  only supplementation study that has been 
conducted with zeaxanthin was a short-term study involving three subjects supplemented 
with a dose of 10 mg/day (Khachik et al., 1995).  
Because of the invasive nature of the studies undertaken and the safety 
considerations associated with potential toxicity at high supplemental doses of lutein and 
zeaxanthin, the  use of an appropriate animal model was necessary. Rhesus Macaque 
primates were chosen for this study because of their similarities to humans; specifically, 
because of their similar metabolism, and their accumulation of lutein, zeaxanthin, and 
their metabolites in the serum and macula (Khachik et al., 1995). The challenging task 
of achieving optimal MPOD in females was posed in this study since MPOD has been 
shown to be lower in women than in men (Hammond et al., 1996). Thus, female Rhesus 
Macaques were chosen rather than males. As discussed throughout this thesis, the 
association between lutein and zeaxanthin and the prevention and treatment of AMD has 
been implied. Yet, while multi-center clinical trials with these carotenoids are in the 
planning stage by the NEI, metabolic and toxicity studies with lutein and zeaxanthin had 
not been conducted prior to this study. For this reason, the experiments outlined in this 
thesis were undertaken. 
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RESEARCH QUESTIONS 
 
 
1) How does long-term chronic supplementation of primates with lutein (9.34 mg/kg 
body weight and 0.66 mg/kg body weight), zeaxanthin (10 mg/kg body weight), 
and a 1:1 combination of the two (lutein and zeaxanthin each at a dose of 0.5 
mg/kg body weight) affect plasma concentrations and tissue deposition of these 
carotenoids and their metabolites over time? 
 
2) How is the concentration of lutein, zeaxanthin, and their metabolites in the ocular 
tissues of primates affected by long-term chronic supplementation with lutein 
and/or zeaxanthin? 
 
3) Can long-term supplementation of primates with lutein, zeaxanthin, and their 
combination provide insight into the metabolic pathways of these carotenoids? 
 
4)  Can long-term chronic supplementation of primates with pharmaceutical doses of 
lutein and zeaxanthin result in ocular toxicity and/or side effects? Pharmaceutical 
doses in this study refer to greater than 60-fold that of the highest amount 
administered (0.16 mg/kg body weight) in a recent human supplementation study 
(Moura et al., 2004; Chew et al., 2003)? 
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METHODS AND ANALYTICAL PROCEDURES 
 
 This study was conducted in collaboration with a number of investigators at 
various institutes of the University of Maryland (Baltimore) and the Wilmer Eye Institute 
(John Hopkins University, Baltimore) under the supervision of Dr. Frederick Khachik, 
the principal investigator. The project collaborators and their respective contributions are 
described herein. 
 
I. Study Investigators  
 Dr. Steve Shipley (DVM) who is a veterinary pathologist at the Veterinary 
Resources Division of the School of Medicine oversaw the care and carotenoid 
supplementation of the primates. The primates were housed at the Medical Student 
Teaching Facility (MSTF) building of the University of Maryland, Baltimore campus. 
Additionally, Dr. Shipley was responsible for conducting standard necropsy of all major 
organs from the sacrificed animals. 
All ocular exams were performed by either Dr. Scott Steidl or Dr. Mary Johnson 
at the University of Maryland, Baltimore School of Ophthalmology who are both board 
certified ophthalmologists.  
Dr. Gerard Lutty and Scott McLeod at the Wilmer Eye Institute at John’s Hopkins 
Medical Center performed complete histopathology of the primate retinas following 
euthanasia.  
 The toxicology evaluation was handled by Dr. Jodi Anne Flaws of the Program in 
Toxicology at the University of Maryland, School of Medicine, Baltimore.  
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 The qualitative and quantitative analysis of lutein, zeaxanthin, and their 
metabolites as well as vitamin A in the plasma and major organs and tissues (including 
ocular tissues) of primates were measured in the laboratory of Dr. Khachik (University of 
Maryland, College Park). 
 
II. Selection of Animal Model for Supplementation Studies with Lutein and Zeaxanthin 
 
 Due to the invasive nature of the study and the safety considerations associated 
with administering pharmaceutical doses of lutein and zeaxanthin, these studies needed to 
be conducted in an appropriate animal model. Primates were chosen because of their 
similar metabolism, and their accumulation of lutein, zeaxanthin, and their metabolites in 
the retina (Khachik et al., 1995). Therefore, female Rhesus Macaques (Macaca mulatta) 
were selected for the chronic supplementation studies with lutein, zeaxanthin, and their 
combination. This selection was based on the assumption that female Rhesus Macaques, 
similar to humans, may accumulate a lower macular pigment optical density (MPOD) 
than their male counterparts. In such a case, establishing a safe dose range at which lutein 
and zeaxanthin supplementation can result in an optimal MPOD was the challenging task 
undertaken in these studies. 
 
Study Primates 
Eighteen female Rhesus Macaque monkeys weighing between 2.6–3.2 kg were 
selected and divided into 3 treatment groups designated as L-treated (L at 9.34 mg/kg/day 
and Z at 0.66 mg/kg/day), Z-treated (Z at 10 mg/kg/day), L/Z-treated (L & Z each at 0.5 
mg/kg/day), and a control group. Each treatment group consisted of 5 animals that was 
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supplemented daily according to their assigned treatment. The control group consisted of 
3 primates that were not supplemented and served as the control group for all 3 studies. 
  
Procedures to Assure Comfort and Appropriate Analgesia 
 The laboratory animal veterinarian (Dr. Steve Shipley) was responsible for the 
selection of the most appropriate analgesic or anesthetic which best met the clinical and 
humane requirements without compromising the scientific data. For analgesia, 
buprenorphine was administered intramuscularly at a dose of 0.015 mg/kg body weight 
of primate. The Rhesus Macaque monkeys were anesthetized with ketamine at an 
intramuscular dose of 10 mg/kg body weight. The health of each animal was monitored 
by performing complete blood chemistry at various intervals throughout the study (Dr. 
Shipley). 
 
Institutional Animal Care and Use Committee (IACUC) Approval  
 The proposed studies were approved by the IACUC of the University of 
Maryland, Baltimore and the University of Maryland, College Park. (See attached letter, 
Appendix A). Tissue distribution complied with the tenets of the Declaration of Helsinki. 
 
III. Selection of Lutein and Zeaxanthin Doses for the Supplementation Studies 
 The oral daily doses chosen for the proposed studies, a lutein supplement of 9.34 mg/kg 
body weight, and a zeaxanthin supplement of 10 mg/kg body weight was approximately 60-
fold that of the highest dose of lutein administered in the study conducted by Moura et al. 
(Moura et al., 2004). These approximately 10 mg/kg of body weight doses of lutein or 
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zeaxanthin corresponded with approximately 149–303 times the average daily carotenoid 
intake in the U.S diet (estimated at 2–4 mg/day) (Chug-Ahuja et al., 1993). 
The L/Z-treated primates were supplemented daily with a combination of lutein 
and zeaxanthinin at the dose of 0.5 mg/kg body weight for each of these carotenoids. The 
lutein dose of 0.5 mg/kg body weight of primates was approximately 3-fold that of the 
highest dose of lutein supplemented to humans by Moura et al., and the zeaxanthin dose 
was approximately 10-fold that of the highest zeaxanthin received by subjects in the same 
study (Moura et al., 2004). 
It is relevant to note that the supplementation levels for the Lutein Supplementation 
Study and Zeaxanthin Supplementation Study are 60-fold that of the highest dose of a 
recent human supplementation, and thus allowed the examination of potential toxicity as 
well as the bioavailability at a relatively high level of supplementation (Moura et al., 
2004; Chew et al., 2003). 
 
Source of Lutein and Zeaxanthin Supplements 
 The supplemental doses of lutein and zeaxanthin were formulated by DSM 
Nutritional Products (Basel, Switzerland) into 5% water-dispersible beadlets. The water-
dispersible beadlet formulation is the most bioavailable form of these carotenoids. All 
supplements were stored in well-sealed aluminum bags within plastic bags at 5°C to 
protect them from moisture, air, and light. The stability and the composition of the 
beadlets were monitored by extraction and HPLC analysis throughout the study. 
 Supplements were given to the animals by adding each dose to a banana and 
providing it to the animal as a treat. 
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IV. Study Design 
The 3 supplementation studies were designated as the Lutein Supplementation 
Study, the Zeaxanthin Supplementation Study, and the Lutein/Zeaxanthin Supplementation 
Study. The Lutein Supplementation Study involved 5 female Rhesus Macaque monkeys 
(L-treated primates) that were supplemented daily with a high dose of lutein for 12 
months. The Zeaxanthin Supplementation Study involved the daily supplementation of 5 
female Rhesus Macaque monkeys with a high dose of zeaxanthin for 12 months, and the 
Lutein/Zeaxanthin Supplementation Study consisted of 5 female Rhesus Macaque 
monkeys that were supplemented daily with a 1:1 combination of lutein and zeaxanthin, 
each at the dose of 0.5 mg/kg for 12 months. The control group (n = 3) was not fed any 
supplements.  
Prior to this study, neither long-term high-dose supplementation with lutein or 
zeaxanthin nor the effects of supplementation with a combination of lutein and zeaxanthin in 
primates or humans had been investigated. The proposed study was designed to investigate 
the safety and efficacy of high-dose supplementation with lutein or zeaxanthin, and the 
effects of combined lutein and zeaxanthin supplementation on plasma and tissue carotenoid 
levels as well as the combined protective effect of these carotenoids against AMD. 
At baseline, months 6, 12, and 18 plasma samples were collected for the analysis of 
carotenoids and their metabolites. Major organs and tissues (liver, lung, colon, breast, kidney, 
spleen, ovary, cervix, adipose) including ocular tissues (retina, ciliary body, lens, iris) of the 
sacrificed animals were analyzed for carotenoids and their metabolites. Additionally, the 
primates’ weights were recorded at baseline and at months 6, 12, and 18. 
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Several other biomarkers were analyzed by other co-investigators of this study 
including urinary creatinine and proteins, histopathology of retinas, and ocular exams that 
included fundus examination and photography, as well as multifocal ERGs. The 
abovementioned urinary analyses and ocular assessments were performed at baseline, months 
6, 12, and 18. Complete histopathology of the retina and in vitro culture of primate 
keratinocyte and retinal cells were completed at either month 12 or month 18 depending on 
which time point the primate was sacrificed. 
 
The Control Group 
The control group consisted of 3 female Rhesus monkeys that were housed with 
the Lutein Supplementation Study animals and served as the control group for the entire 
study. These animals were fed a standardized monkey diet, which is described later in 
this section, and was identical to that fed to the other study primates. The collection of 
biomarkers for the control group followed the same timeline as that of the animals in the 
Lutein Supplementation Study. One control primate was sacrificed at month 12 and the 
remaining 2 were sacrificed at month 18. 
 
The Lutein Supplementation Study 
 A total of 5 female Rhesus monkeys comprised the treatment group. The L-
treated primates of the Lutein Supplementation Study received daily lutein supplements 
at the dose of 10 mg/kg for the duration of 12 months. The lutein in these supplements 
contained approximately 6.6% zeaxanthin by weight so each 10 mg dose consisted of 
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approximately 9.34 mg of lutein and 0.66 mg of zeaxanthin. Therefore, the L-treated 
primates actually received 9.34 mg/kg of lutein and 0.66 mg/kg of zeaxanthin daily. 
 Due to the high supplemental dose given to the primates in the L-treated group, 
statistically significant differences in measurements of the various biomarkers at the 
months 6 and 12 of supplementation were expected. At the end of the supplementation 
period, 2 of the L-treated primates were sacrificed and the remaining 3 animals remained 
under observation for 6 months to assess whether there was any toxicity associated with 
these high supplemental doses. At month 18, the remaining L-treated primates were 
sacrificed.  
 
The Zeaxanthin Supplementation Study 
 A total of 5 female Rhesus Macaque monkeys were supplemented daily with 
zeaxanthin at the dose of 10 mg/kg body weight for 12 months. At the end of the 
supplementation period (month 12), 2 of the Z-treated primates were sacrificed and the 
remaining 3 animals were kept under observation for 6 months. After 6 months of post-
supplementation observation (month 18), the remaining 3 Z-treated primates were 
sacrificed.  
 
The Lutein/Zeaxanthin Supplementation Study 
 A total of 5 female Rhesus Macaques monkeys were supplemented daily with a 
1:1 mixture of lutein and zeaxanthin to provide a lutein dose of 0.5 mg/kg body weight 
and a zeaxanthin dose of 0.5 mg/kg body weight for 12 months. All 5 of the L/Z-treated 
primates were sacrificed after 12 months of supplementation. 
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V. Collection, Handling, and Shipping of the Primate Plasma and Tissue Samples  
for Measurement of Biomarkers  
 
Collection of Plasma Samples for Carotenoid Analysis 
 
Two fasting blood samples, 10 mL each, were drawn from each primate via 
venipuncture at the specified intervals for these studies. The collected blood samples 
were immediately placed on ice, protected from light, and centrifuged (1000 x g) for 20 
minutes at 4°C within 1 hour after collection to separate the plasma. Approximately 4−5 
ml of plasma was expected from each 10 ml blood sample drawn from each primate. 
The plasma samples were dated and coded with the appropriate number for each 
primate known only to the study coordinator in Baltimore (Dr. Shipley) and stored at -70°C 
or lower. The samples for carotenoid analysis were transported to our laboratories on Dry 
Ice for analysis. Upon arrival, the plasma samples were immediately stored at -70°C; the 
samples were extracted and analyzed by HPLC as promptly as possible. 
 
Method of Euthanasia  
 
The Rhesus Macaque monkeys were euthanized at the end of the study. The 
animals were first anesthetized with an intramuscular dose of ketamine of 10 mg/kg body 
weight. The animals were then humanely euthanized with a 100 mg/kg dose of 
pentobarbitol injected intravenously consistent with the 1993 Report of the American 
Veterinary Medical Association panel on euthanasia. The procedures were performed and 
monitored by Dr. Shipley and his colleagues. 
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Collection, Handling, and Shipping of Tissues and Organs 
 
At sacrifice, all tissues and organs to be analyzed were removed, dated, and coded 
with the appropriate number for each primate known only to the study coordinator at 
Baltimore (Dr. Shipley) and stored at -70°C or lower until they were transported on Dry 
Ice to our laboratories (UMD, College Park) for analysis. 
One of the eyes from each primate was dissected under the supervision of Dr. 
Steidl or Dr. Johnson and the various ocular tissues were stored at -70°C or lower. The 
dissected eye tissues of one eye from each animal was labeled and coded with the 
appropriate number for each primate known only to the study coordinator at Baltimore 
(Dr. Shipley) and stored at -70°C or lower until they were shipped via Express Mail on 
Dry Ice to our laboratories (UMD, College Park) for analysis. 
The other intact eye from each primate was labeled and coded with an appropriate 
number for each primate and stored at -70°C or lower until they were transported to Dr. 
Gerard Lutty (Wilmer Eye Institute, JHU, Baltimore) for histhopathology.  
 
 
Collection of Urine for Analysis of Urinary Creatinine and Proteins 
 
Urine samples for creatinine and protein analyses were collected by placing the 
animals in metabolic cages with free access to water for 24-hour urine collections. The 
urine samples was collected in foil-wrapped containers containing sodium carbonate, 24-
hour urine volumes was measured and recorded prior to being frozen at –80°C.  
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VI. Measurement of Biomarkers  
Biomarkers of Toxicity 
 
Specific biomarkers associated with skin, liver and kidney function were probed 
as these organs are actively involved in the metabolism and excretion of various organic 
substances and tend to concentrate dietary carotenoids. The 3 toxicological evaluations 
that were conducted by Dr. Flaws included: 1) culturing of skin epithelial cells and 
consequent examination for any alterations in gene expression patterns; 2) urinary 
creatinine excretion patterns and potential hepatoxic effects; and 3) identification of 
chemical-specific urinary proteins using N-terminal sequence analysis which was 
performed by Dr. Flaws of the University of Maryland, School of Medicine, Baltimore. 
 
Ocular Toxicity 
Possible retinopathy was monitored throughout the supplementation trials. Whenever 
the monkeys’ eyes were dilated, a board certified ophthalmologist (Dr. Steidl or Dr. 
Johnson) examined the retinas with indirect ophthalmoscopy. Any detected abnormalities 
were recorded using Fundus photography. Histopathology of the retina was performed by 
Dr. Gerard Lutty and Scott McLeod (Wilmer Eye Institute). Dr. Mary Johnson also 
performed multifocal, scotopic, and photopic electroretinography. At various intervals 
(baseline, months 6, 12 and 18) multifocal ERGs was taken from the monkeys to monitor 
for any electrophysiological evidence of carotenoid- induced toxicity. 
 
Primate Plasma Analysis 
 Plasma that was collected from each of the treatment and control primates at the 
various intervals (baseline, months 6, 12, and 18) was sent to our laboratories for 
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qualitative and quantitative analysis (UMD, College Park). Normal phase HPLC-
UV/visible-photodiode array detection was employed for identification and quantification 
of lutein, zeaxanthin and related geometrical isomers, as well as metabolites and retinol. 
The procedures for plasma carotenoid extraction and HPLC analysis is described later in 
this section. 
 
Primate Tissue Analysis 
The qualitative and quantitative distributions of carotenoids in major organs and 
tissues [adipose, cervix, colon, kidney, liver, lung, breast, spleen, ovaries] as well as 
ocular tissues (retina, iris, lens, ciliary body) of the necropsied primates were determined 
in our laboratories (UMD, College Park) by extraction and HPLC analysis. 
Normal phase HPLC-UV/visible photodiode array detection was employed for 
identification and quantification of lutein, zeaxanthin and related geometrical isomers as 
well as their metabolites and retinol. HPLC-UV/visible photodiode array detection on a 
chiral column was employed for the identification and quantification of (3R,3’R)-
zeaxanthin and (3R,3’S; meso)-zeaxanthin in the retina tissues. These procedures are 
described later in this thesis. 
 
VII. Standardized Monkey Diet 
 The standardized monkey diet was purchased in bulk once every 6 weeks from 
Harlan Tekland (Madison, WI). The feed chosen as the standard diet, Harlan Tekland-
8775, contained the highest concentrations of lutein and zeaxanthin available (total lutein 
content: 5.49 µg/g feed; total zeaxanthin content: 1.47 µg/g feed). Prior to the beginning 
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of the supplementation period of these studies, a sample of this feed (Harlan Telkand-
8775) was extracted and analyzed by HPLC to determine the carotenoid levels of the diet.  
All primates in the study were kept on the same standard monkey diet. The diet 
came in the form of biscuits, each weighing approximately 12 grams. Each monkey ate 
between 15 and 20 monkey biscuits per day equaling 180 to 240 grams of feed. This 
amount of feed supplied the primates with between 0.99 and 1.32 mg of lutein, and 0.26 
and 0.35 mg of zeaxanthin per day. The light cycle for all the animals was maintained at 
12 hours of light and 12 hours of dark. 
 
VIII. Extraction and Analysis of Lutein and Zeaxanthin Beadlets 
A suspension of 300 mg of the beadlets of lutein or zeaxanthin and approximately 
100 mg of protease Maxatase P 440,000 (DSM Nutritional Products, Basel, Switzerland) 
in 10 mL of deionized water in a 100 mL volumetric flask was sonicated in an ultrasonic 
water bath for 30 minutes. Ethanol (30 mL) and dichloromethane (40 mL) were added 
and the mixture was sonicated for 10 minutes. The solution was brought up to a final 
volume of 100 mL using dichloromethane, and after mixing, the solids were allowed to 
settle. A 1 mL aliquot of the solution was transferred into a vial and evaporated to 
dryness under nitrogen. The residue was dissolved in the HPLC eluent (a 3:1 mixture of 
hexane:dichloromethane) and filtered through a 0.45 µm disposable polyvinylidene 
fluoride filter assembly (Acrodisk; VWR Scientific products, Bridgeport, NJ) into a 25 
mL volumetric flask and brought up to volume for HPLC analysis on a silica-based nitrile 
bonded column according to our published procedures (Khachik et al., 1992; Khachik et 
al., 1997a; ). For spectrophotometric analysis, a 1 mL aliquot of the solution of lutein or 
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zeaxanthin was similarly filtered into 25 mL volumetric flask and brought up to volume 
using ethanol. The concentrations of lutein (λmax = 445 nm, E1% = 2550) and zeaxanthin 
(λmax = 450 nm, E1% = 2540) in the extracts were measured in ethanol at their corresponding 
absorption maximum and extinction coefficient (Britton, 1995). 
 
IX. Extraction of Carotenoids from Primate Plasma 
 All primate plasma samples were shipped from the University of Maryland, 
Baltimore to the laboratory of Dr. Khachik on dry ice. Upon receipt, primate plasma 
samples were catalogued and stored in a freezer at -80°C. Primate plasma samples were 
first thawed, and accurately measured using a disposable syringe (latex-free syringe, 5 
mL, VWR Scientific Products) and then transferred into a 50 mL centrifuge tube (Blue 
Max™, polypropylene conical tube). Each sample was treated with 5 mL ethanol to 
precipitate the proteins. The plasma carotenoids were extracted by adding tetrahydrofuran 
(THF) containing 0.1 % 2,6-di-tert-butyl-4-methylphenol (BHT); the amount of THF 
added was equal to the plasma volume plus the volume of ethano l previously added. The 
tube was then vortexed for 2 minutes, and then centrifuged at 2000 g for 5 minutes to 
separate the protein solids from the supernatant liquid. The extract was removed with a 
pipette and saved, and the solid was reextracted by adding 5 mL of THF (with 0.1% 
BHT) to the protein residue and then repeating the vortexing and centrifuging processes 
as outlined above. The combined extracts were evaporated to dryness using an evaporator 
(RapidVap Vacuum, model 79000-02, LABCONCO Co., MO). The dried extract was 
dissolved in dichloromethane, sonicated, centrifuged, and then filtered through a 0.45 µm 
disposable polyvinyl fluoride filter (VWR, Scientific Products, NJ) into a 5mL graduated 
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micro-sample vial. The solvent was evaporated under nitrogen (Nitrogen Evaporator, N-
EVAP™ 112, Organomation Associates, Inc., MA) and 250 µL of the HPLC injection solvent  
(hexane 75%, dichloromethane 25%, methanol 0.35%, N,N-diisopropylethylamine 0.10%) 
was added to the dried extract. The vial was then sonicated and centrifuged. For normal 
phase HPLC, 120 µL of the extract was transferred to a chromatography vial and 50 µL 
was injected into the HPLC system. The remaining extract was stored at -80°C in the 
event that the HPLC analysis needed to be repeated.  
 
X. Extraction of Carotenoids from Primate Tissues 
 All primate tissue samples were shipped on dry ice to Dr. Khachik’s laboratory 
(UMD, College Park). Upon receipt, primate tissue samples were stored in a freezer at -80°C. 
Tissue samples were thawed to room temperature and blood was removed by washing 
with water; the excess water was removed by blotting the tissue samples with paper 
towels and applying gentle pressure with a mortar. Each tissue sample was cut into 
smaller pieces to facilitate the extraction of carotenoids by increasing the surface area. 
Samples were accurately weighed and then placed into a beaker and anhydrous sodium 
sulfate (10% by weight of the tissue) and sufficient volume of tetrahydrofuran (THF) 
containing 0.1 % BHT to completely cover the sample was then added. The  samples were 
sonicated for 1 hour in an ice bath (10−15°C) and the extract was then decanted into a 
round bottom flask. The tissue was reextracted by adding more THF, crushing the sample 
with a mortar, and then sonicating for 30 minutes. The extracts were combined and 
filtered on a Buchner funnel. The solids were washed with THF and the filtrate was 
transferred to the round bottom flask and combined with previously saved extracts. The 
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combined extract was then evaporated on a rotary evaporator at 40°C. The round bottom 
flask was thoroughly rinsed with dichloromethane, sonicated to remove the residual 
sample from the sides of the flask, and the extract was then filtered through a 0.45 µm 
disposable polyvinyl fluoride filter (VWR, Scientific Products, NJ) and diluted to an 
appropriate volume. The solvent was evaporated to dryness under nitrogen (Evaporator, 
N-EVAP™ 112, Organomation Associaties, Inc., MA). An appropriate volume of HPLC 
injection solvent was added to the residue and depending upon the carotenoid 
concentration, the sample was diluted to a final volume of 0.3, 1.0, 3.0, or 5.0 mL. The 
extract (120 µL) was transferred to a chromatography vial and 50 µL was injected into 
the HPLC system. The remaining sample was stored at -80°C in the event that additional 
HPLC analysis was required. 
 
XI. HPLC Analysis of Carotenoids  
Carotenoid Separation by HPLC Normal Phase Column 
 Plasma and tissue extracts were analyzed using a normal phase HPLC system 
according to a published procedure (Khachik et al., 1997b). HPLC separations were 
carried out on a silica-based nitrile bonded HPLC column (Spherisorb®; 250 mm length x 
4.6 mm i.d.; 5 µm spherical particle; Waters Company, U.S.). The column was protected 
with a nitrile-bonded guard cartridge (3 cm length x 4.6 mm i.d.; 5 µm spherical particle). 
The mobile phase consisted of an isocratic mixture of hexanes (75%), dichloromethane 
(25%), methanol (0.35%), and N,N-diisopropylethylamine (DIPEA, 0.1%). The column 
flow rate was 0.8 ml/min. HPLC runs were simultaneously monitored at 325, 446, and 
456 nm. Carotenoids were identified by comparison of their HPLC retention times and 
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UV-visible absorption spectra with those of authentic standards. Carotenoids were 
quantified from calibration tables obtained from the HPLC response factors of standards 
at five or six known concentrations using linear regression analysis. 
 For the retina tissues, zeaxanthin concentrations were initially determined using a 
normal phase column, but because dietary zeaxanthin and nondietary meso-zeaxanthin 
cannot be separated by this method, further HPLC analysis of the extracts on a chiral 
column was necessary. 
 
Carotenoid Separation of Retina Tissue Extracts by HPLC Chiral Column 
 Retina extracts were also analyzed on a chiral HPLC column according to a 
previously published procedure (Khachik et al., 2003). HPLC separations were carried 
out on a [amylose tris-(3,5-dimethylphenyl-carbamate) coated on 10 µm silica gel] chiral 
HPLC column. This allowed for the simultaneous separation of (3R,3’R)-zeaxanthin,  
(3R,3’S; meso)-zeaxanthin, (3S,3’S)-zeaxanthin, (3R,3’R,6’R)- lutein, and 3’-epilutein. 
This analysis was not performed on the ciliary body, iris, or lens tissues because the 
concentrations of zeaxanthin and meso-zeaxanthin were too low for chiral HPLC 
analysis. Therefore, only the total concentration of (3R,3’S; meso)-zeaxanthin and dietary 
(3R,3’R)-zeaxanthin were reported. 
 
XII. Accuracy and Reproducibility of HPLC Results 
 The accuracy of extractions was monitored regularly by the extraction, 
identification, and quantification of carotenoids in standardized Red Cross plasma. No 
internal standard in the extraction and analysis of various samples was employed because 
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of the possibility that its HPLC peak could interfere with the presence of possible 
unknown carotenoids. 
 The reproducibility of the normal phase HPLC analysis of carotenoids was 
monitored regularly by HPLC analysis of a calibrated solution containing known 
concentrations of (3R,3’R,6’R)- lutein, (3R,3’R)-zeaxanthin, and 3’-epilutein. 
 
XIII. Statistical Analysis 
 Statistical analysis of the data obtained from plasma and ocular tissue carotenoid 
analyses were performed by Analysis of Variance and Covariance (ANCOVA) with 
repeated measurements using SAS version 8.2 (SAS Institute Inc., Cary, NC). The least 
significant difference (LSD) protected test was used to determine which treatment 
groups’ mean plasma and ocular tissue levels of  lutein, zeaxanthin, and their metabolites 
were significantly different from one another at baseline and months 6, 12, and 18. 
Similarly, the interactions between the body weight or age of the animals and the plasma 
lutein and zeaxanthin levels were also examined. A p value of less than 0.05 was 
considered statistically significant.  
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RESULTS 
Lutein Supplementation Study: Daily Supplementation of Female Rhesus Macaque 
Monkeys with Lutein (9.34 mg/kg L, 0.66 mg/kg Z) for 12 Months  
 
Plasma Carotenoid Analysis of Primates in the Lutein Supplementation Study 
 The plasma of 3 control and 5 L-treated primates was collected at baseline, month 
6, and month 12 of the 12-month supplementation period. The control and treatment 
groups ate the same standardized monkey diet which provided each primate with 0.99–
1.32 mg of lutein and 0.26–0.35 mg of zeaxanthin per day. The bioavailability of these 
carotenoids in the feed was not known. At month 12, one control and 2 L-treated primates 
were euthanized. The remaining animals were kept under observation for 6 months after 
the end of the supplementation period and then sacrificed. Plasma samples from these primates 
were also taken at month 18, at the conclusion of the 6-month post-supplementation period. All 
plasma samples were analyzed for lutein, zeaxanthin, their metabolites, and retinol. 
The mean plasma lutein levels for primates in the control group at baseline (0.244 
± 0.021 µmol/L) compared to the baseline values for the primates in the L-treated group 
(0.223 ± 0.023 µmol/L) were not significantly different (p = 0.84). The data fo r plasma 
lutein concentrations are shown in Table 1. The mean plasma lutein concentration for the 
control group at baseline was not significantly different compared to the mean levels 
measured at month 6 (0.235 ± 0.024 µmol/L; p = 0.89) and month 12 (0.228 ± 0.041 
µmol/L; p = 0.84). However, the mean plasma lutein level of the L-treated group at 
baseline (0.223 ± 0.023 µmol/L) was significantly different compared to the mean levels at 
month 6 (0.573 ± 0.079 µmol/L; p < 0.001) and at month 12 (0.709 ± 0.101 µmol/L; p < 
0.001) (Figure 4). Mean plasma lutein levels for the L-treated group were also significantly 
different (p = 0.01) between 6 and 12 months. The mean plasma lutein level for the L-treated 
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primates at month 18 (0.227 ± 0.05 µmol/L) was not significantly different than their mean 
baseline levels or than the mean levels of the control primates. 
 
Table 1. Plasma lutein concentrations (µmol/L, mean ± SEM)* of the control and the L-treated 
primates (9.34 mg/kg L and 0.66 mg/kg Z daily for 12 months) at baseline, months 6, 12, and 18.  
Total Lutein Concentration in Plasma (µmol/L) † 
Primate ID Baseline  6 Months  12 Months  18 Months  
Control Group 
RQ4107 0.253 0.280 0.309 0.257 
RQ4142 0.275 0.227 0.181 0.166 
RQ4079 0.205 0.199 0.194 --‡ 
Mean ± SEM 0.244 ± 0.021a 0.235 ± 0.024a 0.228 ± 0.041a 0.212 ± 0.046a 
Treatment Group 
RQ4087 0.122 0.315 0.411 --‡ 
RQ4078 0.253 0.801 0.961 0.250 
RQ4122 0.253 0.582 0.798 --‡ 
RQ4189 0.241 0.524 0.537 0.135 
RQ4175 0.247 0.644 0.838 0.295 
Mean ± SEM 0.223 ± 0.084a 0.573 ± 0.062b 0.709 ± 0.070c 0.227 ± 0.052a  
* SEM = standard error of the mean; † Total lutein refers to the combined concentrations of all-trans-lutein 
and its cis-isomers in plasma; ‡ Primate sacrificed at the end of 12-month supplementation period; Values 
with different letters (a, b, c) denote statistical significance across each row and within each column  
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Figure 4. Changes in the plasma concentrations of lutein (µmol/L) in the control and the L-treated 
primates during the 12-month supplementation period and 6 months post-supplementation. 
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Figure 5. Changes in the mean (±SEM) plasma concentrations of lutein (µmol/L) for the L-
treated group (9.34 mg/kg L and 0.66 mg/kg Z daily for 12 months) and the control group at 
baseline, months 6, 12, and 18. 
 
 
 
 It is critical to note that the lutein supplements given to the primates contained 
approximately 6.6% zeaxanthin, thus supplying the L-treated primates with a daily dose 
of 9.34 mg/kg (16.42 µmol/kg) of lutein plus 0.66 mg/kg (1.16 µmol/kg) of zeaxanthin. 
Extraction and HPLC analysis of lutein (and zeaxanthin) beadlets revealed no significant 
changes in quantitative and qualitative profiles throughout the study. As shown in Table 2 
and Figure 6, the plasma concentrations of zeaxanthin in the L-treated group increased 
during the 12-month supplementation period. The mean plasma zeaxanthin level at 
baseline for primates in the control group (0.118 ± 0.009 µmol/L) compared with the 
mean baseline value for the primates in the L-treated group (0.111 ± 0.018 µmol/L) was 
not significantly different (p = 0.80) (Figure 7). At baseline, the mean plasma zeaxanthin 
level for the control group (0.118 ± 0.009 µmol/L) was not significantly different from 
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the mean levels measured at 6 months (0.069 ± 0.010 µmol/L; p = 0.05) and 12 months 
(0.120 ± 0.027 µmol/L; p = 0.92). For the L-treated group, the mean plasma zeaxanthin 
level at baseline (0.111 ± 0.018 µmol/L) was not significantly different than the  mean 
level at six months (0.123 ± 0.018 µmol/L; p = 0.09), but was significantly lower (p < 
0.001) than the mean plasma level at 12 months (0.147 ± 0.018 µmol/L). The mean 
plasma zeaxanthin levels were also significantly different (p = 0.005) between months 6 
and 12. At the end of month 18, 6 months post-supplementation, the mean plasma 
zeaxanthin level of the L-treated group (0.107 ± 0.027 µmol/L) had nearly returned to its 
baseline level (0.111 ± 0.018 µmol/L). 
 
 
Table 2. Plasma zeaxanthin concentrations (µmol/L) in the control and the L-treated primates 
(9.34 mg/kg L and 0.66 mg/kg Z daily for 12 months) at baseline, months 6, 12, and 18. 
Total Zeaxanthin Concentrations in Plasma (µmol/L)* 
 
Primate ID 
Baseline  6 Months  12 Months  18 Months  
Control Group 
RQ4107 0.133 0.081 0.174 0.147 
RQ4142 0.129 0.079 0.094 0.095 
RQ4079 0.092 0.049 0.091 --† 
Mean ± SEMb 0.118 ± 0.009a 0.069 ± 0.010a 0.120 ± 0.027a 0.120 ± 0.026a 
 
Treatment Group 
RQ4087 
 
0.061 
 
0.058 
 
0.840 
 
--† 
RQ4078 0.116 0.142 0.167 0.132 
RQ4122 0.136 0.161 0.186 --† 
RQ4189 0.129 0.119 0.141 0.070 
RQ4175 0.111 0.133 0.155 0.118 
Mean ± SEM 0.111 ± 0.018a 0.123 ± 0.018a 0.147 ± 0.018b 0.107 ± 0.027a 
* Total zeaxanthin refers to the combined concentrations of all-trans-zeaxanthin and its cis-isomers in plasma;    
† Primate sacrificed at the end of 12-month supplementation period; ‡ SEM = standard error of the mean; 
Values with different letters (a, b) denote statistical significance across each row and within each column  
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Figure 6. Changes in plasma concentrations of zeaxanthin  (µmol/L) in the L-treated group (9.34 
mg/kg L and 0.66 mg/kg Z daily for 12 months) and the control group at baseline, months 6, 12, and 18. 
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Figure 7. Changes in the mean plasma concentrations of zeaxanthin (µmol/L) in the L-treated 
primates (9.34 mg/kg L and 0.66 mg/kg Z daily for 12 months) and the control primates at 
baseline, months 6, 12, and 18. 
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Plasma Concentrations of Lutein and Zeaxanthin Metabolites in Primates in the 
Lutein Supplementation Study 
 
 Two of the lutein and zeaxanthin metabolites analyzed in the plasma of the L-
treated primates were (3R,3’S,6’R)-lutein (3’-epilutein) and 3-hydroxy-β,ε−caroten-3’-one 
(3’-oxolutein). The structures of these metabolites are shown in Figure 8, and the proposed 
pathway for their in vivo formation is depicted in Figure 2. Plasma concentrations of these 
carotenoids were measured at baseline, months 6 and 12, and also at 6 months post-
supplementation (month 18) in the primates that were kept under observation after the 
supplementation period (n = 3).  
 The data for 3’-epilutein plasma levels, presented in Table 3, show that the mean 
plasma 3’-epilutein level for the control group at baseline (0.012 ± 0.0012 µmol/L) and 
the mean baseline level for the L-treated group (0.013 ± 0.0028 µmol/L) were not 
significantly different (p = 0.92). Additionally, the mean plasma 3’-epilutein level for the 
control group at baseline compared to that at 6 months (0.0073 ± 0.0021 µmol/L) was not 
significantly different (p = 0.13), nor was the mean baseline value significantly different 
(p = 0.29) from the mean level for the control group at month 12 (0.0089 ± 0.0021 
µmol/L). See Figure 9 for a comparison of the mean 3’-epilutein levels for the control and the 
L-treated primates. While the mean plasma 3’-epilutein levels for the L-treated group were 
not significantly different between baseline (0.0173 ± 0.0028 µmol/L) and month 6 (0.0182 ± 
0.0042 µmol/L; p = 0.60), the mean 3’-epilutein level at month 12 (0.0423 ± 0.0113 µmol/L) 
was significantly higher (p = 0.01) than the mean level at baseline. For the L-treated group, 
the mean plasma concentrations of 3’-epilutein between months 6 and 12 were also 
significantly different (p = 0.03). The mean plasma 3’-epilutein level for the L-treated group 
at month 18 had returned to near the mean baseline level. 
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Figure 8. Lutein and zeaxanthin metabolites measured in the plasma of the study primates: (3R, 
3’S, 6’R)-lutein (3’-epilutein) and 3-hydroxy-β,ε−caroten-3’-one (3’-oxolutein). 
 
 
 
 
 
Results from plasma carotenoid analysis showed an increase in 3’-oxolutein levels 
in the L-treated primates. 3’-Oxolutein is presumably formed from in vivo oxidation of 
dietary or supplemental lutein. The data for 3’-oxolutein levels in L-treated primates 
compared to the control primates are shown in Table 4.  
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Table 3. Plasma concentrations (µmol/L) of 3’-epilutein in the L-treated group (9.34 mg/kg L and 
0.66 mg/kg Z daily for 12 months) and the control group at baseline, months 6, 12, and at 6 months 
post-supplementation (month 18). 
3’-Epilutein Concentration in Plasma (µmol/L) 
Primate ID Baseline  6 Months  12 Months  18 Months  
Control Group 
                        RQ4107 0.0106 0.0113 0.0093 0.0104 
                        RQ4142 0.0139 0.0070 0.0051 0.0086 
                        RQ4079 0.0114 0.0037 0.0123 --† 
              Mean ± SEMb  0.0120 ± 0.001a 
 
0.0074 ± 0.002a 
 
0.0090 ± 0.002a 
 
0.0095± 0.001a 
 
Treatment Group 
                        RQ4087 0.0060 0.0051 0.0204 --† 
                        RQ4078 0.0090 0.0185 0.0410 0.0090 
                        RQ4122 0.0211 0.0150 0.0835 --† 
                        RQ4189 0.0102 0.0312 0.0236 0.0102 
                        RQ4175 0.0173 0.0208 0.0431 0.0173 
               Mean ± SEM 0.0127 ±  0.003a 0.0181 ± 0.004a 0.0422 ± 0.011b 0.0122 ± 0.003c 
† Primate sacrificed after 12 months of supplementation; ‡ SEM = standard error of mean; Values with 
different letters (a, b, c) denote statistical significance across each row and within each column. 
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Figure 9. Changes in the mean plasma concentrations of 3’-epilutein in the control and the L-
treated primates at baseline, months 6, 12, and 18. 
 
 
At baseline, the mean plasma concentration of 3’-oxolutein for primates in the 
control group (0.041 ± 0.01 µmol/L) compared with the mean value at baseline for the 
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primates in the treatment group (0.029 ± 0.004 µmol/L) was not significantly different 
(p = 0.49) (Figure 10). Also, the mean concentrations of 3’-oxolutein for the control 
group at baseline and at month 6 (0.0334 ± 0.010 µmol/L) were not significantly 
different (p = 0.59) nor were the mean values at baseline and month 12 (0.0327 ± 0.010 
µmol/L; p = 0.56). However, the mean concentration of 3’-oxolutein for the primates in 
the L-treated group at baseline (0.029 ± 0.004 µmol/L) was significantly lower than the 
mean levels at month 6 (0.071  ± 0.012 µmol/L; p = 0.001) and month 12 (0.085 ± 0.012 
µmol/L; p < 0.0010). However, the mean concentrations of 3’-oxolutein in the plasma of 
the L-treated primates were not significantly different (p = 0.19) between months 6 and 
12 of the supplementation period. The mean plasma 3’-oxolutein level for the treatment 
group 6 months after the end of the supplementation period (0.0319 ± 0.009 µmol/L) 
returned to the mean baseline level (0.0290 ± 0.005 µmol/L). 
 
 
Table 4. Plasma concentrations (µmol/L) of 3’-oxolutein in the control group and the L-treated group 
(9.34 mg/kg L and 0.66 mg/kg Z daily for 12 months) at baseline, months 6, 12, and at 18. 
3’-Oxolutein Concentration in Plasma (µmol/L) 
Primate ID Baseline  6 Months  12 Months  18 Months  
Control Group 
                          RQ4107 0.0625 0.0291 0.0521 0.0338 
                          RQ4142 0.0362 0.0518 0.0239 0.0198 
                          RQ4079 0.0224 0.0189 0.0223 --a 
                Mean ±SEMb 0.0405 ± 0.012a 
 
0.0334 ± 0.010a 
 
0.0327 ± 0.010a 
 
0.0268 ± 0.00 a 
 
Treatment Group 
                          RQ4087 0.0157 0.0309 0.0505 --a 
                          RQ4078 0.0247 0.0758 0.0891 0.0281 
                          RQ4122 0.0353 0.0627 0.1168 --a 
                          RQ4189 0.0272 0.0819 0.0237 0.0191 
                          RQ4175 0.0417 0.1005 0.0637 0.0484 
                 Mean ± SEM 0.0290 ± 0.004a 0.0714 ± 0.012b 0.0852 ± 0.012b 0.0319± 0.009a 
a Primate sacrificed after  12 month supplementation period; b SEM = standard error of mean; Values with 
different letters (a, b, c) denote statistical significance across each row and within each column. 
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Figure 10. Changes in the mean plasma concentrations of 3’-oxolutein (µmol/L) in the L-treated 
primates (9.34 mg/kg L and 0.66 mg/kg Z daily for 12 months) and the control primates at baseline 
and months 6, 12, and 18. 
 
 
 
 
Carotenoid Concentrations in the Ocular Tissues of Primates in the Lutein Supple-
mentation Study 
 
After 12 months of supplementation, one primate from the control group and 2 
primates from the group supplemented daily with lutein (9.34 mg/kg) and a lower dose of 
zeaxanthin (0.66 mg/kg) were sacrificed. The ocular tissues (retina, ciliary body, iris, 
lens) from one eye of each animal were extracted and analyzed for carotenoids and their 
metabolites (Table 5). Six months after the end of the supplementation period (month 
18), the remaining 2 control and 3 L-treated primates were sacrificed. The ocular tissues 
described above from one eye of each animal were similarly extracted and analyzed for 
carotenoids and their metabolites. In addition to 3’-oxolutein, meso-zeaxanthin, a 
metabolite of lutein that is absent in plasma was also measured in the retinas of the  
primates. Because the primates in the control group were not supplemented with lutein 
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and/or zeaxanthin, the mean values for carotenoid concentrations in the ocular tissues of 
all 3 animals were used for the statistical analysis. The data for the mean values of each 
group are shown in Table 5 and the complete data for each primate are included as 
Appendix B. 
 
 
Table 5. Concentrations (ng/tissue; mean ± SEM) of lutein, zeaxanthin, meso-zeaxanthin, and 3’-
oxolutein in the ocular tissues of  2 L-treated primates (9.34 mg/kg L and 0.66 mg/kg Z daily for 12 
months) at month 12, and 3 L-treated primates at month 18 in comparison with the mean levels 
for the control primates (n = 3).  
Concentrations (ng/tissue) of Carotenoids and Their Metabolites 
in Primates Ocular Tissues * 
Retina Ciliary Body Iris Lens  
 
 
Primate 
ID lutein zea-
xanthin 
meso-
zea-
xanthin 
3’-oxo-
lutein 
lutein zea-
xanthin 
3’-oxo-
lutein 
lutein lutein 
Control 
Mean ± 
SEM 
 
 
11.05± 
2.19 
(0.117)** 
 
4.78± 
0.62 
(0.117) 
 
3.20± 
0.30 
(0.117) 
 
1.24± 
0.10 
(0.117) 
 
4.03± 
0.17 
(0.058) 
 
1.67± 
0.38 
(0.058) 
 
0.597± 
0.06 
(0.058) 
 
0.40± 
0.01 
(0.012) 
 
0.60± 
0.10 
(0.140) 
Treatment 
Month 12 
Mean± 
SEM 
 
 
Month 18 
Mean± 
SEM 
 
 
40.35± 
1.30 
(0.120) 
 
 
6.20± 
0.70 
(0.044) 
 
 
7.56± 
0.71 
(0.120) 
 
 
2.34± 
0.78 
(0.044) 
 
 
4.87± 
0.70 
(0.120) 
 
 
1.45± 
0.44 
(0.044) 
 
 
3.97± 
0.55 
(0.120) 
 
 
0.66± 
0.08 
(0.044) 
 
 
7.12± 
0.22 
(0.046) 
 
 
3.64± 
1.2 
(0.052) 
 
 
1.84± 
0.58 
(0.046) 
 
 
1.39± 
0..36 
(0.052) 
 
 
1.09± 
0.06 
(0.046) 
 
 
N.D. 
 
 
1.68± 
0.91 
(0.024) 
 
 
0.59± 
0.19 
(0.005) 
 
 
0.76± 
0.08 
(0.165) 
 
 
1.36± 
0.33 
(0.042) 
* Month 18 values refer to the concentrations measuring in the L-treated primates that were sacrificed 6 
months after the end of the supplementation period and month 12 values are those measured in the primates 
sacrificed immediately following 12 months of supplementation; ** Tissue weights in grams  are shown in 
parentheses . 
 
 
The data shown in Table 5 indicate a significant increase in the mean concentration 
of lutein in the retinas of the supplemented animals in comparison to the control group. 
Figure 11 depicts the changes in mean lutein and zeaxanthin concentrations in the retina 
and ciliary body of the L-treated primates compared to the controls. The mean lutein 
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concentration for the retinas of the L-treated group at month 12 (40.35 ± 1.30 ng/tissue) 
was nearly 4-fold the mean value for the control group (11.05 ± 2.19 ng/tissue) (p < 
0.0001). At month 18, after 6 months of follow-up without supplementation, the mean 
lutein level in the retinas of the L-treated primates (6.20 ± 0.70 ng/tissue) was not 
significantly different (p = 0.28) from the mean lutein level of the control group (11.05 
±2.19 ng/tissue). The mean lutein concentration in the ciliary body of the L-treated 
animals at month 12 (7.12 ± 0.22 ng/tissue), although almost twice that of the control 
group (4.03 ± 0.17 ng/tissue), was not significant ly higher (p = 0.22), nor was it 
significantly higher than the mean level at month 18 (p = 0.17). It should be noted that 
small sample size and inter- individual variability made it difficult to detect smaller 
differences between groups. The mean concentrations of lutein in the iris was higher in 
the L-treated group when compared to the controls  and the L-treated group at 18-months, 
but the overall levels were low and variability among animals within the L- treated 
group  was high. Lutein levels in the lens do not appear to have been affected by 
supplementation.  
After 12 months of supplementation, the mean zeaxanthin level in the retina for 
the L-treated primates was not significantly different (p = 0.35) from the control mean or 
from the mean level at month 18 (p = 0.10). Similarly, the mean zeaxanthin level in the 
ciliary body of the L-treated primates was not significantly different from that of the 
control group or the mean level measured at month 18 in the L-treated group. No 
detectable amounts of zeaxanthin were found in the iris and lens tissues of the control and 
L-treated primates at months 12 or 18. 
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The mean level of meso-zeaxanthin in the retina of the L-treated primates at 
month 12 was not significantly different (p = 0.11) from the control group, but was 
significantly higher (p = 0.004) than the mean level of the L-treated primates after 18 
months.  
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Figure 11. Mean concentrations of lutein, zeaxanthin, meso-zeaxanthin, and 3’-oxolutein (ng/tissue) 
in the retina and ciliary body of the L-treated primates (9.34 mg/kg L and 0.66 mg/kg Z daily for 12 
months) at month 12 (n=2) and month 18 (n=3) compared to the control primates (n= 3). (One 
control primate was sacrificed at month 12 and 2 were sacrificed at month 18.) 
 
The mean level for the metabolite 3’-oxolutein in the L-treated primates at month 
12 was significantly higher (p = 0.002) when compared to the control group, and was also 
significantly higher (p < 0.001) than the mean level for the L-treated primates at month 
18. This 18 month value, however, was not significantly different from the control mean.  
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Carotenoid Concentrations in the Major Organs and Tissues of Primates in the Lutein 
Supplementation Study 
 
The major organs and tissues of one control primate (RQ4079) and 2 L-treated 
primates (9.34 mg/kg L and 0.66 mg/kg Z daily for 12 months ) (RQ4087, RQ4122) were 
sacrificed at the end of the 12-month supplementation period and were analyzed for 
carotenoids, their metabolites, and retinol. The data for the control primate in comparison 
to the mean values for the L-treated group are shown in Table 6. Complete data for each 
primate are included as Appendix C. Lutein, zeaxanthin, and 3’-oxolutein were detected 
in all tissues analyzed with the exception of the livers which did not contain any 
detectable amounts of 3’-oxolutein. Although there was considerable inter- individual 
variability among the primates in the L-treated group, the mean lutein levels in the primates 
supplemented with lutein were significant ly higher than the mean levels measured in all 
tissues of the control group. The highest concentrations of carotenoids and retinol were 
found in the liver of the primates. Another point worth noting is that inconsistencies in 
the adipose tissue samples analyzed resulted from the varied sources of adipose tissue. 
Multiple adipose samples were provided for each of the primates that was sacrificed, but 
the locations from which these adipose tissues were collected were not specified.  
Two of the control primates and 3 of the L-treated primates were sacrificed at 
month 18, following 6 months of observation. The liver, lung, colon, and breast tissues of 
these primates were analyzed for carotenoids, their metabolites, and retinol. As shown in 
Table 7, the mean lutein levels observed in the L-treated primates at month 18 were 
considerably lower than the mean levels observed in the L-treated primates that were 
sacrificed after 12 months of supplementation. Complete data for each of these primates 
are tabulated in Appendix D. There was considerable inter- individual variability in the 
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lutein concentrations in the breast tissue of the primates, making these results difficult to 
interpret. Mean lutein levels in lung and colon tissues of the L-treated primates at 18 
months were closer to the mean levels observed for the control group than they were to 
the mean levels for the L-treated primates whose tissues were analyzed at month 12. 
While the mean concentration of lutein in the liver tissues of the L-treated primates was 
still high at month 18, the value was lower that that of the L-treated primates at month 12.  
 
Table 6. Concentrations (µg/g tissue) of lutein, zeaxanthin, 3’-oxolutein, and retinol in tissues of 
one control primate and 2 primates supplemented daily (9.34 mg/kg L and 0.66 mg/kg Z) for 12 
months; carotenoids were measured at the end of the 12 month supplementation period. 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-
Oxolutein, and Retinol in Primates’ Tissues* 
 
Tissue 
 
 
Primate ID 
lutein zeaxanthin 3’-oxolutein retinol 
Liver 
 
Control                RQ4079 
 
Treatment        Mean ± SEM 
1.653 
 
3.076 ± 0.57 
0.7751 
 
0.918 ± 0.29 
N.D. 
 
N.D. 
11.331 
 
20.402 ± 8.40 
Lung 
 
Control                RQ4079 
 
Treatment        Mean ± SEM 
0.100 
 
0.228 ± 0.02 
0.051 
 
0.052 ± 0.01 
0.006 
 
0.024 ± 0.002 
0.164 
 
0.104 ± 0.044 
Colon 
 
Control                 RQ4079 
 
Treatment        Mean ± SEM 
0.090 
 
0.231 ± 0.13 
0.060 
 
0.084 ± 0.05 
0.036 
 
0.088 ± 0.04 
0.234 
 
0.144 ± 0.030 
Kidney 
 
Control                 RQ4079 
 
Treatment        Mean ± SEM 
0.049 
 
0.205±0.07 
0.027 
 
0.074±0.03 
0.005 
 
0.035±0.007 
1.442 
 
1.249±0.026 
Breasta 
 
Control            Mean ± SEM 
 
Treatment        Mean ± SEM 
0.037 ± 0.017 
 
0.362 ± 0.26 
0.020 ± 0.008 
 
0.098 ± 0.06 
0.009 ± 0.003 
 
0.069 ± 0.05 
0.032 ± 0.021 
 
0.054±0.007 
Ovariesb 
 
Control                   RQ4079 
 
Treatment        Mean ± SEM 
0.026 
 
0.071 ± 0.03 
0.017 
 
0.019 ± 0.003 
0.003 
 
0.013 ± 0.008 
0.033 
 
0.058 ± 0.004 
Spleen 
 
Control                   RQ4079 
 
Treatment        Mean ± SEM 
0.322 
 
0.620 ± 0.06 
0.138 
 
0.143 ± 0.02 
0.029 
 
0.062±0.01 
0.134 
 
0.125 ± 0.015 
Cervix 
 
Control                   RQ4079 
 
Treatment        Mean ± SEM 
0.017 
 
0.051 ± 0.01 
0.013 
 
0.019 ± 0.01 
0.002 
 
0.011±0.004 
0.028 
 
0.057 ± 0.037 
Adipose 
 
Control                   RQ4079 
 
Treatment       Mean ± SEM 
0.163 
 
0.794 ± 0.82 
0.095 
 
0.187 ± 0.16 
0.072 
 
0.407 
0.147 
 
0.133 
 
* Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans 
isomers and given as total lutein and zeaxanthin values, respectively; a Value for control breast tissue is the mean of 
the right and left breast tissues for primate 4079; b Concentrations of carotenoids and retinol for ovaries are expressed 
in µg/0.1 g of ovaries rather than µg/g of tissue; the weight of each ovary is between 0.2-0.6 g; N.D., Not detected. 
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Table 7. Mean concentrations (µg/g tissue) of lutein, zeaxanthin, 3’-oxolutein, and retinol in 
tissues of 2 control primates and 3 primates supplemented daily with lutein (9.34 mg/kg L and 
0.66 mg/kg Z) at month 18 (12 months supplementation plus 6 months treatment-free).  
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-
Oxolutein,and Retinol in Primate Tissues* 
 
Tissue 
 
 
Primate ID 
lutein zeaxanthin 3’-oxolutein retinol 
Liver 
 
 
Control            Mean ±SEM 
 
Treatment        Mean±SEM 
 
0.937 ± 0.44 
 
2.006 ± 0.99 
 
0.577 ± 0.30 
 
0.745 ± 0.19 
 
N.D. 
 
0.035 ± 0.007 
 
35.101 ± 6.79 
 
25.461 ± 2.67 
Lung 
 
 
Control*           Mean±SEM 
 
Treatment*       Mean±SEM 
 
0.102 ± 0.002 
 
0.136 ± 0.12 
 
0.059 ± 0.005 
 
0.061 ± 0.022 
 
0.010 ± 0.001 
 
0.018 ± 0.008 
 
0.094 ± 0.001 
 
0.177 ± 0.010 
Colon 
 
 
Control*           Mean±SEM 
 
Treatment*       Mean±SEM 
 
0.256 ± 0.033 
 
0.199 ± 0.065 
 
0.144 ± 0.008 
 
0.081 ± 0.027 
 
0.055 ± 0.016 
 
0.038±0.012 
 
0.276 ± 0.078 
 
0.217 ± 0.074 
Breast 
 
 
Control*           Mean±SEM 
 
Treatment*       Mean±SEM 
 
 
0.457 ± 0.17 
 
0.347 ± 0.053 
 
0.289 ± 0.24 
 
0.121 ± 0.029 
 
0.125 ± 0.033 
 
0.137 ± 0.038 
 
0.210 ± 0.075 
 
0.084 ± 0.051 
* Trace amount of  3’-epilutein was also detected; N.D. = not detected. 
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Zeaxanthin Supplementation Study: Daily Supplementation of Female Rhesus 
Macaque Monkeys with Zeaxanthin (10 mg/kg) for 12 Months  
 
Plasma Carotenoid Analysis of Primates in the Zeaxanthin Supplementation Study 
The concentrations of zeaxanthin in the plasma of the Z-treated primates at 
baseline, 6 and 12 months of supplementation, and 6 months post-supplementation (18 
months) are shown in Table 8 and depicted in Figure 12.  The changes in mean plasma 
zeaxanthin concentrations of the Z-treated primates compared to those of the control 
group are depicted in Figure 13. 
 
Table 8. Concentrations (µmol/L) of zeaxanthin in the plasma of 5 primates supplemented daily 
with zeaxanthin (10 mg/kg) for 12 months at baseline, 6 and 12 months of supplementation, and 
at 6 months post-supplementation (month 18). 
Total Zeaxanthin Concentration in Plasma (µmol/L)* 
Primate ID Baseline  6 Months  12 Months  18 Months  
Control Group 
Mean ± SEM 0.118 ± 0.009a 0.069 ± 0.010a 0.120 ± 0.027a 0.120 ± 0.026a 
Treatment Group 
                      RQ4120 0.254 0.598 0.840 0.088 
                     RQ4092 0.228 0.760 0.988 0.153 
                     RQ4094 0.172 1.025 1.063 0.150 
                     RQ4146 0.347 0.945 1.147 --a 
                     RQ4173 0.150 0.781 0.550 --a 
          Mean ± SEM  b 0.230 ± 0.035a 0.822 ± 0.075b 0.918 ± 0.104b 0.130 ± 0.021a 
* Total zeaxanthin refers to the combined concentrations of all-trans-zeaxanthin and its cis-isomers; a 
primate sacrificed after 12 months of supplementation; b SEM = standard error of mean; Values with 
different letters (a, b, c) denote statistical significance across each row and within each column. 
 
 
 
 
For plasma carotenoid analysis the mean baseline values for the Z-treated 
primates served as their own controls for comparing the mean carotenoid concentrations  
at other time points. These mean values were also compared to those of the control group. 
Statistical analysis of the data shown in Table 8 indicates that the mean plasma 
concentration of zeaxanthin for the primates at baseline (0.230 ± 0.035 µmol/L) was 
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significantly different than the mean levels at month 6 (0.822 ± 0.075 µmol/L; p < 0.001) 
and at month 12 (0.918 ± 0.104 µmol/L; p < 0.001) (see Figures 12 and 13). However, it 
must be noted that the mean plasma concentration for this group was nearly 2-fold that of 
the mean plasma zeaxanthin concentration at baseline for the control group (0.118 ±  
0.009 µmol/L). The mean plasma zeaxanthin level in the Z-treated primates was not 
significantly different (p = 0.38) between months 6 and 12. This suggests that the plasma 
concentration of zeaxanthin plateaus  at some point between 6 and 12 months of daily 
supplementation with zeaxanthin. The mean plasma zeaxanthin concentration at month 
18 (0.130 ± 0.021 µmol/L) was lower than the baseline value for this group (0.230 ± 
0.030 µmol/L) at month 18 (12 months supplementation plus 6 months treatment-free).  
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Figure 12. Changes in the plasma concentrations (µmol/L) of zeaxanthin in the Z-treated 
primates (10 mg zeaxanthin/kg daily for 12 months) at baseline, months 6, 12, and 18.  
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Figure 13. Changes in the mean plasma zeaxanthin concentrations (µmol/L) of the Z-treated 
primates (10 mg/kg Z daily for 12 months) in comparison with the control primates at baseline, 
months 6, 12 , and 18. 
 
 
 
The mean plasma concentration of lutein of the Z-treated primates at baseline 
(0.250 ± 0.06 µmol/L) was not significantly different (p = 0.81) in comparison with the 
mean level at month 12 (0.316 ± 0.088 µmol/L) (Figure 14). And, while the mean lutein 
level did increase between baseline and month 6 (0.416 ± 0.071 µmol/L), this increase 
was not significant (p = 0.07), nor was the decrease observed in the mean plasma lutein 
concentration between months 6 and 12 (p = 0.10). The mean plasma lutein level at 
month 18 (0.316 ± 0.067 µmol/L) was not significantly different from the mean plasma 
lutein level at baseline (0.303 ± 0.050 µmol/L) (Figure 14). It must be noted that the 
zeaxanthin supplements did not contain any lutein. 
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Figure 14. Changes in the plasma concentrations of lutein in the Z-treated primates (10 mg /kg  
of Z daily for 12 months) at baseline and months 6, 12, and 18. 
 
 
 
 
Plasma Concentrations of Lutein and Zeaxanthin Metabolites in Primates in the 
Zeaxanthin Supplementation Study 
 
Supplementation of primates with zeaxanthin for 12 months did not seem to alter 
the plasma concentrations of 3’-epilutein. While trace amounts of 3’-epilutein were 
detected at baseline, this metabolite was no t detected at month 6 and only trace amounts 
were detected in a couple of the primates at month 12.  
 The results showed that the mean plasma concentration of 3’-oxolutein at baseline 
(0.057 ± 0.011 µmol/L) was significantly lower than the mean levels observed at month 6 
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(0.079 ± 0.011 µmol/L; p = 0.04) and month 12 (0.086 ± 0.011 µmol/L; p = 0.01). 
However, the mean plasma 3’-oxolutein levels were not significantly different (p = 0.54) 
between months 6 and 12 of supplementation. These data are listed in Table 9 and are 
shown in Figure 15. The mean plasma concentration of 3’-oxolutein measured at month 
18 (0.041 ± 0.024 µmol/L) decreased below the mean baseline level (0.057 ± 0.007 
µmol/L); although it should be noted that the inter- individual variability in plasma 
concentrations at month 18 was larger than that observed at baseline. 
 
Table 9. Concentrations (µmol/L) of 3’-oxolutein in the plasma of primates supplemented daily 
with zeaxanthin (10 mg/kg) for 12 months at baseline, months 6, 12, and 18. 
3’-Oxolutein Concentration in Plasma (µmol/L)  
 
Primate ID Baseline  6 Months  12 Months  18 Months  
RQ4120 0.044 0.052 0.074 0.020 
RQ4092 0.075 0.064 0.076 0.093 
RQ4094 0.052 0.110 0.096 0.041 
RQ4146 0.075 0.109 0.132 --† 
RQ4173 0.040 0.061 0.049 --† 
Mean ± SEM‡ 0.057 ± 0.007a 0.079 ± 0.026b 0.086 ± 0.014b 0.041 ± 0.024a 
 
† Primate sacrificed after 12 months of supplementation; ‡ SEM = standard error of mean; Values with 
different letters (a, b) denote statistical significance between the mean values. 
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Figure 15. Changes in the mean plasma concentrations (µmol/L) of 3’-oxolutein in the Z-treated 
primates at baseline, months 6, 12, and 18. 
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Concentrations of Carotenoids in the Ocular Tissues of Primates in the Zeaxanthin 
Supplementation Study 
 
After 12 months of daily supplementation with zeaxanthin (10 mg/kg), 2 primates 
were sacrificed and the ocular tissues (retina, ciliary body, iris, lens) from one eye of each 
animal were extracted and analyzed for zeaxanthin, lutein, their metabolites, and retinol. 
Six months post-supplementation, the remaining 3 primates were sacrificed, and in most 
cases, the tissues from both the right and left eyes of each animal were analyzed. The 
mean concentrations of carotenoids in the ocular tissues of the Z-treated group at month 
12 and month 18 compared to the control group are shown in Table 11. Complete data for 
carotenoid and metabolite concentrations of the ocular tissues of each of the Z-treated 
primates are attached as Appendix E. The mean concentrations of lutein, zeaxanthin, 
meso-zeaxanthin, and 3’-oxolutein in the ocular tissues of the Z-treated primates at month 
12 were compared to the mean values for the 3 control primates (RQ4079, RQ4107, and 
RQ4142). 
The data depicted in Figure 16 clearly indicate increases in the mean 
concentrations of zeaxanthin in the retina and ciliary body of the Z-treated primates at 
month 12 in comparison to the mean levels of the control primates as well as the Z-
treated primates at month 18. The mean concentration of zeaxanthin in the retina of the 
Z-treated primates at month 12 (20.43 ± 3.88 ng/tissue) was greater than 4-fold that of the 
mean value of the control primates (4.78 ± 0.62 ng/tissue) (p < 0.001). The month 12 
value for the Z-treated primates was also significantly higher (p < 0.001) than that of the 
Z-treated primates at month 18 (6.85 ± 0.82 ng/tissue) which was not significantly 
different (p = 0.89) from that of the control. It should be noted that the mean retina weight 
for the control primates was 0.117 g and that the mean retina weight of the Z-treated 
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primates sacrificed at month 18 was only 0.041 g. The mean concentration for total 
zeaxanthin in the ciliary body of the Z-treated primates at month 12 (12.85 ± 4.28 
ng/tissue) was significantly higher (p < 0.001) than that of the control primates (1.67 ± 
0.38 ng/tissue), and was also significantly higher (p = 0.003) than the mean level for the 
Z-treated primates at month 18 (3.53 ± 0.62 ng/tissue). While there was no zeaxanthin 
detected in the iris tissues of either the control primates or the Z-treated primates at 
month 18, a small amount of this carotenoid was detected in the Z-treated group at month 
12. The amounts of zeaxanthin detected in the lens were also small, yet the mean level at 
month 12 was almost twice that of the control group. No zeaxanthin was detected in the 
lens of the Z-treated primates at month 18.  
 
Table 10. Mean concentrations (ng/tissue) of lutein, zeaxanthin, meso-zeaxanthin and 3’-oxolutein 
in ocular tissues of the Z-treated primates at month 12 (n=2) and at month 18 (n=3) compared to the 
mean levels of the control group (n=3). 
Concentrations (ng/tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, and Retinol 
in Primates Ocular Tissues (Tissue Weight, g)* 
Retina Ciliary Body Iris Lens 
 
 
 
Primate 
Group 
lutein zea-
xanthin 
meso-
zea-
xanthin 
3’-oxo-
lutein 
lutein zea- 
xanthin 
3’-oxo-
lutein 
lutein/ 
zeaxanthin 
lutein/ 
zeaxanthin 
Control 
Mean ± 
 SEM 
 
 
11.05± 
2.19 
(0.117) 
 
 
4.78± 
0.62 
(0.117) 
 
3.20± 
0.30 
(0.117) 
 
0.82± 
0.10 
(0.117) 
 
4.03± 
0.17 
(0.058) 
 
1.67± 
0.38 
(0.058) 
 
0.60± 
0.06 
(0.058) 
 
0.26±.01/ 
N.D. 
(0.012) 
 
0.60±.10/ 
0.18±..05 
(0.140) 
Z-Treated 
12 months 
Mean ± 
 SEM 
 
 
18 months 
Mean ± 
 SEM 
 
 
 
19.15± 
9.07 
(0.105) 
 
 
7.842± 
1.03 
(0.041) 
 
 
20.43± 
3.88 
(0.105) 
 
 
3.93± 
0.66 
(0.041) 
 
 
7.20± 
1.37 
(0.105) 
 
 
1.78± 
0.26 
(0.041) 
 
 
3.87± 
0.10 
(0.105) 
 
 
0.58± 
0.27 
(0.041) 
 
 
4.97± 
2.55 
(0.053) 
 
 
7.18± 
1.04 
(0.095) 
 
 
12.85± 
4.28 
(0.053) 
 
 
3.53± 
0.62 
(0.095) 
 
 
1.34± 
0.50 
(0.053) 
 
 
0.95± 
0.19 
(0.095) 
 
 
0.26±.05/ 
0.30±..01 
(0.028) 
 
 
0.65±..01/ 
N.D. 
(0.013) 
 
 
0.34±.01/ 
0.37±..05 
(0.163) 
 
 
0.63± .01/ 
N.D. 
(0.169) 
* Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-
trans isomers and reported as total lutein and total zeaxanthin, respectively; N.D., Not detected; SEM = 
standard error of the mean. 
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The mean concentration of lutein in the retina  of the Z-treated animals at month 
12 was nearly double that of the control primates, but there was a large inter- individual 
variability, and thus, this difference was not statistically significant (p = 0.12). 
Interestingly, the mean concentration of lutein in the retina of the Z-treated primates at 
month 12 was significantly higher (p = 0.04) than that of the Z-treated primates at month 
18. However, the mean concentration of lutein in the retina of the Z-treated animals at the 
month 18 was not significantly different (p = 0.47) than that of the control. The mean 
lutein levels in the ciliary body were higher in the Z-treated primates than the control at 
both months  12 and 18, but there was a high degree of inter-animal variability associated 
with the levels of lutein in this tissue and consequently, the differences were not 
statistically significant. 
 
0
5
10
15
20
25
lutein zeaxanthin meso-
zeaxanthin
3'-oxolutein lutein zeaxanthin 3'-oxolutein
Retina Ciliary Body 
n
g
/t
is
su
e
Control Group
Z-Treated Group (Month 12)
Z-Treated Group (Month 18)
 
Figure 16. Mean concentrations (ng/tissue) of lutein, zeaxanthin, and their metabolites in the 
retina and ciliary body of the Z-treated primates at months 12 (n=2) and 18 (n=3) in comparison 
to the control primates (n=3). (One control primate was sacrificed at month 12 and 2 were 
sacrificed at month 18.) 
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The mean concentration of meso-zeaxanthin in the retinas of the Z-treated 
primates at month 12 was significantly higher (p = 0.001) than that of the control 
primates, and that of the Z-treated primates at month 18 (p < 0.001).  
The mean concentration of 3’-oxolutein in the retina of the Z-treated primates at 
month 12 was significantly higher than that of the control group (p = 0.002) and the Z-
treated primates at month 18 (p < 0.001). However, the mean level of 3’-oxolutein in the 
Z-treated group at month 18 was not significantly different from the control mean (p = 0.52). 
The mean concentration of 3’-oxolutein in the ciliary body of the Z-treated 
primates had increased by month 12 of supplementation, and levels of this metabolite 
then decreased during the post-supplementation period (Figure 16). 
 
 
Carotenoid Concentrations in the Major Organs and Tissues of Primates in the 
Zeaxanthin Supplementation Study 
 
Other major organs and tissues of the sacrificed animals were also analyzed for 
carotenoids, their metabolites, and retinol. The organs and tissues analyzed in the 
primates sacrificed at month 12 were: liver, lung, colon, kidney, breast, ovaries, spleen, 
cervix, and adipose. The mean concentrations of lutein, zeaxanthin, their metabolites, and 
retinol for the 2 Z-treated primates sacrificed at month 12 were compared to that of the  
control primate (RQ4079). These data are listed in Table 11 and the complete data for 
each primate are attached as Appendix F. In all cases, the concentrations of zeaxanthin in the 
tissues and organs of the Z-treated primates were significantly higher than the values 
obtained for the control primate. As expected, the liver tissues accumulated the highest 
concentrations of carotenoids and retinol. 
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Table 11. Mean concentrations (µg/g tissues) of lutein, zeaxanthin, 3’-oxolutein, and retinol in 
tissues of two Z-treated primates (10 mg/kg Z daily for 12 months) in comparison with those of 
the control primate (RQ4079). 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, 
and Retinol in Primates’ Tissues* 
 
Tissue 
 
Primate Group 
lutein zeaxanthin 3’-oxolutein retinol 
Liver 
 
Control a                                 
 
Treatment b     
1.653 
 
1.732 ± 0.991 
0.775 
 
3.890 ± 0.828 
N.D. 
 
0.147 ± 0.044 
11.331 
 
11.116 ± 0.623 
Lung 
 
Control                 
                    
Treatment       
0.100 
 
0.052 ± 0.00 
0.051 
 
0.166 ± 0.051 
0.006 
 
0.013 ± 0.009 
0.164 
 
0.082± 0.062 
Colon 
 
Control                 
                    
Treatment       
0.090 
 
0.288 ± 0.215 
0.060 
 
1.085 ± 1.468 
0.036 
 
0.023 ± 0.00 
0.234 
 
0.036 ± 0.003 
Breast 
 
Control           
 
Treatment       
0.037 ± 0.017 
 
0.081± 0.025 
0.020 ± 0.008 
 
0.365 ± 0.074 
0.009 ± 0.003 
 
0.044 ± 0.012 
0.042 ± 0.019 
 
0.042 ± 0.005 
Kidney 
 
Control                                   
 
Treatment       
0.049 
 
0.055 ± 0.029 
0.027 
 
0.125 ± 0.036 
0.005 
 
0.012 ± 0.004 
1.442 
 
1.149 ± 0.056 
Ovaries** 
 
Control                                  
 
Treatment       
0.026 
 
0.013 ± 0.001 
0.017 
 
0.041 ± 0.014 
0.003 
 
0.002 ± 0.001 
0.033 
 
0.016 ± 0.004 
Spleen 
 
Control                                  
 
Treatment       
0.322 
 
0.169 ± 0.109 
0.138 
 
0.373 ± 0.27 
0.029 
 
0.022 ± 0.004 
0.134 
 
0.045 ± 0.004 
Cervix 
 
Control                                 
 
Treatment       
0.017 
 
0.043 ± 0.028 
0.013 
 
0.082 ± 0.032 
0.002 
 
0.009 ± 0.004 
0.028 
 
0.037 ± 0.003 
Adipose 
 
Control                 
                    
Treatment       
0.163 
 
0.040 ± 0.026 
0.095 
 
0.125 ± 0.048 
0.072 
 
0.016 ± 0.010 
0.147 
 
0.017 ± 0.003 
 
* Concentrations of cis-isomers of lutein and zeaxanthin were combined with their corresponding all-trans 
isomers; ** Concentrations of carotenoids and retinol for ovaries are expressed in µg/0.1 g of tissue rather than µg/g of 
tis sue; the weight of each ovary was between 0.2-0.3 g; a Control values are the concentrations for primate 
RQ4079; b Treatment values are the mean ± SEM for primates RQ4146 and RQ4173; N.D., Not detected. 
 
 
After the 6-month post-supplementation (observation) period, the remaining 3 
primates in the Zeaxanthin Supplementation Study were sacrificed and the following 
organs and tissues were analyzed for lutein, zeaxanthin, their metabolites, and retinol: 
liver, lung, colon, and breast. These concentrations were compared to those of the 2 
control primates sacrificed at month 18. The mean tissue concentrations of carotenoids 
for the Z-treated and control primates are shown in Table 12; the complete set of data for 
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each primate is attached as Appendix G. The mean level of zeaxanthin in each of these 
tissues at month 18 was significantly lower than the mean level observed in the 
corresponding tissues of the Z-treated primates at month 12. Although there was a large 
variability among the primates, the levels of zeaxanthin in these tissues at month 18 
appear to be in the same range of concentrations as those of the control primates. 
 
 
Table 12. Mean concentrations (µg/g tissue) of lutein, zeaxanthin, 3’-oxolutein, and retinol six  
months post-supplementation in the tissues of three Z-treated primates in comparison to those of 
the control primates. 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 
3’-Oxolutein, and Retinol in Primate Tissues * 
 
Tissue 
 
 
Primate ID 
lutein zeaxanthin 3’-oxolutein retinol 
Liver 
 
 
Control         Mean±SEM 
 
Treatment    Mean±SEM 
 
0.937 ± 0.537 
 
1.610 ± 0.133 
 
0.577 ± 0.296 
 
0.746 ± 0.149 
 
N.D. 
 
N.D. 
 
35.101 ± 6.79 
 
147.58 ±31.40 
Lung 
 
 
Control         Mean±SEM 
 
Treatment    Mean±SEM 
 
0.102 ± 0.065 
 
0.152 ± 0.010 
 
0.059 ± 0.005 
 
0.078 ± 0.005 
 
0.010 ± 0.00 
 
0.013 ± 0.002 
 
0.094 ± 0.001 
 
0.191 ± 0.035 
Colon 
 
 
Control         Mean±SEM 
 
Treatment    Mean±SEM 
 
0.256 ± 0.033 
 
0.266 ± 0.072 
 
0.144 ± 0.121 
 
0.135 ± 0.050 
 
0.055 ± 0.016 
 
0.026 ± 0.007 
 
0.276 ± 0.078 
 
0.237 ± 0.051 
Breast 
 
 
Control         Mean±SEM 
 
Treatment    Mean±SEM 
 
0.457 ± 0.167 
 
0.227 ± 0.087 
 
0.289 ± 0.129 
 
0.178 ± 0.077 
 
0.125 ± 0.033 
 
0.064 ± 0.022 
 
0.210 ± 0.075 
 
0.119 ± 0.083 
 
* Concentrations of cis-isomers of lutein and zeaxanthin were combined with their corresponding all-trans 
isomers; N.D., Not detected. 
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Lutein/Zeaxanthin (L/Z) Supplementation Study: Daily Supplementation of Female 
Rhesus Macaque Monkeys with a 1:1 Combination of Lutein and Zeaxanthin (0.5 
mg/kg of each) for 12 Months  
 
Plasma Carotenoid Analysis of Primates in the Lutein/Zeaxanthin Supplementation 
Study 
 
 For the L/Z Supplementation Study, 5 primates were supplemented daily with a 
combination of lutein and zeaxanthin each at a dose of 0.5 mg/kg for 12 months. At the 
end of the 12-month supplementation period, all of the primates were sacrificed. As in the 
2 previously described studies, primate plasma samples were analyzed at baseline, 6 
months, and 12 months for lutein, zeaxanthin, their metabolites, and retinol. These data 
are summarized in Table 13 and Figure 17.  
 
 
Table 13. Concentrations (µmol/L) of carotenoids and their metabolites in the plasma of 5 L/Z-
treated primates (0.5mg/kg L & 0.5mg/kg Z daily for 12 months) at baseline and months 6 and 12. 
Concentration in Plasma (µmol/L)* Primate ID 
 lutein zeaxanthin 3’-epilutein 3’-oxolutein 
Baseline           RQ4086 
                       RQ4154 
                       RQ4118 
                       RQ4126 
                      RQ4104 
              Mean ± SEM† 
0.320 
0.243 
0.214 
0.182 
0.332 
0.258 ± 0.029a 
0.098 
0.153 
0.090 
0.062 
0.147 
0.111 ± 0.017a 
0.013 
0.033 
0.015 
0.015 
0.019 
0.019 ± 0.004a 
0.044 
0.044 
0.038 
0.016 
0.031 
0.034 ± 0.005a 
6 Months         RQ4086 
                       RQ4154 
                       RQ4118 
                       RQ4126 
                       RQ4104 
              Mean ± SEM† 
0.689 
0.614 
0.621 
0.756 
0.390 
0.614 ± 0.061b 
0.384 
0.409 
0.282 
0.397 
0.200 
0.334 ± 0.040b 
0.015 
0.066 
0.028 
0.031 
0.011 
0.030 ± 0.010a 
0.082 
0.062 
0.071 
0.061 
0.033 
0.062 ± 0.008b 
12 Months        RQ4086 
                         RQ4154 
                        RQ4118 
                        RQ4126 
                        RQ4104 
             Mean ± SEM† 
0.408 
0.210 
0.209 
0.236 
0.273 
0.278 ± 0.037a 
0.188 
0.081 
0.106 
0.108 
0.199 
0.1356 ± 0.0238a 
0.021 
0.026 
0.021 
0.029 
0.008 
0.021 ± 0.004a 
0.030 
0.030 
0.026 
0.038 
0.026 
0.030 ± 0.002a 
 
* Concentrations of cis-isomers of lutein and zeaxanthin were combined with their corresponding all-trans 
isomers; † SEM = standard error of mean; Values with different letters (a, b) denote statistical significance 
within each column. 
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From baseline to month 6 of supplementation there was a 2-fold increase in the 
mean plasma level of lutein among the L/Z-treated primates. The mean plasma lutein 
level increased significantly (p < 0.001) between baseline (0.258 ± 0.029 µmol/L) and 6 
months (0.614 ± 0.061 µmol/L). However, despite the fact that supplementation with 
lutein and zeaxanthin continued between months 6 and 12, there was no significant 
difference (p = 0.89) between the mean plasma levels of lutein at baseline (0.258 ± 0.029 
µmol/L) and month 12 (0.267 ± 0.037 µmol/L). The mean plasma concentrations of 
lutein in the L/Z-treated primates in comparison with the controls  are shown in Figure 18. 
These values indicate that in primates supplemented daily with lutein (0.5 mg/kg) and zeaxanthin 
(0.5 mg/kg), the plasma concentration of lutein is increased within 6 months of supplementation, 
but then returns to the baseline level between months 6 and 12. 
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Figure 17. Changes in the plasma lutein concentrations (µmol/L) of the L/Z-treated primates 
(0.5mg/kg L and 0.5mg/kg Z daily for 12 months) at baseline and months 6 and 12. 
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Figure 18. Changes in the mean plasma concentrations of lutein in the L/Z-treated primates (n = 5) 
(0.5mg/kg L and 0.5mg/kg Z daily for 12 months) and the control primates (n = 3). 
 
 
A 3-fold increase in the mean plasma zeaxanthin concentration was observed 
between baseline and month 6 of supplementation. Plasma zeaxanthin concentrations for 
each primate are depicted in Figure 19 and the mean levels for the L/Z-treated primates 
compared to those of the control primates are shown in Figure 20. The mean plasma 
zeaxanthin level at month 6 (0.334 ± 0.040 µmol/L) was significantly higher (p < 0.001) 
than the mean level measured at baseline (0.111 ± 0.017 µmol/L). Interestingly, as seen 
in the mean lutein levels of the L/Z-treated primates, the mean plasma concentration of 
zeaxanthin at month 12 of supplementation (0.136 ± 0.024 µmol/L) was not significantly 
different (p = 0.48) than that at baseline (0.111 ± 0.017 µmol/L).  
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Figure 19. Changes in the mean plasma concentrations of zeaxanthin (µmol/L) in the L/Z-treated 
primates at baseline and months 6 and 12. 
 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
Baseline 6 Months 12 Months
P
la
sm
a 
Z
ea
xa
n
th
in
 (
µm
o
l/L
) Control Group
L/Z-Treated Group
 
Figure 20. Changes in the mean plasma zeaxanthin concentrations (µmol/L) of the L/Z-treated primates 
in comparison to the control group at baseline and months 6 and 12. 
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Plasma Concentrations of Lutein and Zeaxanthin Metabolites in Primates in the 
Lutein/Zeaxanthin Supplementation Study 
 
There were no significant changes in the mean plasma concentrations of lutein 
and zeaxanthin metabolites between baseline and month 12 of supplementation. Plasma 
concentrations of 3’-oxolutein and 3’-epilutein for each of the L/Z-treated primates are 
tabulated in Table 13. Plasma levels of 3’-oxolutein and 3’-epilutein increased between 
baseline and month 6, but decreased thereafter and returned to nearly the ir baseline levels 
at month 12. A significant increase (p = 0.003) in the mean plasma concentration of 3’-
oxolutein occurred between baseline (0.034 ±  0.005 µmol/L) and month 6 (0.062 ± 0.008 
µmol/L), yet there was no significant difference (p = 0.69) between the mean level of this 
metabolite at month 12 (0.030 ± 0.002 µmol/L) and baseline (0.034 ± 0.005 µmol/L). The 
mean 3’-oxolutein plasma levels for the L/Z-treated primates are depic ted in Figure 21. 
Although the mean plasma concentration of 3’-epilutein increased by 1.5-fold between 
baseline and month 6, there were no statistically significant differences between the mean 
levels at baseline and month 6 (p = 0.22) or month 12 (p = 0.60). 
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Figure 21. Changes in the mean plasma concentrations of 3’-oxolutein in the L/Z-treated 
primates in comparison to the control primates at baseline and months 6 and 12. 
 
 
 
 
Concentrations of Carotenoids in the Ocular Tissues of Primates in the L/Z 
Supplementation Study 
 
 The ocular tissues (retina, ciliary body, iris, lens) from both right and left eyes of 
the L/Z-treated primates were extracted and analyzed for lutein, zeaxanthin, meso-
zeaxanthin, and 3’-oxolutein at the end of the 12-month supplementation period. The 
mean values for lutein, zeaxanthin, and their metabolites for the right and left eyes were 
used except for several instances in which the  tissues from both right and left eyes of a 
primate were not available; these cases are noted in Appendix H which includes the 
complete data for the ocular tissues of the L/Z-treated primates. These data are listed in 
Table 14 and are also shown in Figure 22. 
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Table 14. Mean concentrations (ng/tissue) of lutein, zeaxanthin, meso-zeaxanthin, and 3’-
oxolutein in ocular tissues of L/Z-treated primates at month 12 compared to those of the control 
primates.* 
Concentrations (ng/tissue) of Lutein, Zeaxanthin, meso-Zeaxanthin, and 3’-Oxolutein 
in Primates’ Ocular Tissues (Tissue Weight, g) 
Retina Ciliary Body Iris Lens 
 
 
Primate 
ID lutein zea-
xanthin 
meso-
zea-
xanthin 
3’-oxo- 
lutein 
lutein zea-
xanthin  
3’-oxo- 
lutein 
lutein/ 
zea-
xanthin 
lutein/ 
zea-
xanthin  
Control 
Mean ± 
SEM 
 
 
11.05± 
2.19 
(0.117) 
 
4.78± 
0.62 
(0.117) 
 
3.20± 
0.30 
(0.117) 
 
1.22± 
0.096 
(0.117) 
 
4.03± 
0.17 
(0.058) 
 
1.64± 
0.38 
(0.058) 
 
0.60 ± 
0.14 
(0.058) 
 
0.26±0.1/ 
N.D. 
(0.014) 
 
0.60 ±0.1/ 
0.18 ±0.2 
(0.14) 
Treatment 
Mean ± 
SEM 
  
 
11.50± 
2.12 
(0.108) 
 
5.660± 
2.02 
(0.108) 
 
1.75± 
0.54 
(0.108) 
 
2.37± 
0.33 
(0.108) 
 
4.89± 
1.66 
(0.060) 
 
3.92± 
1.17 
(0.060 
 
0.80± 
0.26 
(0.060) 
 
0.77±.18/ 
0.52±.15 
(0.010) 
 
0.56±.07/ 
0.39±.06 
(0.107) 
 
* Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; N.D., 
Not detected. 
 
 
 
 
 The data for the ocular tissues for the L/Z-treated primates show that there were 
no clear increases in the concentrations of lutein or zeaxanthin in the retina. There were 
no statistically significant differences in the concentrations of lutein, zeaxanthin, meso-
zeaxanthin, or 3’-oxolutein in the retina of the primates supplemented daily with 0.5 
mg/kg of lutein plus 0.5 mg/kg of zeaxanthin at month 12 when compared to the control 
group. When examining the total levels of lutein and zeaxanthin, the mean levels of 
combined total lutein and zeaxanthin in the retina are nearly equal in the control group 
(19.03 µg/retina) and the L/Z-treated group (18.91 µg/retina). Therefore, the 
concentrations of lutein and zeaxanthin do not appear to have increased after 12 months 
of supplementation with the dose of 0.5 mg/kg of each of these carotenoids. 
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Figure 22. Mean concentrations of lutein, zeaxanthin, meso-zeaxanthin, and 3’-oxolutein 
(ng/tissue) in the retina and ciliary body of the L/Z-treated primates at month 12 (n=5) in 
comparison with the control primates (n=3). (One control primate was sacrificed at month 12 and 
2 were sacrificed at month 18.) 
 
 
 
The mean concentrations of lutein, zeaxanthin, and 3’-oxolutein in the ciliary 
bodies were not significantly higher in the L/Z-treated group at month 12 when compared 
to those of the control group. The mean concentration of zeaxanthin in the ciliary body of 
the L/Z-treated primates was greater than 2-fold that of the control group, but it should be 
noted that there was a high degree of inter-individual variability with regard to these 
values. 
The mean concentration of lutein in the iris of the L/Z-treated primates was almost 
3-fold that of the controls. Additionally, while no zeaxanthin was detected in the iris of the 
control primates, trace amounts were detected in the iris of the L/Z-treated primates. Only 
low levels of lutein and zeaxanthin were detected in the lens. However, supplementation of the 
primates with lutein and zeaxanthin resulted in a 2-fold increase in the  mean 
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concentration of zeaxanthin in the lens when compared to that of the control group. 
Meanwhile, the mean level of lutein did not appear to be affected by supplementation. 
 
 
Carotenoid Concentrations in the Major Organs and Tissues of Primates in the 
Lutein/Zeaxanthin Supplementation Study 
 
 At the end of the 12-month supplementation period, the major organs and tissues 
of the 5 L/Z-treated primates were extracted and analyzed for lutein, zeaxanthin, their 
metabolites, and retinol. The mean concentrations of these carotenoids in this group were 
compared to those measured in the control primate (RQ4079) (Table 15). Complete data 
for organs and tissues of each L/Z-treated primate compared to the control primate are 
presented in Appendix I. 
In the colon, kidney, breast, ovary, cervix, and adipose tissues, the mean lutein 
and zeaxanthin levels were considerably higher in the L/Z-treated primates than in the 
control primate. For instance, the mean lutein and zeaxanthin concentrations in the colon 
tissues of the L/Z-treated group were more than 6-fold higher than the concentrations 
measured for the control animal. Interestingly, the mean levels of lutein and zeaxanthin 
were higher in the liver tissue of the control primate in comparison to the mean levels 
observed in the L/Z-treated group. The lutein concentration in the liver of the control 
primate (1.65 µg/g) was more than 2-fold the mean concentration of the L/Z-treated 
group (0.72 µg/g). Meanwhile, the zeaxanthin concentration in the liver was almost 2-
fold higher in the control primate in comparison to the mean level of the L/Z-treated 
group. 
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Table 15. Mean concentrations (µg/g tissue) of lutein, zeaxanthin, 3’-oxolutein, and retinol in the 
tissues of the L/Z-treated primates (n=5) compared to control primate RQ4079. 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, 
and Retinol in Primates’ Tissues* 
 
Tissue 
 
Primate Group 
lutein zeaxanthin 3’-oxolutein retinol 
Liver 
 
Controla 
 
Treatmentb 
 
1.653 
 
0.719 ± 0.12 
0.755 
 
0.479 ± 0.09 
N.D. 
 
N.D. 
0.113 
 
5.781 ±  3.11 
Lung 
 
Control 
 
Treatment 
 
0.100 
 
0.088 ± 0.02 
0.051 
 
0.067 ± 0.02 
0.006 
 
0.014 ± 0.03 
0.164 
 
0.072 ± 0.006 
Colon 
 
Control 
 
Treatment 
 
0.090 
 
0.550 ± 0.19 
0.060 
 
0.376 ± 0.16 
0.036 
 
0.060 ± 0.02 
0.234 
 
0.383 ± 0.09 
Kidney 
 
Control 
 
Treatment 
 
0.049 
 
0.241 ± 0.13 
0.027 
 
0.144 ± 0.06 
0.005 
 
0.028 ± 0.01 
1.442 
 
1.467 ± 0.13 
Breast 
 
Control 
 
Treatment 
 
0.037 
 
0.440 ± 0.09 
0.020 
 
0.318 ± 0.07 
0.009 
 
0.068 ± 0.02 
0.032 
 
0.501 ± 0.14 
Ovaries 
 
Control 
 
Treatment 
 
0.026 
 
0.478 ± 0.25 
0.017 
 
0.326 ± 0.23 
0.003 
 
0.089 ± 0.05 
0.033 
 
1.336 ± 0.79 
Spleen 
 
Control 
 
Treatment 
 
0.322 
 
0.418 ± 0.06 
0.138 
 
0.341 ± 0.09 
0.029 
 
0.085 ± 0.02 
0.134 
 
0.266 ± 0.025 
Cervix 
 
Control 
 
Treatment 
 
0.017 
 
0.052 ± 0.01 
0.013 
 
0.032 ± 0.01 
0.002 
 
0.010 ± 0.003 
0.028 
 
0.100 ± 0.14 
Adipose 
 
Control 
 
Treatment 
 
0.163 
 
0.638 ± 0.34 
0.095 
 
0.403 ± 0.26 
0.072 
 
N.D. 
0.147 
 
7.661 ± 5.01 
 
* Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-
trans isomers; a Value for the control primate RQ4079; b Mean ± standard error of the mean (SEM) for L/Z-
treated primates; N.D., Not detected. 
 
 
 
 
Safety of High Supplemental Doses (~10mg/kg) of Lutein or Zeaxanthin 
 
 Toxicology assays for this study were conducted by other co- investigators of this 
study. Therefore only a brief summary of these results is included in this thesis. 
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Fundus Photography and Retina Histopathology 
The results from fundus photography and histopathology of retina revealed no 
abnormalities in any of the animals supplemented daily with a high dose of lutein or 
zeaxanthin for 12 months. The retinal pigment epithelium (RPE) of all monkeys appeared 
normal and showed a normal distribution of melanosomes and lipofuscin granules. 
Bruch's membranes were normal and free of deposits. The choroids and their cellular 
components were also normal. In addition, there are no signs of inflammation or 
abnormal numbers of circulating leukocytes in retinal or choroidal blood vessels. The 
refractile elements seen in gross examination were not evident in histologic sections. 
Therefore supplementation with lutein or zeaxanthin at high doses would not be expected 
to cause ocular toxicity. 
 
Urinary Creatinine and Total Protein 
The results of studies on total urinary protein excretion showed no statistically 
significant alterations in protein excretion patterns based upon per milligram of creatinine 
excreted. Overall, these data suggest that the various lutein and zeaxanthin treatments did 
not produce any clinical renal damage to the monkeys. The statistically non-significant 
increase in the urinary protein excretion per mg of creatinine that was observed in the 
L/Z-treated group was undoubtedly a reflection of the lower urinary creatinine values 
seen in this group in comparison to the other treatment groups. This is most likely the 
result of a more dilute urine samples in some of these animals but general maintenance of 
the protein/creatinine ratio. 
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DISCUSSION 
 
 The study described in this thesis was undertaken in order to determine the effects 
of high-dose dietary supplementation with lutein and zeaxanthin, and their 1:1 
combination on the deposition of these carotenoids and their metabolites in the plasma, 
ocular tissues, and other organs and major tissues in female Rhesus Macaque primates. 
To date, several lutein and zeaxanthin supplementation studies in various species of 
primates have been conducted (Snodderly et al., 1990; Snodderly et al., 1997; Leung et 
al., 2001; Neuringer et al., 2004). The results discussed in this thesis were part of a larger 
study that involved ocular examinations including fundus photography and multifocal 
electroretinograms (ERGs), retina histopathology, and the measurement of various 
biomarkers associated with toxicity. Thus, this study aimed to explore the efficacy of 
high-dose lutein and zeaxanthin supplementation as a potential treatment in the 
prevention and/or attenuation of AMD and to investigate the safety of such treatments. 
Prior to this study no data were available concerning the potential toxicity from high 
(pharmaceutical) doses of lutein and zeaxanthin such as those selected for the L-treated 
and the Z-treated primates. The dose of approximately 10 mg/kg/day that was chosen for 
lutein and zeaxanthin was approximately 60 times the highest dose selected for a recent 
clinical trial in older adults with and without AMD (Moura et al., 2004), and 5 times 
higher than the dose selected for the primates in the study by Neuringer et al. (2004). This 
amount is approximately 100 times the amount considered to be a high dietary intake 
level of combined lutein and zeaxanthin relative to the average American diet (Seddon et 
al., 1994). 
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Another aim of this study was to examine the effectiveness of supplementation 
with equal amounts of lutein and zeaxanthin and to gain insight into the effects of 1:1 
supplementation with these carotenoids and to identify whether there is an interaction. 
Rhesus Macaque monkeys were selected as the animal model for this study 
because of their low serum xanthophylls concentrations relative to other species studied 
(Snodderly et al., 1990; Neuringer et al., 2004; Slifka et al., 1999; Crissey et al., 1999). 
Additionally, women have been shown to have lower MPOD than men (Hammond et al., 
1996) and a higher risk of AMD (Kle in et al., 1992; Pieramici et al., 1994), so the 
selection of female Rhesus monkeys  posed the challenge of increasing plasma and ocular 
concentrations of lutein and zeaxanthin through dietary supplementation. As this study 
was nearing completion, another group of researchers reported on their studies in which 
Rhesus monkeys raised to adulthood on a xanthophyll- free diet were fed lutein and 
zeaxanthin as dietary supplements (Neuringer et al., 2004; Leung et al., 2004; Johnson et 
al., 2005; Leung et al., 2005). The mean serum concentrations reported for the control 
primates used in these studies was 74 ± 9 nmol/L for lutein and 81 ± 7 nmol/L for 
zeaxanthin, whereas the baseline levels in our study were considerably higher. The mean 
plasma lutein levels for the primates in our study were 240 ± 20 nmol/L for lutein and 
120 ± 10 nmol/L for zeaxanthin. The diet selected for the primates in our study provided 
approximately 0.99–1.32 mg (1.74–2.32 µmol) of lutein, and 0.26–0.35 mg (0.46–0.62 
µmol) of zeaxanthin per day, and the diet chosen in the primate studies conducted by 
Neuringer et al. provided nearly equal amounts of lutein (0.72–2.18 mg/day) and 
zeaxanthin (0.72–1.82 mg/day). The differences between the two diets cannot provide a 
reasonable explanation for the differences in serum or plasma concentrations of 
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carotenoids that were observed in the 2 studies. Both the mean age and mean body weight 
of the xanthophyll- free primate studies were nearly 3 times the mean values for the 
primates in our study which may have contributed to the disparities in serum/plasma 
carotenoid levels. At the outset of our study the animal weights ranged from 2.9 to 4.4 kg, 
and ages ranged from 1.9 to 3.9 years (Appendix J). The inter- individual variability with 
respect to weight and age was not significant, but there was considerable variability 
among the primates in their responses to the 3 treatments. The differences in baseline 
plasma levels suggest that younger Rhesus Macaque monkeys may absorb and 
metabolize lutein and zeaxanthin more efficiently than their older counterparts. However, 
because of these differences as well as differences in supplemental doses and duration, 
study design, and analytical procedures, the results of these studies are difficult to 
compare to those of our study. Where applicable in this thesis discussion, further 
comparisons of the results of these studies are made. 
 
Changes in the Plasma Concentrations  of Lutein, Zeaxanthin, and Their 
Metabolites in the Control, L-Treated, Z-Treated, and L/Z-Treated Primates 
 
Plasma Concentrations of Lutein and Zeaxanthin 
 
Mean plasma concentrations of both lutein and zeaxanthin in the L-treated group, 
the Z-treated group, and the L/Z-treated group increased during the initial 6 months of 
supplementation (Figure 23). It is important to note that the all-trans- and the cis- isomers 
of lutein (9-cis, 9’-cis, 13-cis, 13’-cis, 15-cis) and zeaxanthin (9-cis, 13-cis, 15-cis) were 
simultaneously separated by HPLC, but because the ratio of these isomers did not 
significantly change during the supplementation period and follow-up, the reported 
plasma concentrations of lutein and zeaxanthin are the combined totals for their 
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respective geometric isomers. See Table 16 for a summary of the mean plasma 
concentrations of lutein and zeaxanthin in the 3 treatment groups and the control group. 
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Figure 23. Changes in the mean plasma lutein concentrations (µmol/L) for the control, L-treated, 
Z-treated, and L/Z-treated primates at baseline and months 6, 12, and 18. 
 
 
An increase in plasma lutein was expected in both the L-treated and L/Z-treated 
primates since the daily supplements contained 9.34 mg/kg and 0.5 mg/kg of lutein, 
respectively. This turned out to be the case, and in fact, it appeared that the bioavailability 
of lutein at month 6 was nearly equal for lutein at a daily dose of 9.34 mg/kg or 0.50 
mg/kg. Interestingly, the mean plasma concentration of lutein in the Z-treated primates 
also increased although not significantly (p = 0.07) between baseline and month 6 of the 
supplementation period even though the zeaxanthin supplements did not contain any 
lutein.  While it is possible that this initial increase in lutein during high-dose 
supplementation with zeaxanthin may have resulted from the in vivo transformation of 
zeaxanthin to lutein (Figure 2), it is not likely as zeaxanthin would have to undergo 2 
conversions to reach this end point. This increase was more likely the result of the large 
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amount of inter- individual variability in plasma lutein levels of this group. It is also 
possible that the high concentration of circulating zeaxanthin may have enhanced the  
absorption of the dietary lutein that was provided in the stock diet. 
 
Table 16. Mean concentrations of total lute in and total zeaxanthin in the plasma of control, L-
treated, Z-treated, and L/Z-treated primates at baseline and months 6, 12, and 18. 
Concentrations of Carotenoids  (µmol/L) in Primate Plasma* 
Lutein Zeaxanthin 
 
 
Primate 
Group 
 
 
Baseline 
6 
Months 
12 
Months 
18 
Months 
 
Baseline 
6 
Months 
12 
Months 
18 
Months 
Control a 
Mean ±  
SEM 
 
0.244 ± 
0.021 
 
0.235 ± 
0.024  
 
0.228 ± 
0.041  
 
0.212 ± 
0.046 
 
0.118 ± 
0.009  
 
0.069 ± 
0.010  
 
0.120 ± 
0.027  
 
0.120 ± 
0.026  
L-Treated b 
Mean ±  
SEM 
 
0.223 ± 
0.084 
 
0.573 ± 
0.062  
 
0.709 ± 
0.070  
 
0.227 ± 
0.052  
 
0.111 ± 
0.018  
 
0.123 ± 
0.003  
 
0.147 ± 
0.018  
 
0.107 ± 
0.027  
Z-Treated b 
Mean ±  
SEM 
 
0.303 ± 
0.058  
0.416 ± 
0.071 
0.316 ± 
0.067  
0.280 ± 
0.046  
 
0.230 ± 
0.035  
 
0.822 ± 
0.075  
 
0.918 ± 
0.104  
 
0.130 ± 
0.067  
L/Z-Treated c 
Mean ±  
SEM 
 
0.258 ± 
0.029  
 
0.614 ± 
0.061  
 
0.278 ± 
0.037  
 
--d 
 
0.111 ± 
0.017  
 
0.334 ± 
0.040  
 
0.136 ±  
0.024  
 
--d 
 
* Lutein and zeaxanthin refer to the total combined amounts of all-trans plus the respective cis-isomers; a For the 
control group, n=3 at baseline, months 6 and 12; n=2 at month 18; b For the L-treated and Z-treated groups, 
n=5 at baseline, months 6 and 12; n=3 at month 18; c For the L/Z-treated primates, n=5 at baseline and 
months 6 and 12; d Data not available since primates were sacrificed at month 12. 
 
The plasma lutein levels measured between months 6 and 12 of the supplementation 
period also yielded interesting results. While the mean plasma concentration of lutein 
increased significantly in the L-treated primates between months 6 and 12, the mean level 
for the L/Z-treated primates at month 12 (0.267 ± 0.037 µmol/L) was significantly lower 
than the 6 month value and was not significantly different from the mean baseline 
concentration (0.2581 ± 0.0294 µmol/L). Since daily supplementation with both lutein and 
zeaxanthin at a dose of 0.5 mg/kg of each continued during this time, it is possible that 
the organs and tissues absorbed more lutein after 6 months of supplementation. It appears 
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that chronic supplementation with the combination of lutein (0.5 mg/kg) and zeaxanthin 
(0.5 mg/kg) in primates does not result in persistent significant increases in plasma lutein 
levels. These results could also suggest an interaction between lutein and zeaxanthin 
when given at this dose that causes decreased absorption of lutein into the bloodstream 
after an initial peak is reached. 
By comparing the L-treated group and the L/Z-treated group we can explore the 
possibility of an interaction caused by concurrent lutein and zeaxanthin supplementation. 
The L-treated primates, in addition to receiving a high dose of lutein (9.34 mg/kg) also 
received a lower daily dose of zeaxanthin (0.66 mg/kg) that was comparable to the dose 
given to the L/Z-treated group (0.5mg/kg). Because the lutein absorption into the plasma 
of the L-treated group did not appear to have been affected by the zeaxanthin 
supplementation between 6 and 12 months, it does not seem likely that zeaxanthin 
decreased the absorption of lutein into the bloodstream. Another interesting finding was 
that while the L/Z-treated group was given equal amounts of lutein and zeaxanthin (0.5 
mg/kg each) plasma lutein levels were approximately twice as high as the zeaxanthin 
levels after 6 months of supplementation. While the higher mean plasma level of lutein at 
baseline compared to that of zeaxanthin can be explained by differences in the 
composition of the stock diet (L:Z ≅ 3.8), the 6 month levels cannot be as easily 
explained. It appears that lutein was better absorbed than zeaxanthin after 6 months of 
supplementation. This is a contrast to the higher mean levels of plasma zeaxanthin found 
at both 6 and 12 months in the primates supplemented daily with 10 mg/kg of zeaxanthin 
when compared to the levels of lutein in those supplemented daily with approximately 
the same amount of lutein (L-treated group). 
 97 
Between baseline and 6 months only the Z-treated and the L/Z-treated primates 
had significant increases in their mean plasma zeaxanthin concentrations, even though the 
L-treated group received a dose of zeaxanthin slightly higher than the dose given to the 
L/Z-treated group. Table 16 and Figure 24 compare the mean zeaxanthin levels for the 
control and treatment groups (L, Z, and L/Z) during the supplementation period and after 
6 months without supplementation.  
While the L-treated primates were supplemented daily with approximately 0.66 
mg/kg of zeaxanthin and the L/Z-treated primates received 0.5 mg/kg of zeaxanthin, the 
mean plasma concentration of zeaxanthin in the L/Z-treated group increased significantly 
(p< 0.0001) between baseline and month 6, but that of the L-treated group did not. 
Conversely, while the mean zeaxanthin level in the L-treated group was not significantly 
higher at month 6 compared to baseline, it was significantly higher between baseline and 
month 12 suggesting a gradual and consistent increase in plasma zeaxanthin concentration 
during the 12 months of supplementation. In the L/Z-treated primates, plasma zeaxanthin 
increased significantly (by 3-fold) between baseline and month 6, and then decreased to 
nearly the baseline concentration at month 12. Interestingly, the mean plasma concentrations  
of zeaxanthin at month 12 among the 2 groups were nearly the same. In the L/Z-treated 
primates a similar trend was observed in the changes in mean plasma lutein levels during 
12 months of supplementation in that the concentration increased significantly between 
baseline and month 6 and declined thereafter to near the baseline level by month 12.  
In comparing the mean plasma concentrations of lutein in the L-treated group 
(9.34 mg/kg L) and the L/Z-treated group (0.5 mg/kg L) at month 6 (Figure 23), it 
appears that supplementation with both a very high dose and a much lower dose of lutein 
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result in the same bioavailability of this carotenoid. Alternatively, examination of the 
mean zeaxanthin concentrations depicted in Figure 24 shows that this trend is not 
observed in of the primates supplemented with 0.5 mg/kg or 10 mg/kg of zeaxanthin. The 
mean plasma concentration of zeaxanthin in the L/Z-treated group was less than half that 
of the Z-treated group at month 6. Additionally, when lutein and zeaxanthin were given at 
the low dose of 0.5 mg/kg each, lutein was better absorbed than zeaxanthin. This suggests 
that lutein may interact with zeaxanthin to lower its bioavailability while the reverse does 
not seem to be the case. 
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Figure 24. Changes in mean plasma zeaxanthin concentrations (µmol/L) in the control, L-
treated, Z-treated, and L/Z-treated primates at baseline and months 6, 12, and 18. 
 
 
In the Z-treated primates, the mean level of zeaxanthin in plasma increased by 
more than 3-fold between baseline and month 6, yet the increase between months 6 and 
12 was not significant. This suggests that while mean plasma zeaxanthin levels increase 
rapidly with supplementation at this dose (10 mg/kg/day) and remain high, mean plasma 
zeaxanthin concentration plateaus at some point after 6 months of supplementation. By 
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month 18, the plasma level of zeaxanthin decreased to below the baseline level. However, 
the baseline concentration of zeaxanthin for this group was almost twice as high as the 
levels of the L-treated, L/Z-treated, and control groups and at 18 months, the mean level 
was nearly the same as those seen in the L-treated and Z-treated primates. 
Comparing plasma concentrations of lutein or zeaxanthin in response to high-dose 
supplementation (~10 mg/kg/day) with these carotenoids provides an insight into the 
bioavailability of these carotenoids. Although the mean concentration for all of the 
primates in the study (n=18) at baseline was 0.259 µmol/L for lutein and 0.145 µmol/L 
for zeaxanthin, the mean concentration of lutein in the L-treated group (9.34 mg/kg of L) 
at month 6 (0.573 ± 0.062 µmol/L) was lower than that of zeaxanthin in the Z-treated 
group (10 mg/kg of Z) at month 6 (0.822 ± 0.075 µmol/L). Similarly, the mean level of 
lutein at month 12 in the L-treated group (0.709 ± 0.070 µmol/L) was also lower than that 
of zeaxanthin in the Z-treated group (0.918 ± 0.104 µmol/L). It is unlikely that the 0.66 
mg/kg difference in supplemental dose could have caused this difference especially since 
the stock diet provided more lutein than zeaxanthin and could therefore balance this 
difference. These results suggest that zeaxanthin is more efficiently absorbed into the 
circulating blood than lutein and/or that lutein may be better absorbed into the tissues and 
organs than zeaxanthin, and is therefore sequestered by the tissues at a higher rate than 
zeaxanthin. It is particularly interesting to note that in the L/Z-treated primates that were 
fed equal doses of lutein and zeaxanthin (0.5 mg/kg of each), lutein appears to be more 
effectively absorbed into the bloodstream after 6 months of supplementation than 
zeaxanthin. This is clearly indicated by the mean concentration of lutein in plasma that 
was nearly twice that of zeaxanthin at month 6 (Figure 24). The doses that were given in 
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the present study were considerably higher than a dose that would be more appropriate 
for a clinical trial involving humans. Nonetheless, the possible interaction between 
supplemental lutein and zeaxanthin at various doses warrants further investigation. 
 
Plasma Concentrations of Lutein and Zeaxanthin Metabolites 
 
Based on evidence from earlier studies, it has been hypothesized that 3’-oxolutein 
is most likely formed via the allylic oxidation of dietary lutein (Khachik et al., 1995; 
Khachik et al, 1997a; Khachik et al., 1997c; Khachik et al., 2002). As shown in the 
proposed metabolic pathways in Figure 2, 3’-oxolutein can then be reduced to form 3’-
epilutein or revert to lutein. It has also been proposed that dietary zeaxanthin can undergo 
stereospecific double-bond isomerization to form 3’-epilutein which can then be oxidized 
to form 3’-oxolutein. Given this overall scheme, it is possible that 3’-oxolutein and 3’-
epilutein can be formed from lutein and/or zeaxanthin. It must be noted, however, that the 
validity of these proposed metabolic transformations can only be confirmed by 
supplementation studies with isotopically labeled lutein and zeaxanthin, which have not 
been conducted to date. 
 The mean plasma concentrations of 3’-oxolutein and 3’-epilutein in the control, 
L-treated, Z-treated, and L/Z-treated groups are compared in Figures 25 and 26, 
respectively. In the L-treated primates, the mean 3’-oxolutein concentration increased 
significantly between baseline and month 6, and continued to increase between months 6 
and 12, although the latter change was not statistically significant. Meanwhile, the 
opposite effect was observed in the mean plasma concentration of 3’-epilutein. The 
increase in the mean level of 3’-epilutein in the L-treated group between baseline and 
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month 6 was not significant, while a statistically significant increase in the level of this 
metabolite occurred between months 6 and 12. These observations are consistent with the 
pathway proposed in Figure 2, and suggest that the oxidation of lutein to 3’-oxolutein 
within the first 6 months increases the level of this metabolite in the plasma to a point at 
which the stereo-controlled reduction of 3’-oxolutein to 3’-epilutein becomes significant. 
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Figure 25. Changes in the mean plasma concentrations of 3’-oxolutein (µmol/L) in the control, 
L-treated, Z-treated, and L/Z-treated primates at baseline and at months 6, 12, and 18. 
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Figure 26. Changes in the mean plasma concentrations of 3’-epilutein (µmol/L) in the L-treated, 
L/Z-treated, and control primates. 3’-Epilutein was not consistently detected in the plasma of the 
Z-treated primates during the study and therefore this group was not included in this figure. 
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The mean plasma concentration of zeaxanthin in the Z-treated primates increased 
significantly within the first 6 months of supplementation (p = 0.0002), but appeared to 
plateau between months 6 and 12. Meanwhile, there was no significant change in the 
mean level of lutein in the plasma of the Z-treated primates between baseline and 12 
months. The data pertaining to the concentration of 3’-epilutein in the Z-treated primates 
have been excluded from Figure 26 because only trace amounts of this metabolite were 
detected in some of the primates. Since daily supplementation with zeaxanthin at a dose 
of 10mg/kg does not appear to affect the mean plasma concentrations of 3’-epilutein, this 
may suggest that 3’-epilutein is predominantly formed from lutein but not zeaxanthin.  
Meanwhile, the mean plasma concentration of 3’-oxolutein in the Z-treated animals is 
significantly higher after 12 months of supplementation than that at baseline. However, 
the mean 3’-oxolutein level in plasma, much like that of zeaxanthin in the Z-treated 
group, seems to plateau after month 6. This pattern for plasma levels of 3’-oxolutein is 
also observed in the L-treated primates. Three primates from the L-treated and the Z-
treated groups were observed for 6 months post-supplementation at which time mean 
plasma levels of these metabolites return to baseline levels. 
The only significant change observed in the mean plasma metabolite concentrations  
in the L/Z-treated primates was that of 3’-oxolutein between baseline and month 6. 
Supplementation with lutein and zeaxanthin (each at 0.5 mg/kg) increases the mean 
concentrations  of lutein and zeaxanthin after 6 months of supplementation, but then these 
levels decline to near the ir baseline values between months 6 and 12. This also appears to 
be the case with 3’-oxolutein levels in the plasma of the L/Z-treated group. Similarly, the 
mean plasma 3’-epilutein concentration in the L/Z-treated group increases between 
 103 
baseline and  month 6 and thereafter returns to its baseline value between months 6 and 
12. The decrease in the mean concentrations of lutein, zeaxanthin, and their metabolites 
between months 6 and 12 in the L/Z-treated primates (0.5 mg/kg each of lutein and 
zeaxanthin) may suggest that during this period the supplemental carotenoids are better 
absorbed into the organs and tissues. The high concentrations of lutein, zeaxanthin, and 
3’-oxolutein in the major organs and tissues of the supplemented animals at month 12 
support this conclusion.  
 
 
Concentrations  of Lutein, Zeaxanthin, and Their Metabolites in the Ocular Tissues, 
Major Organs and Other Tissues of the Control and Supplemented Primates 
 
Concentrations of Lutein, Zeaxanthin, and Their Metabolites in Ocular Tissues 
 Lutein and zeaxanthin were identified as the major carotenoids in the ocular 
tissues (retina, ciliary body, lens, iris) of the primates. The metabolites 3’-oxolutein and 
meso-zeaxanthin were detected in the retina while the former was also detected in the 
ciliary body. Due to the low concentration of carotenoids in the ciliary body, iris, and 
lens, no attempt was made to measure meso-zeaxanthin in these tissues. It has been 
proposed that 3’-oxolutein can be formed from lutein and/or zeaxanthin and that its 
presence in the ocular tissues may be the result of its transport from circulating blood or 
the in vivo enzymatic and light-induced metabolic transformation of lutein and/or 
zeaxanthin in the eye (Khachik et al., 1997a; Bernstein et al., 2001; Khachik et al., 1995). 
However, it has been demonstrated that meso-zeaxanthin, which is not of dietary origin is 
present in the retina yet is absent from both human plasma and liver (Khachik et al., 
2002). Therefore, while the origin of 3’-oxolutein in the ocular tissues is unclear, meso-
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zeaxanthin is most likely formed in the retina from lutein. Additional support for this 
metabolic transformation comes from the supplementation studies of xanthophyll- free 
primates by Johnson et al. (2005), who demonstrated that meso-zeaxanthin was absent in 
the retinas of xanthophyll- free and zeaxanthin-fed primates, but was present in the 
primates supplemented with lutein. These researchers showed that meso-zeaxanthin was 
present only in the macula (innermost 4-mm area of retina) of the primates that were 
supplemented with lutein (Johnson et al., 2005). One of the objectives of our study was to 
identify and quantify 3’-oxolutein and meso-zeaxanthin in the retina of the Rhesus 
monkeys that were supplemented with high doses of lutein and zeaxanthin. The central 
and peripheral regions of the retina s were not examined separately, because the low 
concentration of these metabolites in the various regions of the retina would not allow 
their unequivocal identification by HPLC-UV/Visible photodiode array detection. 
Consequently, the mean concentrations of carotenoids are expressed for the whole retina. 
Similarly, because the concentrations of carotenoids in the ciliary body, iris, and lens 
were very low, no attempt was made to quantify meso-zeaxanthin in these tissues. 
After 12 months of supplementation, significant increases in the mean 
concentrations of lutein were found in the retina and iris of the L-treated primates in 
comparison to the control primates. The results depicted in Figure 27 clearly show the 
significant increases in the mean concentrations of lutein in the retina and iris of the 
primates that were supplemented daily with lutein (9.34 mg/kg L and 0.66 mg/kg Z) for 
12 months in comparison with those of the control group. Six months after the end of 
supplementation with lutein (month 18), the mean level of lutein in the retina of the L-
treated group was not significantly different than that of the control group (p = 0.28). The 
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mean concentrations of lutein in the ciliary body and lens after 12 months of daily 
supplementation with 9.34 mg/kg of lutein and 0.66 mg/kg of zeaxanthin did not change 
significantly compared to those of the control group although the mean level of lutein in 
lens increased in the animals that were sacrificed after 18 months. While the mean 
concentration of zeaxanthin in the retina of the L-treated primates at month 12 appeared 
to be much higher than that of the control group and the L-treated group at month 18, the 
differences were not statistically significant due to the large amount of inter- individual 
variability. The mean concentration of zeaxanthin in the ciliary body at month 12 was 
also higher than that of the control group, but this difference was not statistically 
significant. This is despite the fact that the mean plasma concentration of zeaxanthin is 
significantly increased after 12 months of supplementation with 0.66 mg/kg zeaxanthin in 
comparison to the mean baseline level.  It should be noted, however, that the high inter-
individual variability observed in the concentrations of this carotenoid was a limitation 
for establishing the true statistical significance. 
There were significant increases in the mean concentrations of the metabolites 3’-
oxolutein and meso-zeaxanthin in the retina of the L-treated (9.34 mg/kg L and 0.66 
mg/kg Z) primates after 12 months of supplementation compared to that of their levels  at 
month 18 (6 months post-supplementation) (Appendix K). There was no significant 
difference between the mean levels of meso-zeaxanthin in the primates supplemented 
with 9.34 mg/kg of lutein at month 12 and tha t of the control group. It should be noted 
that the mean concentration of meso-zeaxanthin in the control group was considerably 
higher than those of either the L-treated or the Z-treated (10 mg/kg Z) groups at month 
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18. Therefore the month 18 data for L-treated group may provide a better measure of the 
mean baseline level of meso-zeaxanthin.  
A comparison of the mean plasma and retina concentrations of lutein in the L-
treated (9.34 mg/kg L and 0.66 mg/kg Z) and the L/Z-treated (L and Z each at 0.5 mg/kg) 
compared to those of the control group are shown in Figure 27. It appears that the plasma 
and retina levels of this carotenoid are proportionally correlated at the 2 supplemental 
doses of 9.34 mg/kg and 0.5 mg/kg. A similar association between the mean lutein levels 
in the plasma and retina is observed in the control group that received no dietary 
supplement. 
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Figure 27. Mean plasma concentrations (µg/dL) and retina concentrations (ng/tissue) of lutein in 
the lutein-supplemented primates [L-treated (9.34 mg/kg), L/Z-treated (0.5 mg/kg)] at month 12 
in comparison to the mean levels in the control primates. 
 
The mean concentration of zeaxanthin in the retina of the Z-treated (10 mg/kg) 
monkeys increased by approximately 4-fold after 12 months compared to that of the 
animals in the control group. Supplementation with zeaxanthin for 12 months did not 
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increase the mean level of lutein in the retina of the Z-treated primates in comparison to 
the control group (11.05 ± 2.19 ng/tissue). However, the mean concentration of lutein in 
the retina of the Z-treated group at month 12 (19.2 ± 9.07 ng/tissue) was significantly 
higher than the ir mean level at month 18 (7.84 ± 1.03 ng/tissue). This may be attributed 
to the considerable amount of variability in the concentration of lutein in the retinas of 
this group in response to supplementation with zeaxanthin at a high dose. In addition,  
supplementation with zeaxanthin at the dose of 10 mg/kg significantly increases the mean 
concentration of this carotenoid in the ciliary body after 12 months in comparison to that 
of control animals.  
Although the zeaxanthin supplements contained no lutein, the mean concentration 
of lutein in the retina of the Z-treated animals appeared to be considerably higher than 
that of the control animals. However, due to the large inter- individual variability in these 
levels, this difference was not significant. Comparisons of the mean concentrations of 
lutein, zeaxanthin, and their metabolites, meso-zeaxanthin and 3’-oxolutein, in the retinas 
among the  control and the 3 treatment groups after 12 months of supplementation are 
depicted in Figure 28. See Appendix J for a summary of the mean concentrations of 
carotenoids and their metabolites in the ocular tissues for the study’s four primate groups. 
It is interesting to note that the mean levels of lutein and zeaxanthin in the  retina of the Z-
treated group were nearly the same. This was a contrast to what was observed in the 
retinas of the L-treated group that had a mean lutein concentration that was more than 8-
fold that of zeaxanthin. This indicates when Rhesus monkeys are given a dose of lutein or 
a comparable high dose of zeaxanthin, lutein accumulates in the retina more effectively 
than zeaxanthin. 
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Figure 28. Mean concentrations (ng/tissue) of lutein, zeaxanthin, meso-zeaxanthin, and 3’-
oxolutein in the retina of the control, L-treated (9.34 mg/kg L and 0.66 mg/kg Z), Z-treated (10 
mg/kg Z), and L/Z-treated (L & Z each at 0.5 mg/kg) primates at month 12. 
 
 
The mean concentration of the metabolite 3’-oxolutein significantly increases in 
the retina after 12 months of supplementation with zeaxanthin at the dose of 10 mg/kg. In 
the ciliary body of these primates, however, no significant change in mean 3’-oxolutein 
concentration is observed. It is interesting that the mean level of meso-zeaxanthin was 
higher in the Z-treated (10 mg/kg) primates than in the L-treated (9.34 mg/kg L and 0.66 
mg/kg Z) primates since it has been proposed that it is lutein and not zeaxanthin that is 
the major precursor for this metabolite. After 12 months of supplementation with 10 
mg/kg of zeaxanthin, the mean concentration of meso-zeaxanthin in the retinas increases 
significantly. This contrasts the results of Johnson et al. who reported the absence of 
meso-zeaxanthin in the macula after supplementation of Rhesus monkeys with 
zeaxanthin. The supplemental dose given to those primates was less than one-fourth of 
that used in our study and the primates had been raised from birth on a xanthophyll- free 
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diet prior to supplementation. These differences make it increasingly difficult to compare 
results of the two studies. 
In our study, we found that the mean level of meso-zeaxanthin in the retina of the 
L-treated primates is not significantly higher after 12 months when compared to the 
control group. Because of the large inter- individual variability, however, the month 18 
values may be a better measure of the baseline level of this metabolite than the control 
value. Without metabolic studies that employ isotopically labeled lutein and zeaxanthin, 
it is not possible to determine the origin of meso-zeaxanthin with certainty. One 
possibility that cannot be ruled out is the formation of meso-zeaxanthin from 3’-oxolutein 
since the mean concentration of the latter metabolite was increased significantly after 12 
months of daily supplementation with zeaxanthin (10 mg/kg) compared to the control 
primates. This metabolic conversion would require the stereospecific reduction of 3’-
oxolutein to 3’-epilutein followed by double-bond migration. Because no measurable 
amount of 3’-epilutein was detected in the retina of the Z-treated primates, this 
transformation would most likely take place in a single step reaction. Alternatively, if 
meso-zeaxanthin is formed exclusively via double-bond isomerization of lutein, our 
results indicate that the high concentration of zeaxanthin in the retina of these primates 
may interact with lutein metabolism in this tissue. In both the iris and lens of the Z-
treated primates, the mean lutein concentration was roughly 2 times as high at month 18 
than at month 12, while zeaxanthin was detected at month 12 but not at month 18. These 
findings suggest the idea that zeaxanthin is cleared from both the iris and lens, while the 
concentrations of lutein in these tissues are actually higher at month 18 than at month 12. 
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 The mean concentrations of the lutein and zeaxanthin in the retinas of the L/Z -
treated group (L & Z each at 0.5 mg/kg) after 12 months of supplementation is not 
significantly different from that of the animals in the control group. This may be because 
the mean concentrations of these carotenoids in plasma of the monkeys peaked around  
month 6 and declined to their baseline values after this point. It appears that this decrease 
is not accompanied by an increase in the uptake of lutein and zeaxanthin by retina or 
ciliary body in Rhesus Macaque monkeys. Therefore, it is likely that lutein and 
zeaxanthin are incorporated into the retinas of the monkeys initially between baseline and 
month 6 of supplementation, and subsequently, as the mean plasma levels of these 
carotenoids decrease significantly between months 6 and 12, the retina levels follow the 
same pattern. The mean concentrations of meso-zeaxanthin and 3′-oxolutein in the retina 
of the L/Z treated animals after 12 months were not significantly different than those of 
the control group. This is not surprising since the levels of these metabolites in the retina 
of the monkeys appear to correlate with those of lutein and zeaxanthin. Figures 27 and 29 
illustrate that plasma concentrations of lutein and zeaxanthin correlate directly with levels 
of these carotenoids in the retina. After 12 months of supplementation with lutein and 
zeaxanthin each at a dose of 0.5 mg/kg, only the concentrations of lutein and zeaxanthin 
appear to increase in the iris of the primates. 
 The high daily dose of supplemental lutein (9.34 mg/kg) led to a considerably 
higher mean concentration of this carotenoid (40.4 ± 1.41 ng/tissue) in the primate retinas 
compared to the mean zeaxanthin level (20.4 ± 3.88 ng/tissue) that resulted from daily 
supplementation with a comparable dose of zeaxanthin (10 mg/kg). 
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Figure 29. Mean concentration of zeaxanthin in plasma (µg/dL) and retina (ng/tissue) in the primates 
supplemented with zeaxanthin at month 12 in comparison to those of the control primates. 
 
 
As shown in Figures 27 and 29, an interesting trend is clearly seen in the 
comparison of the changes in mean plasma carotenoid levels with the corresponding 
changes in the concentration of carotenoids in the retinas of the supplemented primates. 
The mean retina concentration of lutein in the L-treated, L/Z-treated, and control groups 
correlate well with the mean retina level of this carotenoid. However, in the Z-treated 
group that was fed a high-dose of zeaxanthin (10 mg/kg), the increase in mean 
concentration of this carotenoid in the retina was not as closely associated with the levels 
in plasma as were the levels of lutein in the L-treated primates. This may suggest that at a 
high supplemental dose of nearly 10 mg/kg, lutein may be better absorbed by the retina 
than zeaxanthin. This is despite the fact that the mean plasma concentrations of both 
carotenoids after 12 months of supplementation with lutein or zeaxanthin (~10 mg/kg) 
reach nearly the same concentration. 
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Concentrations of Lutein, Zeaxanthin and Their Metabolites in Major Organs and  
Other Tissues 
 
Daily supplementation with a high dose of either lutein (9.34 mg/kg) or 
zeaxanthin (10 mg/kg) significantly increased the concentrations of lutein and zeaxanthin 
in most of the major organs and tissues of the primates after 12 months.  For each group, 
the highest mean concentrations of these carotenoids were found in the liver. However, 
levels of lutein and zeaxanthin in the liver were considerably lower in the L/Z-treated 
group when compared to the L- and the Z-treated groups. This suggests that when plasma 
levels of lutein and/or zeaxanthin are chronically high the liver may act a storage 
repository for these carotenoids. Interestingly, the mean levels of lutein and zeaxanthin in 
the liver were significantly higher in the primates in the control group in comparison to 
those of the L/Z-treated group. 
The mean concentrations of lutein and zeaxanthin in the lung were also much 
lower in the L/Z-treated group in comparison with those of the L-treated and the Z-
treated groups. Additionally, the mean concentration of zeaxanthin in the lung tissues of 
the Z-treated group (1.65 µg/g) was nearly 7-fold that of lutein in the L-treated group 
(0.23 ± 0.02 µg/g). Similarly, in the colon the mean level of lutein in the L-treated group 
(0.23 ± 0.13 µg/g) was considerably lower than that of zeaxanthin in the Z-treated group 
(1.34 ± 0.78 µg/g). This suggests that while both carotenoids are effectively accumulated 
in the lung and colon tissue when administered at a high dose, zeaxanthin is absorbed 
more efficiently than lutein. The bioavailability of lutein and zeaxanthin in the other 
organs and tissues (liver, kidney, breast, ovary, spleen, cervix) appear to be about the 
same irrespective of the supplemental dose of lutein and zeaxanthin.  
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Lutein and zeaxanthin are also absorbed effectively into the major organs and 
tissues of the L/Z-treated monkeys (L & Z each at 0.5 mg/kg). The highest concentrations 
of these carotenoids were found in the liver, colon, breast, ovary, and spleen. In fact, at 
the dose of 0.5 mg/kg of lutein and zeaxanthin each, these carotenoids are equally as 
bioavailable in most organs and tissues of the primates as they are at the substantially 
higher dose of approximately 10 mg/kg of lutein or zeaxanthin fed separately (L-treated 
& Z-treated groups). 
Overall, the the liver accumulates the highest levels of lutein and zeaxanthin 
among all 3 treatment groups as well as the control group. Both lutein and zeaxanthin are 
absorbed well into the organs and tissues of the primates, but the uptake of zeaxanthin 
into the lung and colon is considerably higher than that of lutein. 
 
Limitations and Strengths of the Study 
 Small sample size was the major limitation of the study. Because there were only 
3 control animals and 5 animals per treatment group it was difficult to detect small 
differences. The issue of small sample size was compounded by the high inter- individual 
variability that was observed in the concentrations of carotenoids in plasma and ocular 
tissues of the primates in response to supplementation. Larger treatment groups would 
have increased the statistical power of the tests (Analysis of Variance and Covariance, 
Least Significant Difference) that were applied to the data. The fact that the start dates for 
the three studies differed from one another by several months was another limitation. 
Furthermore, the control group was housed with the animals from the Lutein 
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Supplementation Study and followed the same timeline as this group. It is not known 
how this housing situation or the different start dates may have affected the results. 
Another limitation lied in the variability in the weights of the retinas and other 
ocular tissues that were analyzed. It is not known whether weight is directly correlated to 
the total amount of carotenoids present in these tissues, and consequently, the extent to 
which this variability affected the data cannot be predicted. 
In retrospect, a couple of aspects of the study design could have been modified to 
provide additional information. First, it would have been interesting to see the effects of 
treatment with a combined high dose of zeaxanthin (e.g., 10 mg/kg) and a low dose of 
lutein (e.g., 0.66 mg/kg); this would be opposite to the doses that were given to the L-
treated group. Such a study would have been useful in further exploring the metabolic 
interaction between lutein and zeaxanthin in the plasma, retina, and various organs and 
tissues. Also, the study design could have been considerably improved by collecting 
additional blood samples between baseline, month 6, month 12 and month 18. This would 
in turn provide valuable information regarding the absorption of carotenoids and their 
metabolites into plasma and their rate of clearance from the circulating blood. 
Additionally, by increasing the number of animals in each group, it would have been 
possible to sacrifice several animals at month 6 and to correlate the concentrations of 
carotenoids and their metabolites in the ocular tissues to their corresponding levels in 
plasma. Unfortunately, the cost associated with procurement and long-term care of 
primates in this NEI-sponsored study did not allow for the inclusion of additional 
animals. 
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 Conversely, this study has several noteworthy strengths. Rhesus Macaque 
monkeys have been shown to be a good animal model in that this species has similar 
carotenoid plasma and tissue deposition and metabolism to that of humans (Khachik et 
al., 1995). Therefore, the results obtained from the studies presented here can be extended 
to humans. Finally, the design of this study allowed us to measure the effects of long-
term supplementation beyond the initial spikes in plasma carotenoid levels that have been 
shown to occur within a few weeks of supplementation (Khachik et al., 1995; Khachik et 
al., 1997c; Landrum et al., 1997b; Richer et al., 2004). By supplementing the animals 
with lutein and zeaxanthin at high doses for 12 months, we were able to determine the 
absorption of these carotenoids and their metabolites into the plasma, ocular tissues, and 
major organs and tissues, and establish their safety. 
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SUMMARY AND CONCLUSIONS 
 
Daily supplementation of female Rhesus Macaque monkeys with lutein (9.34 
mg/kg, 17.58 µmol/kg) for one year results in a 3.2-fold increase in the mean 
concentrations of this carotenoid in plasma and a 6.5-fold increase in that of the retina. 
Following treatment, these levels return to the baseline level after 6 months without 
further supplementation. This supplemental dose of lutein also results in 3.4- and 6-fold 
increases in the mean concentrations of meso-zeaxanthin and 3′-oxolutein in the retina of 
the monkeys, respectively.  
Daily supplementation of Rhesus Macaque monkeys with zeaxanthin at nearly the 
same dose level (10 mg/kg) for one year increases the mean concentrations of zeaxanthin 
in the plasma and retina by 3.6-fold and 4.6-fold, respectively. These levels return to 
approximately the same levels measured at baseline by 6 months post-supplementation. 
Supplementation with a high-dose of zeaxanthin also results in significant increases in the 
mean levels of meso-zeaxanthin and 3’-oxolutein in the retina of the primates. These 
results suggest that although meso-zeaxanthin is most likely formed in the retina of the 
monkeys from dietary lutein, it may also be formed from 3’-oxolutein by the 
stereospecific reduction to 3′-epilutein followed by double bond isomerizaton. 
Daily supplementation of primates with a combination of lutein and zeaxanthin 
(each at the dose of 0.5 mg/kg) for one year increases the mean plasma concentration of 
these carotenoids within the first 6 months, but thereafter, the levels of these carotenoids 
return to their baseline values. This is also reflected in the mean concentrations of lutein 
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and zeaxanthin in the retina of the L/Z-treated monkeys after 12 months that are not 
significantly different from the levels found in the control group. 
Chronic supplementation of Rhesus Macaque monkeys with lutein, zeaxanthin or 
their 1:1 combination (0.5 mg/kg of each) increases the mean concentrations of these 
carotenoids in most of the major organs and major tissues, yet zeaxanthin is more 
efficiently absorbed than lutein in lung and colon when given at comparable doses. The 
highest accumulation of these carotenoids occurs in the liver regardless of the 
supplemental dose. The bioavailability of lutein and zeaxanthin in most of the major 
organs and tissues is nearly equal for this group (L & Z each at 0.5 mg/kg) in comparison 
with the groups that were supplemented with a high dose of these carotenoids. Retina 
histopathology revealed no ocular toxicity and measurement of biomarkers associated 
with kidney toxicity revealed no toxicity as well. This work was conducted by other co-
investigators of the study presented in this thesis. Thus, supplementation of female 
Rhesus monkeys with lutein or zeaxanthin for one year at the dose of approximately 10 
mg/kg (17.58 µmol/kg) does not cause ocular toxicity and has no effect on biomarkers 
associated with kidney toxicity.  
This study provides a foundation for future clinical trials with a combination of 
lutein and zeaxanthin involving human subjects. For a 60 kg human, the chronic dose of 
lutein and zeaxanthin given to the L- and Z-treated primates is equivalent to 600 mg/day 
of lutein or zeaxanthin. Consequently, future long-term human supplementation studies 
with lutein and zeaxanthin that plan to investigate the efficacy of these carotenoids in the 
prevention of AMD at a much lower dose (e.g. 0.5 mg/kg or lower), should not present 
any problems associated with toxicity. 
 
APPENDIX A. APPROVAL FROM INSTITUTIONAL ANIMAL CARE & USE COMMITTEE  
 
 
 
APPENDIX B. CAROTENOIDS IN THE OCULAR TISSUES OF L-TREATED PRIMATES AT MONTHS 12 AND 18 
 
 
Concentrations (ng/tissue) of lutein, zeaxanthin, meso-zeaxanthin, and 3’-oxolutein in ocular tissues of primates supplemented daily 
with lutein (10 mg/kg) after 12 months of treatment and after 18 months (12 months treatment plus 6 months follow-up) 
Concentrations (ng/tissue) of Carotenoids in Primates Ocular Tissues (Tissue Weight, g)* 
 
Retina Ciliary Body Iris Lens  
 
 
Primate ID 
lutein zeaxanthin meso-zea-
xanthin 
3’-oxo-
lutein 
lutein zeaxanthin 3’-oxo-
lutein 
lutein lutein 
 
Control 
RQ4079 
 
 
RQ4107 
 
 
RQ4142 
 
 
Mean ± SEM 
 
  
 
 
14.52 
(0.103) 
 
11.63 
(0.137) 
 
6.99 
(0.111) 
 
11.05±2.19 
(0.117) 
 
 
5.35 
(0.103) 
 
4.31 
(0.137) 
 
3.54 
 (0.111) 
 
4.78±0.62 
(0.117) 
 
 
3.25 
(0.103) 
 
3.69 
(0.137) 
 
2.66 
(0.111) 
 
3.20±0.30 
(0.117) 
 
 
1.33 
(0.103) 
 
1.14 
(0.137) 
 
N.D. 
 
 
1.24±0.10 
(0.117) 
 
 
4.25 
(0.0707) 
 
4.13 
(0.0598) 
 
3.70 
(0.0419) 
 
4.03±0.17 
(0.0576) 
 
 
2.00 
(0.0707) 
 
2.11 
(0.0598) 
 
0.907 
(0.0419) 
 
1.67±0.38 
(0.0576) 
 
 
0.651 
(0.0707) 
 
0.668 
(0.0598) 
 
0.472 
(0.0419) 
 
0.597±0.06 
(0.0576) 
 
 
0.391 
(0.0160) 
 
0.401 
(0.0111) 
 
N.D. 
 
 
0.40±0.01 
(0.0115) 
 
 
0.771 
(0.136) 
 
0.437 
(0.218) 
 
0.576 
(0.0646) 
 
0.60±0.10 
(0.140) 
L Treatment 
12 months 
RQ4087 
 
 
RQ4122 
 
 
Mean ± SEM 
 
 
41.76 
(0.110) 
 
38.94 
(0.129) 
 
40.35±1.30 
(0.120) 
 
 
8.26 
 (0.110) 
 
6.85 
 (0.129) 
 
7.56±0.71 
(0.120) 
 
 
5.57 
(0.110) 
 
4.17 
(0.129) 
 
4.87±0.70 
(0.120) 
 
 
3.42 
(0.110) 
 
4.52 
(0.129) 
 
3.97±0.55 
(0.120) 
 
 
7.34 
(0.063) 
 
6.90 
(0.029) 
 
7.12±0.22 
(0.046) 
 
 
1.26 
(0.063) 
 
2.42 
(0.029) 
 
1.84±0.58 
(0.046) 
 
 
1.03 
(0.063) 
 
1.15 
(0.029) 
 
1.09±0.06 
(0.046) 
 
 
2.58 
(0.027) 
 
0.77 
(0.020) 
 
1.68±0.91 
(0.024) 
 
 
0.68 
(0.147) 
 
0.83 
(0.182) 
 
0.76±0.08 
(0.165) 
* Weight of tissues are shown in parentheses (grams); N.D., not detected. 
 
APPENDIX B. (continued) 
Concentrations (ng/tissue) of Carotenoids in Primates Ocular Tissues (Tissue Weight, g)* 
 
Retina Ciliary Body Iris Lens  
 
 
 
Primate ID lutein zeaxanthin meso-zea-
xanthin 
3’-oxo-
lutein 
lutein zeaxanthin 3’-oxo-
lutein 
lutein lutein 
L Treatment  
18 months 
RQ4078 
 
 
RQ4175 
 
 
RQ4189 
 
 
Mean ± SEM 
 
 
 
 
7.49 
(0.0609) 
 
5.08 
(0.0405) 
 
6.03 
(0.0312) 
 
6.20±0.70 
(0.0442) 
 
 
2.78 
 (0.0609) 
 
0.939 
(0.0405) 
 
3.40 
(0.0312) 
 
2.34±0.78 
(0.0442) 
 
 
2.32 
(0.0609) 
 
0.821 
(0.0405) 
 
1.11 
(0.0312) 
 
1.45±0.44 
(0.0442) 
 
 
0.80 
(0.0609) 
 
0.54 
(0.0405) 
 
0.65 
(0.0312) 
 
0.66±0.08 
(0.0442) 
 
 
2.81 
(0.0673) 
 
6.00 
(0.0545) 
 
2.12 
(0.0350) 
 
3.64±1.20 
(0.0523) 
 
 
1.08 
(0.0673) 
 
2.12 
(0.0545) 
 
0.98 
(0.0350) 
 
1.39±.0.36 
(0.0523) 
 
 
N.D 
 
 
N.D. 
 
 
N.D. 
 
 
N.D. 
 
 
0.78 
(0.0020) 
 
0.40 
(0.0085) 
 
N.D. 
 
 
0.59±0.19 
(0.0053) 
 
 
1.42 
(0.0019) 
 
0.75 
(0.1041) 
 
1.90 
(0.0839) 
 
1.36±0.33 
(0.0423) 
* Weight of tissues are shown in parentheses (grams); N.D., not detected. 
 
APPENDIX C. CAROTENOIDS IN THE MAJOR ORGANS AND TISSUES OF THE L-TREATED PRIMATES  
 
 
Concentrations (µg/g tissue) of lutein, zeaxanthin, 3’-oxolutein, and retinol in organs and tissues of one control and 2 L-treated primates (10 
mg/kg/day of lutein) for 12 months. 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, 
and Retinol in Primates’ Tissues* 
 
 
Tissue 
 
 
Primate ID 
lutein zeaxanthin 3’-oxolutein retinol 
Liver 
 
 
Control                      RQ4079 
 
Treatment                  RQ4122 
       RQ4087 
Mean ± SEM 
 
1.653 
 
3.644 
2.508 
3.076 ± 0.57 
 
0.7751 
 
1.211 
0.625 
0.918 ± 0.29 
 
N.D. 
 
N.D. 
N.D. 
N.D. 
 
11.331 
 
11.999 
28.806 
20.402±8.40 
Lung 
 
 
Control                       RQ4079 
 
Treatment                  RQ4122 
RQ4087 
Mean±SEM 
 
0.100 
 
0.250 
0.207 
0.228 ± 0.02 
 
0.051 
 
0.063 
0.041 
0.052 ± 0.01 
 
0.006 
 
0.027 
0.022 
0.024 ± 0.002 
 
0.164 
 
0.061 
0.148 
0.104±0.044 
Colon 
 
 
Control                      RQ4079 
 
Treatment                  RQ4122 
RQ4087 
Mean±SEM 
 
0.090 
 
0.360 
0.102 
0.231 ± 0.13 
 
0.060 
 
0.140 
0.027 
0.084 ± 0.05 
 
0.036 
 
0.049 
0.127 
0.088 ± 0.04 
 
0.234 
 
0.114 
0.173 
0.144±0.030 
*Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; a Concentrations of carotenoids and 
retinol for ovaries are expressed in nmol/0.1 g of ovaries rather than nmol/g of tissue; b Right and left tissues have been designated with (r), (l), respectively; 
N.D., Not detected. 
 
 
 
 
 
APPENDIX C. (continued) 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, 
and Retinol in Primates’ Tissues* 
 
 
Tissue  
 
Primate ID 
lutein zeaxanthin 3’-oxolutein retinol 
Kidney 
 
 
Control                      RQ4079 
 
Treatment                  RQ4122 
RQ4087 
Mean ± SEM 
 
0.049 
 
0.271 
0.139 
0.205 ± 0.07 
 
0.027 
 
0.105 
0.044 
0.074 ± 0.03 
 
0.005 
 
0.042 
0.029 
0.035 ± 0.007 
 
1.442 
 
1.228 
1.268 
1.249±0.026 
Breasta 
 
 
Control                  RQ4079(r) 
RQ4079 (l) 
Mean ± SEM 
 
Treatment             RQ4122 (r) 
RQ4122 (l) 
RQ4087(r) 
RQ4087 (l) 
Mean ± SEM 
 
0.020 
0.054 
0.037 ± 0.017 
 
0.549 
0.701 
0.085 
0.113 
0.362 ± 0.26 
 
0.012 
0.028 
0.020 ± 0.008 
 
0.134 
0.177 
0.019 
0.064 
0.098 ± 0.06 
 
0.006 
0.012 
0.009 ± 0.003 
 
0.101 
0.143 
0.015 
0.018 
0.069 ± 0.05 
 
0.023 
0.060 
0.032±0.021 
 
0.059 
0.063 
0.032 
0.061 
0.054±0.007 
Ovariesb 
 
 
Control                      RQ4079 
 
Treatment                  RQ4122 
RQ4087 
Mean ± SEM 
 
0.026 
 
0.046 
0.096 
0.071 ± 0.03 
 
0.017 
 
0.019 
0.019 
0.019 ± 0.003 
 
0.003 
 
0.004 
0.021 
0.013 ± 0.008 
 
0.033 
 
0.054 
0.061 
0.058±0.004 
*Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; a Concentrations of carotenoids and 
retinol for ovaries are expressed in nmol/0.1 g of ovaries rather than nmol/g of tissue; b Right and left tissues have been designated with (r), (l), respectively; 
N.D., Not detected. 
 
 
 
 
 
 
APPENDIX C. (continued) 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, 
and Retinol in Primates’ Tissues* 
 
 
Tissue  
 
Primate ID 
lutein zeaxanthin 3’-oxolutein retinol 
Spleen 
 
 
Control                      RQ4079 
 
Treatment                  RQ4122 
RQ4087 
Mean ± SEM 
 
0.322 
 
0.679 
0.561 
0.620 ± 0.06 
 
0.138 
 
0.163 
0.123 
0.143 ± 0.02 
 
0.029 
 
0.073 
0.052 
0.062 ± 0.01 
 
0.134 
 
0.139 
0.110 
0.125 ± 0.015 
Cervix 
 
Control                      RQ4079 
 
Treatment                  RQ4122 
RQ4087 
Mean±SEM 
0.017 
 
0.037 
0.065 
0.051 ± 0.01 
0.013 
 
0.014 
0.034 
0.019 ± 0.01 
0.002 
 
0.011 
N.D. 
0.011 ± 0.004 
0.028 
 
0.020 
0.094 
0.057 ± 0.037 
Adipose 
 
Control                      RQ4079 
 
Treatment                  RQ4122 
RQ4087 
Mean±SEM 
0.163 
 
1.539 
0.050 
0.794 ± 0.82 
0.095 
 
0.346 
0.027 
0.187 ± 0.16 
0.072 
 
0.407 
N.D. 
0.407 
0.147 
 
0.133 
N.D. 
0.133 
*Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; a Concentrations of carotenoids and 
retinol for ovaries are expressed in nmol/0.1 g of ovaries rather than nmol/g of tissue; b Right and left tissues have been designated with (r), (l), respectively; 
N.D., Not detected. 
 
APPENDIX D. CAROTENOIDS IN THE MAJOR ORGANS AND TISSUES OF L-TREATED PRIMATES AT MONTH 18  
 
Concentrations (µg/g tissue) of lutein, zeaxanthin, 3’-oxolutein, and retinol in organs and tissues 6 months post-supplementation (month 18) of 2 
control primates and 3 primates supplemented daily with lutein (10 mg/kg) for 12 months. 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, and 
Retinol in Primate Tissues* 
 
Tissue 
 
 
Primate ID 
Lutein Zeaxanthin 3’-Oxolutein Retinol 
Liver 
 
Control                                 RQ4107 
 
RQ4142 
 
Mean ±SEM 
 
Treatment                            RQ4078 
 
RQ4175 
 
RQ4189 
 
Mean±SEM 
1.374 
 
0.499 
 
0.937 ± 0.44 
 
1.261 
 
3.963 
 
0.795 
 
2.006 ± 0.99 
 
0.873 
 
0.282 
 
0.577 ± 0.30 
 
0.709 
 
1.093 
 
0.433 
 
0.745 ± 0.19 
N.D. 
 
N.D. 
 
N.D. 
 
0.028 
 
0.042 
 
N.D. 
 
0.035 ± 0.007 
28.309 
 
41.894 
 
35.101 ± 6.79 
 
25.781 
 
20.680 
 
29.925 
 
25.461 ± 2.67 
Lung** 
 
 
Control                                RQ4107 
 
         RQ4142 
 
Mean±SEM 
       
Treatment                            RQ4078 
 
RQ4175 
 
RQ4189 
 
Mean±SEM 
0.101 
 
0.104 
 
0.102 ± 0.002 
 
0.084 
 
0.244 
 
0.080 
 
0.136 ± 0.12 
0.055 
 
0.064 
 
0.059 ± 0.005 
 
0.040 
 
0.106 
 
0.039 
 
0.061 ± 0.022 
0.011 
 
0.009 
 
0.010 ± 0.001 
 
0.009 
 
0.034 
 
0.011 
 
0.018 ± 0.008 
0.093 
 
0.095 
 
0.094 ± 0.001 
 
0.181 
 
0.193 
 
0.159 
 
0.177 ± 0.010 
* Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; ** Trace amounts of 3’-epilutein 
detected; N.D., Not detected. 
 
 
APPENDIX D. (continued) 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein,and 
Retinol in Primate Tissues* 
 
Tissue 
 
Primate ID 
Lutein Zeaxanthin 3’-Oxolutein Retinol 
Colon 
 
Control                              RQ4107** 
 
RQ4142** 
 
Mean±SEM 
     
Treatment                         RQ4078** 
 
RQ4175** 
 
RQ4189** 
 
Mean±SEM 
0.223 
 
0.289 
 
0.256 ± 0.033 
 
0.195 
 
0.314 
 
0.090 
 
0.199 ± 0.065 
 
0.137 
 
0.152 
 
0.144 ± 0.008 
 
0.081 
 
0.128 
 
0.033 
 
0.081 ± 0.027 
0.071 
 
0.039 
 
0.055 ± 0.016 
 
0.040 
 
0.057 
 
0.017 
 
0.038 ± 0.012 
0.354 
 
0.198 
 
0.276 ± 0.078 
 
0.132 
 
0.365 
 
0.154 
 
0.217 ± 0.074 
Breast 
 
Control                              RQ4107** 
 
RQ4142** 
 
Mean±SEM 
      
Treatment                         RQ4078** 
 
RQ4175** 
 
RQ4189** 
 
Mean±SEM 
0.624 
 
0.290 
 
0.457 ± 0.17 
 
0.234 
 
0.332 
 
0.476 
 
0.347 ± 0.053 
0.417 
 
0.160 
 
0.289 ± 0.24 
 
0.083 
 
0.104 
 
0.178 
 
0.121 ± 0.029 
0.158 
 
0.092 
 
0.125 ± 0.033 
 
0.081 
 
0.121 
 
0.209 
 
0.137 ± 0.038 
0.285 
 
0.135 
 
0.210 ± 0.075 
 
0.056 
 
0.048 
 
0.199 
 
0.084 ± 0.051 
*Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; ** Trace amounts of 3’-epilutein 
detected; N.D., Not detected. 
 
APPENDIX E. CAROTENOIDS IN THE OCULAR TISSUES OF Z-TREATED PRIMATES AT MONTHS 12 AND 18 
 
Concentrations (ng/tissue) of lutein, zeaxanthin, meso-zeaxanthin and 3’-oxolutein in ocular tissues of 5 primates supplemented daily with 
zeaxanthin (10 mg/kg) at month 12 (n=2) and at 6 months post-supplementation (n=3) compared to 3 control primates. 
 
Concentrations (ng/tissue) of Carotenoids in Primates Ocular Tissues (Tissue Weight, g)1 
 
Retina Ciliary Body Iris Lens 
 
 
Primate ID 
lutein zea-
xanthin 
meso-zea- 
xanthin 
3’-oxo-
lutein 
lutein zea-
xanthin 
3’-oxo-
lutein 
lutein/ 
zeaxanthin 
lutein/ 
zeaxanthin 
Control Group 
RQ4079 
 
 
RQ4107 
 
 
RQ4142 
 
 
Mean ±  
SEM 
 
 
14.52 
(0.103) 
 
11.63 
(0.137) 
 
6.99 
(0.111) 
 
11.05± 
2.19 
(0.117) 
 
5.35 
(0.103) 
 
5.45 
(0.137) 
 
3.54 
(0.111) 
 
4.78± 
0.62 
(0.117) 
 
3.25 
(0.103) 
 
3.64 
(0.137) 
 
2.66 
(0.111) 
 
3.20± 
0.30 
(0.117) 
 
1.33 
(0.103) 
 
1.14 
(0.137) 
 
N.D. 
 
 
0.82± 
0.10 
(0.117) 
 
4.25 
(0.071) 
 
4.13 
(0.060) 
 
3.70 
(0.042) 
 
4.03± 
0.17 
(0.058) 
 
2.00 
(0.071) 
 
2.11 
(0.060) 
 
0.907 
(0.042) 
 
1.67± 
0.38 
(0.058) 
 
0.65 
(0.071) 
 
0.668 
(0.060) 
 
0.472 
(0.042) 
 
0.60± 
0.06 
(0.058) 
 
0.39/00 
(0.016) 
 
0.40/00 
(0.0111) 
 
N.D. 
 
 
0.26±.01/ 
N.D. 
(0.012) 
 
0.77/00 
(0.136) 
 
0.44/00 
(0.218) 
 
0.58/.532 
(0.065) 
 
0.60±.10/ 
0.18±.05 
(0.140) 
Treatment  (Z) Group 
(12 months) 
 
RQ4146 
 
 
RQ4173 
 
 
Mean ± 
 SEM 
 
 
 
 
28.19 
(0.184) 
 
10.10 
(0.126) 
 
19.15± 
9.07 
(0.105) 
 
 
 
24.30 
 (0.184) 
 
16.56 
(0.126) 
 
20.43± 
3.88 
(0.105) 
 
 
 
8.56 
(0.184) 
 
5.83 
(0.126) 
 
7.20± 
1.37 
(0.105) 
 
 
 
4.69 
(0.184) 
 
3.05 
(0.126) 
 
3.87± 
0.10 
(0.105) 
 
 
 
7.51 
(0.049) 
 
2.42 
(0.057) 
 
4.97± 
2.55 
(0.053) 
 
 
 
17.12 
(0.049) 
 
8.58 
(0.057) 
 
12.85± 
4.28 
(0.053) 
 
 
 
1.83 
(0.049) 
 
0.84 
(0.057) 
 
1.34± 
0.50 
(0.053) 
 
 
 
0.31/0.39 
(0.034) 
 
0.21/0.20 
(0.021) 
 
0.26±.05/ 
.30±.01 
(0.028) 
 
 
 
0.34/0.32 
(0.163) 
 
0.33/0.41 
(0.163) 
 
0.34±.01/ 
.37±.05 
(0.163) 
* Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; N.D., Not detected. 
 
APPENDIX E. (continued) 
Concentrations (ng/tissue) of Lutein, Zeaxanthin, meso-Zeaxanthin, and 3’-Oxolutein 
in Primates Ocular Tissues (Tissue Weight, g)1 
Retina Ciliary Body Iris Lens 
 
 
Primate ID 
lutein zeaxanthin meso-zea-
xanthin 
3’-oxo-
lutein 
lutein zea-
xanthin 
3’-oxo-
lutein 
lutein/ 
zeaxanthin 
lutein/ 
zeaxanthin 
 Treatment (Z) Group 
   (18 months) 
 
RQ4092 (right) 
 
 
(left) 
 
 
RQ4094 (right) 
 
 
(left) 
 
 
RQ4120 (right) 
 
 
(left) 
 
 
Mean ± SEM 
 
  
 
 
13.31  
(0.056) 
 
5.81 
(0.061) 
 
11.13 
(0.044) 
 
0.852 
(0.011) 
 
10.92 
(0.054) 
 
5.03 
(0.020) 
 
7.842± 
1.03 
(0.041) 
 
 
 
4.50 
(0.056) 
 
3.48 
(0.061) 
 
3.70 
(0.044) 
 
N.D. 
 
 
6.51 
(0.054) 
 
5.14 
(0.020) 
 
3.93± 
0.66 
(0.041) 
 
 
 
2.32 
(0.056) 
 
1.43 
(0.061) 
 
0.92 
(0.044) 
 
N.D. 
 
 
1.98 
(0.054) 
 
2.23 
(0.020) 
 
1.78± 
0.26 
(0.041) 
 
 
 
1.56 
(0.056) 
 
0.629 
(0.061) 
 
N.D. 
 
 
N.D. 
 
 
0.57 
(0.054) 
 
0.57 
(0.020) 
 
0.58± 
0.27 
(0.041) 
 
 
 
8.12 
(0.075) 
 
10.32 
(0.076) 
 
5.85 
(0.074) 
 
7.06 
(0.102) 
 
7.13 
(0.116) 
 
4.57 
(0.083) 
 
7.18± 
1.04 
(0.095) 
 
 
 
4.91 
(0.075) 
 
4.37 
(0.076) 
 
2.94 
(0.074) 
 
4.00 
(0.102) 
 
2.91 
(0.116) 
 
2.06 
(0.083) 
 
3.53± 
0.62 
(0.095) 
 
 
 
1.04 
(0.075) 
 
1.34 
(0.076) 
 
0.87 
(0.074) 
 
1.14 
(0.102) 
 
0.78 
(0.116) 
 
0.55 
(0.083) 
 
0.95± 
0.19 
(0.095) 
 
 
 
0.88/00 
(0.012) 
 
0.40/00 
(0.009) 
 
N.A. 
 
 
0.70/00 
(0.009) 
 
0.90/00 
(0.008) 
 
0.35/00 
(0.013) 
 
0.65±.01/ 
N.D 
(0.013) 
 
 
 
0.87/00 
(0.118) 
 
0.48/00 
(0.146) 
 
0.40/00 
(0.083) 
 
0.47/00 
(0.169) 
 
1.02/ 00 
(0.163) 
 
0.54/00 
(0.155) 
 
0.63± .01/ 
N.D. 
(0.169) 
* Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; N.D., Not detected. 
 
APPENDIX F. CAROTENOIDS IN THE MAJOR ORGANS AND TISSUES OF Z-TREATED PRIMATES AT MONTH 12 
 
Concentrations (:g/g tissues) of lutein, zeaxanthin, 3’-oxolutein, and retinol in tissues of one control and 2 primates supplemented daily with 
zeaxanthin (10 mg/kg) at month 12. 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, 
and Retinol in Primates’ Tissues* 
 
Tissue 
 
Primate ID lutein zeaxanthin 3’-oxolutein retinol 
Liver 
 
Control                             RQ4079 
                   
Treatment                        RQ4146 
         RQ4173 
Mean ± SEM 
1.653 
 
2.723 
0.74 
1.732 ± 0.991 
0.775 
 
4.718 
3.063 
3.890 ± 0.828 
N.D. 
 
0.191 
0.103 
0.147 ± 0.044 
11.331 
 
11.739 
10.492 
11.116 ± 0.623 
Lung 
 
Control                             RQ4079 
                   
Treatment                        RQ4146 
         RQ4173 
Mean ± SEM 
0.100 
 
0.052 
0.052 
0.052 ± 0.00 
0.051 
 
0.115 
0.216 
0.166 ± 0.051 
0.006 
 
0.008 
0.018 
0.013 ± 0.009 
0.164 
 
0.020 
0.144 
0.082± 0.062 
Colon 
 
Control                             RQ4079  
                  
Treatment                        RQ4146 
         RQ4173 
Mean ± SEM 
0.090 
 
0.503 
0.073 
0.288 ± 0.215 
0.060 
 
2.114 
0.562 
1.085 ± 1.468 
0.036 
 
0.023 
0.023 
0.023 ± 0.00 
0.234 
 
0.034 
0.040 
0.036 ± 0.003 
Breast a 
 
Control                        RQ4079(r) 
RQ4079(l) 
Mean ± SEM 
                   
Treatment                  RQ4146 (r) 
               RQ4146 (l) 
RQ4173 (r) 
                  RQ4173 (l) 
Mean ± SEM 
0.020 
0.054 
0.037 ± 0.017 
 
0.086 
0.047 
0.149 
0.042 
0.081± 0.025 
0.012 
0.028 
0.020 ± 0.008 
 
0.328 
0.227 
0.575 
0.329 
0.36 5± 0.074 
0.006 
0.012 
0.009 ± 0.003 
 
0.041 
0.017 
0.077 
0.042 
0.044 ± 0.012 
0.023 
0.060 
0.042 ± 0.019 
 
0.045 
0.031 
0.054 
0.038 
0.042 ± 0.0045 
*Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; a Right and left tissues have been 
designated with (r), (l), respectively; bConcentrations of carotenoids and retinol for ovaries are expressed in µg/0.1 g of ovaries rather than µg/g of tissue; N.D., 
Not detected. 
 
 
APPENDIX F. (continued) 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, 
and Retinol in Primates’ Tissues* 
 
Tissue  
 
Primate ID 
lutein zeaxanthin 3’-oxolutein retinol 
Kidney 
 
Control                            RQ4079 
                   
Treatment                        RQ4146 
         RQ4173 
Mean ± S EM 
0.049 
 
0.084 
0.025 
0.055 ± 0.029 
0.027 
 
0.161 
0.089 
0.125 ± 0.036 
0.005 
 
0.016 
0.08 
0.012 ± 0.004 
1.442 
 
1.093 
1.204 
1.149 ± 0.056 
 
Ovariesb 
 
Control                            RQ4079  
                  
Treatment                        RQ4146 
         RQ4173 
Mean ± SEM 
0.026 
 
0.014 
0.012 
0.013 ± 0.001 
0.017 
 
0.028 
0.054 
0.041 ± 0.014 
0.003 
 
0.001 
0.003 
0.002 ± 0.001 
0.033 
0.013 
0.020 
 
0.016 ± 0.004 
Spleen 
 
Control                            RQ4079 
                   
Treatment                        RQ4146 
RQ4173 
Mean ± SEM 
0.322 
 
0.277 
0.060 
0.169 ± 0.109 
0.138 
 
0.723 
0.227 
0.475 ± 0.351 
0.029 
 
0.026 
0.017 
0.022 ± 0.004 
0.134 
 
0.041 
0.049 
0.045 ± 0.004 
Cervix 
 
Control                             RQ4079 
                   
Treatment                        RQ4146 
                  RQ4173 
Mean ± SEM 
0.017 
 
0.071 
0.015 
0.043 ± 0.028 
0.013 
 
0.114 
0.050 
0.082 ± 0.032 
0.002 
 
0.013 
0.005 
0.009 ± 0.004 
0.028 
 
0.034 
0.039 
0.037 ± 0.003 
Adipose 
 
Control                            RQ4079 
                   
Treatment                        RQ4146 
                   RQ4173 
Mean ± SEM 
0.163 
 
0.066 
0.014 
0.040 ± 0.026 
0.095 
 
0.174 
0.077 
0.125 ± 0.048 
0.072 
 
0.026 
0.006 
0.016 ± 0.010 
0.147 
 
0.020 
0.014 
0.017 ± 0.003 
*Concentrations of cis-isomers of lutein and zeaxa nthin have been combined with their corresponding all-trans isomers; a Right and left tissues have been 
designated with (r), (l), respectively; bConcentrations of carotenoids and retinol for ovaries are expressed in µg/0.1 g of ovaries rather than µg/g of tissue; N.D. 
Not detected. 
 
APPENDIX G. CAROTENOIDS IN THE MAJOR ORGANS AND TISSUES OF Z-TREATED PRIMATES AT MONTH 18 
 
 
Concentrations (µg/g tissue) of lutein, zeaxanthin, 3’-oxolutein, and retinol in organs and tissues 6 months post-supplementation (month 18) of 3 
primates supplemented daily with zeaxanthin (10 mg/kg) for 12 months and 2 control primates. 
Concentrations (µg/g  tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, 
and Retinol in Primate Tissues 
 
 
Tissue 
 
 
Primate ID 
lutein zeaxanthin 3’-oxolutein retinol 
Liver 
 
Control        
  RQ4107 
                      RQ4142 
Mean ± SEM 
 
Treatment    
RQ4092**  
RQ4094** 
RQ4120 
Mean ± SEM 
 
1.374.34 
0.498.71 
0.936.53 ± 0.536.53 
 
 
1.572.42 
2.355.63 
0.901.87 
1.609.97 ± 0.132.8 
 
0.872.85 
0.281.53 
0.577.19 ± 0.295.7 
 
 
0.756.01 
0.999.87 
0.483.07 
0.746.32 ± 0.149.3 
 
N.D. 
N.D. 
 
 
 
N.D. 
N.D. 
N.D. 
 
28.309.3 
41.893.9 
35.101.2 ± 6.792.1 
 
 
108.348 
209.662 
124.720 
147.577 ± 31.400 
Lung** 
 
Control        
 RQ4107 
                     RQ4142 
Mean±SEM 
 
Treatment    
RQ4092 
RQ4094 
RQ4120 
Mean±SEM 
 
0.101 
0.104 
0.102 ± 0.065 
 
 
0.172 
0.142 
0.140 
0.152 ± 0.010 
 
0.055 
0.064 
0.059 ± 0.005 
 
 
0.088 
0.072 
0.074 
0.078 ± 0.005 
 
0.011 
0.009 
0.010 ± 0.001 
 
 
0.016 
0.015 
0.010 
0.013 ± 0.002 
 
0.093 
0.095 
0.094 ± 0.001 
 
 
0.142 
0.173 
0.258 
0.191 ± 0.035 
* Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; ** Trace amounts of 3’-epilutein 
detected; N.D., Not detected. 
 
 
 
 
 
APPENDIX G. (continued) 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, 
and Retinol in Primate Tissues 
 
 
Tissue 
 
Primate ID 
lutein zeaxanthin 3’-oxolutein retinol 
Colon** 
 
Control         
RQ4107 
                     RQ4142 
Mean±SEM 
 
Treatment    
RQ4092 
RQ4094 
RQ4120 
Mean±SEM 
 
0.223 
0.289 
0.256 ± 0.033 
 
 
0.349 
0.123 
0.327 
0.266 ± 0.072 
 
0.137 
0.152 
0.144 ± 0.121 
 
 
0.193 
0.037 
0.177 
0.135 ± 0.050 
 
0.071 
0.039 
0.055 ± 0.016 
 
 
0.039 
0.018 
0.021 
0.026 ± 0.007 
 
0.354 
0.198 
0.276 ± 0.078 
 
 
0.168 
0.207 
0.337 
0.237 ± 0.051 
Breast** 
 
Control         
RQ4107 
                     RQ4142 
Mean±SEM 
 
Treatment    
RQ4092 
RQ4094 
RQ4120 
Mean±SEM 
 
0.624 
0.290 
0.457 ± 0.0167 
 
 
0.117 
0.163 
0.399 
0.227 ± 0.088 
 
0.417 
0.160 
0.289 ± 0.129 
 
 
0.074 
0.130 
0.329 
0.178 ± 0.077 
 
0.158 
0.092 
0.125 ± 0.033 
 
 
0.030 
0.057 
0.105 
0.064 ± 0.022 
 
0.285 
0.135 
0.210 ± 0.075 
 
 
0.040 
0.033 
0.284 
0.119 ± 0.083 
* Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; ** Trace amounts of 3’-epilutein 
detected; N.D.:, Not detected. 
 
APPENDIX H. CAROTENOIDS IN THE OCULAR TISSUES OF L/Z-TREATED PRIMATES AT MONTH 12 
 
Concentrations (ng/tissue) of lutein, zeaxanthin, meso-zeaxanthin, and 3’-oxolutein in ocular tissues of 3 control and 5 L/Z-treated primates (each 
at 0.5 mg/kg) at month 12. 
Concentrations (ng/tissue) of Lutein, Zeaxanthin, meso-Zeaxanthin, and 3’-Oxolutein 
in Primates’ Ocular Tissues (Tissue Weight, g)* 
Retina Ciliary Body Iris Lens 
 
Primate 
ID 
lutein zea-
xanthin 
meso-zea-
xanthin 
3’-oxo-
lutein 
lutein zea-
xanthin 
3’-oxo-
lutein 
lutein zea-
xanthin 
lutein zea-
xanthin 
Control 
 
RQ4079 
 
 
RQ4142 
 
 
RQ4107 
 
 
Mean ±  
SEM 
 
 
14.52 
(0.103) 
 
6.99 
(0.113) 
 
11.63 
(0.137) 
 
11.05±  
2.19 
 (0.117) 
 
 
5.35 
(0.103) 
 
3.54 
(0.113) 
 
5.45 
(0.137) 
 
4.78 ±  
0.62 
(0.117) 
 
 
3.25 
(0.103) 
 
2.66 
(0.113) 
 
3.69 
(0.137 
 
3.20 ±  
0.30 
(0.117) 
 
 
1.33 
(0.103) 
 
N.D. 
 
 
1.14 
(0.137) 
 
1.22 ±  
0.096 
(0.117) 
 
 
4.25 
(0.071) 
 
3.697 
(0.042) 
 
4.13 
(0.060) 
 
4.03 ±  
0.17 
(0.058) 
 
 
2.00 
(0.071) 
 
0.91 
(0.042) 
 
2.11 
(0.060) 
 
1.64 ±  
0.38 
(0.058) 
 
 
0.65 
(0.071) 
 
0.47 
(0.042) 
 
0.67 
(0.060) 
 
0.60 ±  
0.14 
(0.058) 
 
 
0.39 
(0.016) 
 
N.D. 
 
 
0.40 
(0.011) 
 
0.26 ±  
0.10 
(0.014) 
 
 
N.D. 
 
 
N.D. 
 
 
N.D. 
 
 
N.D. 
 
 
0.77 
(0.136) 
 
0.58 
(0.065) 
 
0.44 
(0.217) 
 
0.60 ±  
0.10 
(0.14) 
 
 
N.D. 
 
 
0.53 
(0.065) 
 
N.D. 
 
 
0.18 ±  
 0.20 
(0.14) 
Treatmenta 
 
RQ4086 
(r) 
 
(l) 
 
 
RQ4104 
(r) 
 
(l) 
 
 
10.69 
(0.120) 
 
14.01 
(0.164) 
 
12.07 
(0.080) 
 
8.07 
(0.120) 
 
 
 
4.51 
(0.120) 
 
6.51 
(0.164) 
 
5.58 
(0.080) 
 
2.54 
(0.120) 
 
 
 
1.09 
(0.120) 
 
0.82 
(0.164) 
 
3.01 
(0.080) 
 
0.65 
(0.120) 
 
 
 
N.D. 
 
 
1.98 
(0.164) 
 
N.D. 
 
 
N.D. 
 
 
 
4.97 
(0.098) 
 
3.21 
(0.059) 
 
3.78 
(0.064) 
 
4.41 
(0.071) 
 
 
 
3.57 
(0.098) 
 
1.77 
(0.059) 
 
2.83 
(0.064) 
 
2.79 
(0.071) 
 
 
0.76 
(0.098) 
 
0.56 
(0.059) 
 
N.D. 
 
 
1.00 
(0.071) 
 
 
 
0.84 
(0.023) 
 
N.A. 
 
 
0.59 
(0.007) 
 
N.A. 
 
 
 
 
0.35 
(0.023) 
 
N.A. 
 
 
0.40 
(0.007) 
 
N.A. 
 
 
 
 
N.D. 
 
 
0.56 
(0.033) 
 
0.77 
(0.179) 
 
0.73 
(0.050) 
 
 
 
N.D. 
 
 
N.D. 
 
 
0.44 
(0.170) 
 
0.52 
(0.050) 
 
*Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; tissue weights are in parentheses (g); a Right and 
left tissues have been designated with (r), (l), respectively; N.D., Not detected; N.A., Tissue not available for analysis. 
 
 
APPENDIX H. (continued) 
Concentrations (ng/tissue) of Lutein, Zeaxanthin, meso-Zeaxanthin, and 
3’-Oxolutein in Primates’ Ocular Tissues (Tissue Weight, g)* 
 
Retina Ciliary Body Iris Lens 
 
 
Primate ID 
lutein zea-
xanthin 
meso-zea-
xanthin 
3’-oxo-
lutein 
lutein zeaxanthin 3’-oxo-
lutein 
lutein zea-
xanthin 
lutein zea-
xanthin 
Treatment 
 
RQ4118 
(r) 
 
(l) 
 
 
RQ4126 
(r) 
 
(l) 
 
 
RQ4154 
(r) 
 
 
(l) 
 
Mean ±  
SEM  
 
 
6.54 
(0.052) 
 
3.17 
(0.038) 
 
5.08 
(0.022) 
 
14.58 
(0.164) 
 
17.50 
(0.337) 
 
23.29 
(0.150) 
 
11.50 ±  
2.12 
(0.108) 
 
 
 
3.95 
(0.052) 
 
0.92 
(0.038) 
 
2.88 
(0.022) 
 
64.93 
(0.164) 
 
12.04 
(0.337) 
 
14.88 
(0.150) 
 
5.66 ±  
2.02 
(0.108) 
 
 
1.78 
(0.052) 
 
0.42 
(0.038) 
 
1.14 
(0.022) 
 
N.A> 
 
 
3.22 
(0.337) 
 
4.12 
(0.150) 
 
1.75 ±  
0.54 
(0.108) 
 
 
N.D. 
 
 
N.D. 
 
 
2.52 
(0.337) 
 
1.66 
(0.164) 
 
N.D. 
 
 
3.55 
(0.150) 
 
2.37 ±  
0.33 
(0.108) 
 
 
1.17 
(0.023) 
 
2.33 
(0.044) 
 
1.75 
(0.072) 
 
4.70 
(0.053) 
 
14.32 
(0.065) 
 
8.36 
(0.053) 
 
4.89 ±  
1.66 
(0.060) 
 
 
1.61 
(0.023) 
 
1.53 
(0.044) 
 
1.74 
(0.072) 
 
2.92 
(0.053) 
 
13.43 
(0.065) 
 
7.00 
(0.053) 
 
3.92 ±  
1.17 
(0.060 
 
 
N.D. 
 
 
N.D. 
 
 
2.26 
(0.065) 
 
1.43 
(0.053) 
 
N.D. 
 
 
1.17 
(0.053) 
 
0.80 ±  
0.26 
(0.060) 
 
 
0.48 
(0.005) 
 
0.47 
(0.025) 
 
0.62 
(0.008) 
 
0.34 
(0.0024) 
 
1.49 
(0.005) 
 
1.38 
(0.0073) 
 
0.77 ±  
 0.18 
 (0.010) 
 
 
0.40 
(0.005) 
 
0.36 
(0.025) 
 
0.38 
(0.008) 
 
0.26 
(0.0024) 
 
1.07 
(0.005) 
 
1.19 
(0.0073) 
 
0.52 ±   
0.15 
(0.010) 
 
 
0.54 
(0.138) 
 
N.A. 
 
 
0.33 
(0.142) 
 
N.A. 
 
 
0.46 
(0.161) 
 
0.80 
(0.045) 
 
0.56 ± 
0.07 
(0.107) 
 
 
0.27 
(0.138) 
 
N.A. 
 
 
N.D. 
 
 
N.A. 
 
 
0.32 
(0.161) 
 
0.53 
(0.045) 
 
0.39 ±   
0.06 
(0.107) 
*Concentrations of cis-isomers of lutein and zeaxanthin have been combined with their corresponding all-trans isomers; tissue weights are in parentheses (g); a Right and 
left tissues have been designated with (r), (l), respectively; N.D., Not detected; N.A., Tissue not available for analysis. 
 
APPENDIX  I. CAROTENOIDS IN THE MAJOR ORGANS AND TISSUES OF L/Z-TREATED PRIMATES AT  MONTH 12 
 
Concentrations (µg/g tissue) of lutein, zeaxanthin, 3’-oxolutein, and retinol in the tissues of 5 primates supplemented daily with 
lutein/zeaxanthin ( each at 0.5 mg/kg) for 12 months compared to control primate RQ4079 from the Lutein Supplementation Study. 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, 
and Retinol in Primate Tissues 
 
Tissue  
 
Primate ID 
lutein zeaxanthin 3’-oxolutein retinol 
Liver 
 
Control            
RQ4079 
Treatment      
RQ4086* 
RQ4104 
RQ4118 
RQ4126* 
RQ4154* 
Mean ± SEM 
 
1.653 
 
0.982 
0.279 
0.855 
0.628 
0.853 
0.719 ± 0.12 
 
0.775 
 
0.605 
0.176 
0.574 
0.360 
0.678 
0.479 ± 0.09 
 
N.D. 
 
N.D. 
N.D. 
N.D. 
N.D. 
N.D. 
 
 
11.330 
 
1.800 
1.100 
4.000 
3.990 
18.012 
5.781 ± 3.11 
Lung 
 
Control            
RQ4079 
Treatment       
RQ4086 
RQ4104 
RQ4118 
RQ4126 
RQ4154 
Mean ± SEM 
 
0.100 
 
0.100 
0.090 
0.033 
0.090 
0.125 
0.088 ± 0.02 
 
0.510 
 
0.699 
51.35 
19.06 
67.28 
126.48 
0.067±0.02 
 
0.006 
 
0.013 
0.009 
0.007 
0.017 
0.023 
0.014±0.003 
 
0.164 
 
0.070 
0.067 
0.057 
0.095 
0.073 
0.072 ± 0.006 
Colon 
 
Control             
    RQ4079 
Treatment     
RQ4086 
RQ4104 
RQ4118 
RQ4126 
RQ4154 
Mean ± SEM 
 
0.090 
 
0.020 
0.528 
0.445 
0.528 
1.232 
0.550± 0.19 
 
0.060 
 
0.007 
0.293 
0.345 
0.252 
0.982 
0.376 ± 0.16 
 
0.036 
 
0.003 
0.045 
0.093 
0.055 
0.104 
0.060 ± 0.02 
 
0.234 
 
0.051 
0.617 
0.443 
0.343 
0.461 
0.383 ± 0.09 
*Trace amounts of 3’-epilutein detected; a Mean value for right and left breast tissues; N.D., Not detected. 
 
 
 
APPENDIX  I. (continued) 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, 
and Retinol in Primate Tissues   
Tissue 
 
Primate ID 
lutein 
zeaxanthin 3’-oxolutein retinol 
Kidney 
 
Control            
RQ4079 
Treatment      
RQ4086* 
RQ4104 
RQ4118 
RQ4126 
RQ4154 
Mean ± SEM 
 
0.049 
 
0.078 
0.058 
0.098 
0.744 
0.227 
0.241 ± 0.13 
 
0.027 
 
0.043 
0.044 
0.052 
0.372 
0.206 
0.144 ± 0.06 
 
0.005 
 
0.018 
0.011 
0.034 
0.015 
0.062 
0.028 ± 0.01 
 
1.442 
 
1.363 
1.302 
1.635 
1.135 
1.900 
1.467 ± 0.13 
Breast 
 
Control          
 RQ4079a 
Treatment       
RQ4086 
RQ4104 
RQ4118 
RQ4126 
RQ4154 
Mean ± SEM 
 
0.037 
 
0.284 
0.720 
0.475 
0.229 
0.491 
0.440 ± 0.09 
 
0.020 
 
0.196 
0.544 
0.271 
0.181 
0.398 
0.318 ± 0.07 
 
0.009 
 
0.100 
N.D. 
N.D. 
0.057 
0.046 
0.068 ± 0.02 
 
0.032 
 
0.129 
0.896 
0.688 
0.310 
0.481 
0.501 ±  0.14 
Ovaries 
 
Control            
RQ4079 
Treatment       
RQ4086 
RQ4104 
RQ4118 
RQ4126 
RQ4154 
Mean ± SEM 
 
0.026 
 
0.270 
0.060 
0.308 
0.286 
1.468 
0.478 ± 0.25 
 
0.017 
 
0.095 
0.452 
0.110 
0.137 
1.248 
0.326 ± 0.23 
 
0.003 
 
0.055 
0.016 
0.067 
0.040 
0.268 
0.089 ±0.05 
 
0.033 
 
0.284 
0.190 
4.270 
1.737 
0.201 
1.336 ± 0.79 
*Trace amounts of 3’-epilutein detected; a Mean value for right and left breast tissues; N.D., Not detected. 
 
 
 
 
 
 
APPENDIX I. (continued) 
Concentrations (µg/g tissue) of Lutein, Zeaxanthin, 3’-Oxolutein, and Retinol in 
Primate Tissues  
 
Tissue  
 
Primate ID 
lutein zeaxanthin 3’-oxolutein retinol 
Spleen 
 
Control            
RQ4079 
Treatment       
RQ4086 
RQ4104 
RQ4118 
RQ4126 
RQ4154 
Mean ± SEM 
 
0.322 
 
0.414 
0.310 
0.315 
0.406 
0.648 
0.418 ± 0.06 
 
0.138 
 
0.285 
0.204 
0.236 
0.297 
0.682 
0.341 ± 0.09 
 
0.029 
 
0.070 
0.044 
0.080 
0.064 
0.165 
0.085 ± 0.02 
 
0.134 
 
0.233 
0.205 
0.326 
0.240 
0.324 
0.266 ± 0.025 
Cervix 
 
Control            
RQ4079 
Treatment       
RQ4086 
RQ4104 
RQ4118 
RQ4126 
RQ4154 
Mean ± SEM 
 
0.017 
 
0.038 
0.050 
0.039 
0.044 
0.091 
0.052 ± 0.01 
 
0.013 
 
0.017 
0.019 
0.015 
0.027 
0.083 
0.032 ±0.01 
 
0.002 
 
0.009 
0.006 
0.010 
0.006 
0.020 
0.010 ±0.003 
 
0.028 
 
0.077 
0.074 
0.136 
0.087 
0.128 
0.100 ± 0.014 
Adipose 
 
Control            
RQ4079 
Treatment       
RQ4086 
RQ4104 
RQ4118 
RQ4126 
RQ4154 
Mean ± SEM 
 
0.163 
 
0.848 
0.311 
0.014 
0.113 
1.855 
0.638 ± 0.34 
 
0.095 
 
0.384 
0.148 
0.008 
0.064 
1.411 
0.403± 0.26 
 
0.072 
 
N.D. 
N.D. 
N.D. 
N.D. 
N.D. 
 
 
0.147 
 
4.090 
27.233 
0.083 
6.190 
0.710 
7.661 ± 5.01 
*Trace amounts of 3’-epilutein detected; a Mean value for right and left breast tissues; N.D., Not detected. 
 
 
 
APPENDIX J. AGE AT BASELINE AND BODY WEIGHTS AT BASELINE, MONTHS 
6, 12, AND 18 FOR L-, Z-, AND L/Z-TREATED PRIMATES 
 
Weight (kg) 
 
 
Primate 
Group 
 
Primate ID 
 
Age at 
Start (y) Baseline Month 6 Month 12 Month 18 
4107* 3.9 3.14 3.84 3.89 3.50 
4142* 3.1 3.34 3.82 3.91 3.92 
4079 3.0 3.28 4.51 4.05  
Control 
Mean±SEM 3.3±0.3 3.25±0.06 4.06±0.23 3.95±0.05 3.71±0.21 
4078* 3.2 3.50 4.37 4.19 4.04 
4189* 3.0 3.84 4.70 4.61 4.57 
4175* 3.3 3.60 4.45 4.61 4.73 
4087 2.3 3.26 3.86 3.88  
4122 1.9 2.92 3.83 3.82  
L-Treated 
Mean±SEM 2.7±0.3 3.42±0.16 4.24±0.17 4.22±0.17 4.45±0.21 
4120* 3.1 4.28 5.39 5.29 5.20 
4092* 3.0 4.44 4.13 4.53 4.50 
4094* 3.1 3.96 3.61 4.37 4.30 
4146 2.7 3.96 3.88 4.49  
4173 3.0 3.94 4.67 5.09  
Z-Treated 
Mean±SEM 3.0±0.1 4.12±0.10 4.34±0.32 4.75±0.18 4.67±0.27 
4086 3.0 3.13 3.60 3.50  
4154 3.3 2.78 3.50 3.84  
4118 3.0 3.58 4.39 4.29  
4126 3.0 3.33 3.87 4.04  
4104 3.3 3.05 3.54 4.05  
L/Z-Treated 
Mean±SEM 3.1±0.1 3.17±0.13 3.78±0.17 3.94±0.13  
* Primate sacrificed at month 18; all other primates were sacrificed at month 12. 
 
 
 
APPENDIX K. SUMMARY OF THE MEAN CAROTENOID CONCENTRATIONS (MEAN ± SEM) IN THE OCULAR TISSUES 
OF L-TREATED, Z-TREATED AND L/Z-TREATED PRIMATES AT MONTHS 12 AND 18 
 
Mean concentrations (ng/tissue) of carotenoids in the ocular tissues of primates 
Retina, ng/tissue 1 
(picomol/tissue)2 
Ciliary Body, ng/tissue 1 Iris 
ng/tissue  
Lens  
ng/tissue  
 
 
 Animals 
lutein zeaxanthin meso-zea-
xanthin 
3’-oxo-
lutein 
lutein zeaxanthin 3’-oxo-
lutein 
lutein/ 
zeaxanthin6 
lutein/ 
zeaxanthin6 
Control3  
 
(n = 3) 
 
 
11.05 ± 2.19b,c 
(19.4 ± 3.8) 
 
 
4.78 ± 0.62b 
(8.4 ± 1.1) 
 
 
3.20 ± 0.30b,c 
(5.6 ± 0.5) 
 
 
1.24 ± 0.10b,c 
(2.2 ± 0.2) 
 
 
4.03 ± 0.17a 
 
 
 
1.67 ± 0.38b 
 
 
0.60 ± 0.06a,b 
 
 
0.40 ± 0.01 
N.D. 
 
 
0.60 ± 0.10 
0.18 ± 0.20 
L-Treated 
 
Month 124 
(n = 2) 
 
Month 185 
(n = 3) 
 
 
40.4 ± 1.41a 
(71.0 ± 2.5) 
 
6.20 ± 0.70c 
(10.9 ± 1.2) 
 
 
7.56 ± 0.71b 
(13.3 ± 1.3) 
 
2.34±0.78b 
(4.1±1.4) 
 
 
4.87 ± 0.70b 
(8.6 ± 1.2) 
 
1.45 ± 0.44c 
(2.5±0.8) 
 
 
3.97 ± 0.55a 
(7.0 ± 1.0) 
 
0.66 ± 0.08c 
(1.2 ± 0.1) 
 
 
7.12 ± 0.22a 
 
 
3.64 ± 1.20a 
 
 
1.84 ± 0.58b 
 
 
1.39 ± 0.36b 
 
 
1.09 ± 0.06a 
 
 
N.D. 
 
 
 
1.68 ± 0.91 
N.D. 
 
0.59 ± 0.19 
N.D. 
 
 
0.76 ± 0.08 
N.D. 
 
1.36 ± 0.33 
N.D. 
Z-Treated 
 
Month 124 
(n = 2) 
 
Month 185 
(n = 3) 
 
 
19.2 ± 9.07b 
(33.8 ± 16) 
 
7.84 ± 1.03c 
(13.8 ± 1.8) 
 
 
20.4 ± 3.88a 
(35.9 ± 6.8) 
 
4.45 ± 0.42b 
(7.8 ± 0.7) 
 
 
7.20 ± 1.37a 
(12.7 ± 2.4) 
 
1.82 ± 0.45c 
(3.2 ± 0.8) 
 
 
3.87 ± 0.82a 
(6.8 ± 1.5) 
 
0.84 ± 0.27c 
(1.5 ± 0.5) 
 
 
4.97 ± 2.55a 
 
 
7.18 ± 1.04a 
 
 
 
12.9 ± 4.28a 
 
 
3.53 ± 0.62b 
 
 
 
1.34 ± 0.50a 
 
 
0.92 ± 0.19a,b 
 
 
 
0.26 ± 0.05 
0.40 ± 0.01 
 
0.64 ± 0.01 
N.D. 
 
 
0.34 ± 0.01 
0.37 ± 0.05 
 
0.63 ± 0.10 
N.D. 
L/Z-Treated 
 
Month 125 
(n = 5) 
 
 
11.5 ± 2.53b,c 
(20.2 ± 4.5) 
 
 
5.66 ± 2.02b 
(10.0 ± 3.6) 
 
 
1.75 ± 0.54c 
(3.1 ± 0.9) 
 
 
2.37 ± 0.33b 
(4.2 ± 0.6) 
 
 
4.90 ± 1.66a 
 
 
3.92 ± 1.59b 
 
 
 
1.17 ± 0.25a 
 
 
 
0.77 ± 0.18 
0.52 ± 0.15 
 
 
0.56 ± 0.07 
0.39 ± 0.06 
 
1 Means followed with identical superscript letters (a, b, c) within the same column are not significantly different at .05 level of significance; 2 Values for retinas 
are also expressed in picomol/tissue in parantheses; 3Average of the values  for 1 control animal sacrificed after 12 months and 2 control animals sacrificed after 
18 months; 4 Only one eye from each animal was available for analysis as the other eye was used for histopathology; 5 Includes average values for the left and the 
right eye; 6combined values for zeaxanthin and meso-zeaxanthin; N.D., Not detected. 
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